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CHAPTER 1 
Introduction 
In the first century BC Aristotle described that he detected fibers in the blood 
of killed animals, but not in the blood of hunted deer. He stated that the blood 
of such animals could not coagulate, not realising that the enhanced fibrinoly-
tic state in the deer was caused by exhaustion (1). Therapeutic enhancement of 
the fibrinolytic system was first reported in 1933, when Tillet and Garner 
demonstrated that cultures of hemolytic streptococci had the capacity to 
liquify clotted human plasma (2). Christensen believed that streptococcal 
activity to be kinase-like and introduced the term streptokinase in 1945 (3). 
Streptokinase was for the first time used as a thrombolytic agent in 1959 when 
Fletcher demonstrated its capability to lyse venous thrombi in healthy volun-
teers (4). Also in 1959, Fletcher observed a low mortality in 22 patients with 
acute myocardial infarction after treatment with high doses of intravenous 
streptokinase ( 5). In later years the efficacy of intravenous streptokinase in the 
treatment of patients with myocardial infarction was tested in randomised 
clinical trials, but the results were not unequivocally in favour of this therapy, 
although beneficial effects were reported in some (6-11). In these trials early 
mortality appeared to be on average 5% lower in patients treated with strep-
tokinase when compared to treatment with heparin. However, it remains 
difficult to draw conclusions from these studies since patients were admitted 
up to 48 hours after onset of symptoms, no intermediate measurements were 
made and the relation between treatment delay and mortality reduction was 
not studied. Moreover, the role of acute thrombotic obstruction of a coronary 
artery as the cause of myocardial infarction was not yet generally accepted 
(12). It was DeWood who settled the controversy whether the thrombotic 
occlusion of a coronary artery was the cause of myocardial infarction or the 
consequence of it by reporting that coronary angiography performed within 
hours after the onset of myocardial infarction showed obstruction of a coro-
nary artery in more than 75% of the cases (13). Although intracoronary lysis 
with fibrinolytic agents had been shown earlier by Boucek and Chazov (14, 
15), the clinical breakthrough came when Rentrop demonstrated in 1979 that 
an occluded coronary artery could be recanalised during coronary angiogra-
phy by the intracoronary application of streptokinase (16). This led to the use 
of intracoronary streptokinase on a large scale in many centres, although 
benefits other than angiographically documented recanalisation had not been 
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proven. Consequently, warnings were sounded that until it became clear 
whether the potential benefits of acute recanalisation, in terms of infarct size 
limitation and mortality reduction, outweighted the risks of the procedure, 
widespread application should be avoided (17,18). To assess whether a 
strategy aimed at early reperfusion of an occluded coronary artery would be of 
benefit for patients with acute myocardial infarction, a randomised trial was 
initiated in 1981 in the Thoraxcenter in Rotterdam and later extended with 
four other hospitals under the auspices of the Interuniversity Cardiology 
Institute of the Netherlands. In this thesis parts of the results of this trial are 
presented. 
The mechanisms of fibrinolysis and the pharmacological properties of 
thrombolytic agents are described in chapter 2. The design of the trial and the 
methodology used is discussed in chapter 3. The main results are presented in 
chapter 4, followed by detailed reports about the observed limitation of infarct 
size (chapter 5) and the value of the admission electrocardiogram to predict 
the outcome of thrombolytic therapy (chapter 6). Subgroup analysis was 
performed to identify which patients benefitted most from the therapy (chap-
ter 7) and benefits were related to the costs of the intervention (chapter 8). The 
additional value of coronary angioplasty, performed immediately after suc-
cessful thrombolysis in selected patients, was assessed in a matched pair 
analysis (chapter 9). A number of other observations from the trial are 
summarised in chapter 10. The results are discussed and compared with results 
of other clinical trials with thrombolytic therapy. Based on these results 
recommendations for application of thrombolytic therapy in acute myocardial 
infarction are presented (chapter 11). 
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CHAPTER2 
Pharmacology 
The fibrinolytic system 
Lesions of the endothelium of an artery trigger a cascade of enzyme reactions, 
finally leading to coagulation of blood by formation of fibrin. Opposing this 
event is the capacity of the fibrinolytic system to resolve blood clots in the 
circulation. Fibrin is fragmented by plasmin into soluble fibrin degradation 
products. Under normal circumstances the fibrinolytic system is in a state of 
"dynamic equilibrium" with the coagulation system in order to maintain an 
intact and patent vascular bed (1 ). In coronary artery disease, platelet aggrega-
tion and coagulation may occur on atherosclerotic lesions in the coronary 
arteries, leading to intravascular fibrin deposits (thrombosis), with eventual 
occlusion of a coronary artery and subsequent myocardial infarction. The 
primary goal of thrombolytic therapy is to enhance fibrinolytic activity when 
pathologic deposition of fibrin has occurred and naturally induced fibrinolysis 
by itself is insufficient to maintain patency of the vascular bed. The mecha-
nisms of fibrinolysis and the role of thrombolytic agents are discussed below. 
Mechanisms of fibrinolysis 
Plasminogen, a single chain glycoprotein (molecular weight 92,000) can be 
converted into plasmin by cleavage of a protein bond. Plasmin has high affinity 
for fibrin and breaks it down rapidly (figure). Free plasmin in the circulating 
blood is in turn rapidly inactivated by a2-antiplasmin, a single chain glycopro-
tein with a molecular weight of 70,000. The conversion of plasminogen into 
plasmin is enhanced by plasminogen activators. Tissue plasminogen activator 
and single and double chain urokinase-type plasminogen activator all have 
been identified as naturally occurring glycoproteins which catalyse the conver-
sion of plasminogen into plasmin. The release of plasminogen activators is 
under control of both central and local control mechanisms. Central control of 
plasminogen activator levels in blood is mediated by catecholamine release by 
either a nervous or a humoral pathway (2). Locally, plasminogen activators 
are probably released by the endothelium in response to local fibrin deposits. 
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Streptokinase 
Streptokinase, a single chain protein with a molecular weight of 46,000, is 
formed by hemolytic streptococci and has antigenic properties. Different 
theories exist about its mode of action. A first theory implies that strep-
tokinase diffuses into thrombi, where it forms equimolar complexes with 
fibrin-bound or penetrating plasminogen, and the resulting complexes further 
enhance the conversion of plasminogen into plasmin (3). A second theory 
states that complexes of streptokinase and plasminogen are formed in blood 
and diffuse into thrombi (4). A third theory suggests that fibrinolysis by 
plasminogen activator in the thrombus is enhanced after depletion of circula-
ting a2-antiplasmin ( 5). Dosage schedules for treatment of patients with acute 
myocardial infarction vary, according to the presumed mode of action ( 6). The 
first theory favours a high concentration of streptokinase in the vicinity of the 
thrombus, which can be best achieved by selective intracoronary application. 
The other theories presume systemic effects of streptokinase preceding its 
thrombolytic activity, favouring intravenous administration. However, in-
tracoronary administration of streptokinase leads to a higher patency rate of 
the infarct related coronary artery than intravenous streptokinase. In-
travenous administration of streptokinase, in dosages varying from 500,000 U 
to 1,500,000 U given over one hour, induced recanalisation of an occluded 
coronary artery in 10 to 62% of patients with acute myocardial infarction (7). 
Intracoronary administration of streptokinase (250,000 U) led under similar 
circumstances to recanalisation rates of 60 to 79% (chapter 11). In the present 
study no differences in final patency i:ate were observed between patients 
treated with 250,000 U of intracoronary streptokinase and those in which this 
treatment was preceded by intravenous application of 500,000 U strep-
tokinase, although initial patency rate rose from 18% to 41% (chapter 4). It 
may be concluded that although selective administration of streptokinase has 
systemic effects, its delivery in the vicinity of the thrombus is superior to 
systemic administration. 
Because of the antigenic properties of streptokinase, short term cor-
ticosteroid therapy has been used in an effort to suppress immunologic reac-
tions (chapter 4). However, in the GISSI trial (1,500,000 U of intravenous 
streptokinase) no steroids were given and allergic reactions were observed in 
only 2.5% of the patients (8). Patients who have suffered streptococci infec-
tions or have been treated previously with streptokinase may have high titers 
of antibodies against streptokinase. In those patients allergic reactions may 
occur and high dosages may then be required to saturate the antibodies. This is 
supported by our, unpublished, observation that in half of the patients with 
persistent occlusion after intracoronary administration of streptokinase there 
was no decrease in fibrinogen level. This finding is similar to that of others ( 6) 
and suggests that presently recommended dosages are insufficient in 10 to 20% 
of the patients, who neutralise streptokinase before thrombolysis has occur-
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red. Furthermore, the use of repeated doses of streptokinase is not advocated 
within 6 to 12 months after its original use, because of possible immunologic 
reactions. 
Urokinase 
Urokinase, a glycoprotein with a molecular weight of 55,000 is a naturally 
occurring protein, produced in the kidney and excreted with urine. It enhances 
the conversion of plasminogen into plasmin by direct proteolytic action and 
not by forming a stable complex with plasminogen as streptokinase does. Its 
other farmacological effects are similar to that of streptokinase, although it 
does not exhibit antigenic properties (9). Dosages vary from 500,000 to 
2,700,000 IU for intravenous administration and up to 700,000 IU for in-
tracoronary use in patients with acute myocardial infarction (9-11). Since the 
production of urokinase is expensive compared to that of streptokinase, its use 
is presently restricted for those patients who have previously been treated with 
streptokinase, or when the latter compound is shown not to have effect during 
intracoronary administration. 
Recombinant tissue-type plasminogen activator (rt-PA) 
Tissue plasminogen activator, a glycoprotein with a molecular weight of 
64,000, is present in practically all tissues. It has originally been isolated from 
human uterus (5). For investigational purposes it was subsequently produced 
by melanoma cell cultures, but recently recombinant DNA techniques have 
become available, leading to production on a large scale of recombinant tissue-
type plasminogen activator. Rt-PA exhibits clot selectivity (see below) and its 
capacity to induce patency in the infarct related coronary artery was demon-
strated to be superior to that of intravenous streptokinase with a lower 
incidence of bleeding complications (chapter 11). Effects of rt-PA on infarct 
size, left ventricular function and mortality in patients with acute myocardial 
infarction are currently subject to investigation in large, multicentre ran-
domised trials. A dosage of 100 mg, given over three hours, is recommended 
for patients with acute myocardial infarction. 
Anisoylated plasminogen-streptokinase activator complex (APSAC) 
APSAC, an acylated complex of streptokinase and plasminogen, is inert and 
does not induce fibrinolysis. It becomes capable of inducing fibrinolysis after 
slow deacylation. APSAC does not exhibit clot selectivity, but due to the slow 
deacylation it has a longer half life (approximately 30 minutes) than the other 
thrombolytic agents (on average 10 minutes). In relatively small series was 
reported that an intravenous bolus of APSAC (30 mg) induced patency in 64 to 
88% of patients with myocardial infarction with an incidence of bleeding 
complications comparable to that of streptokinase (chapter 11). 
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Recombinant single chain urokinase-type plasminogen activator (rscu-PA) 
Single chain urokinase-type plasminogen activator was once considered to be 
an inactive precursor form of urokinase, but it is now known that the single 
chain form has plasminogen activator activity. Its clot selective fibrinolytic 
properties have been demonstrated in vitro (12), in animal experiments (13-
15) and in patients with acute myocardial infarction (16-18). A bolus of 10 mg 
followed by intravenous infusion of 60 mg rscu-PA over one hour has induced 
patency of the infarct related coronary artery in 13 out of 17 patients (76%) 
without significant bleeding complications (17). In larger clinical trials, which 
are presently underway, the efficacy and safety of rscu-PA will have to be 
demonstrated before its use in patients with myocardial infarction can be 
recommended. 
THE FIBRINOlYTIC SYSTEM 
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Figure 2.1 
Reaction A: Conversion of plasminogen into plasmin. This reaction is enhanced by fibrinolytic 
agents. 
Reaction B: Inactivation of free plasmin by alpha2-antiplasmin. 
Reaction C: Fragmentation offibrine into soluble fibrin degradation products (clot resolution). 
Reaction D: Fibrinogenolysis, leading to a "general lytic state" with markedly impaired blood 
coagulation and augmented risks of bleeding. 
Clot selectivity 
Thrombolytic agents that do not show clot selectivity (streptokinase, APSAC 
and urokinase) enhance the conversion of plasminogen into plasmin (reaction 
A in the figure), almost independent of the presence of fibrin. Consequently, 
therapeutic dosages of these drugs convert practically all available 
plasminogen into plasmin. High doses of plasmin enter the circulation, leading 
to depletion of alpha2-antiplasmin (reaction B), and to proteolytic degrada-
tion of fibrin deposits (reaction C). Free plasmin has fibrinogenolytic proper-
ties resulting in dep~etion of fibrinogen (reaction D), thereby creating a 
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"general lytic state" in which blood coagulation is markedly impaired and 
bleeding risks are augmented. This general lytic state lasts for 24 to 48 hours, 
before alpha2-antiplasmin and fibrinogen levels return to normal (18). The 
recently developed clot selective thrombolytic agent rt-P A has a low affinity 
for plasminogen in the absence of fibrin, but the affinity and the rate of 
conversion of plasminogen into plasmin increase markedly (50 to 500 times) in 
the presence of fibrin (19). The background of the clot selectivity of rscu-PA is 
less well understood. The presence of a rscu-PA inhibitor in plasma has been 
postulated (20), while in another study a higher affinity of rscu-PA to fibrin 
bound plasminogen rather than to free plasminogen was observed (21). 
Because of clot selectivity systemic depletion of fibrinogen occurs less and 
plasminogen, alpha2-antiplasmin and fibrinogen levels in serum decrease only 
to a lesser extent than after use of streptokinase, APSAC or urokinase (22, 
23). 
Conclusions 
Therapeutic enhancement of fibrinolysis may be beneficial when blood supply 
to tissue is menaced by thrombotic obstruction in the vascular bed. Nowadays, 
thrombolytic therapy is used or proposed in the treatment of acute myocardial 
infarction, unstable angina pectoris, peripheral artery thrombosis, pulmonary 
embolism and deep vein thrombosis. The major part of our present knowledge 
about the risks and benefits of thrombolytic therapy has been derived from 
studies with streptokinase and urokinase. It is only in the last decade that other 
thrombolytic agents have been developed which differ in their mode of action 
from streptokinase and urokinase. The efficacy, costs, and safety of these 
newer fibrinolytic agents should be compared with the presently available 
methods for thrombolytic therapy in acute myocardial infarction, before 
recommendations can be given as to what might be considered optimal therapy 
for these patients. 
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CHAPTER3 
Study design 
Status of thrombolytic therapy in 1981 
In 1979 Rentrop and co-workers demonstrated that early recanalisation of an 
occluded coronary artery could be achieved with intracoronary infusion of 
streptokinase, a finding later confirmed by others (1-3). Also it was observed 
that successful reperfusion led to improvement in left ventricular function, and 
left ventricular ejection fraction appeared to be higher in successfully 
recanalised patients than in patients with persistent occlusion of the infarct 
related artery ( 4-6). Furthermore, data from animal experiments had indi-
cated that reperfusion within hours after the onset of myocardial infarction 
could lead to limitation of infarct size (7). On the other hand, serious complica-
tions of the interventions were also reported, such as fatal complications 
during acute angiography, severe bleeding and intramyocardial hemorrhage 
(5, 8, 9). It was also pointed out that results of large scale clinical trials with 
intravenous streptokinase or urokinase had not been unequivocally in favour 
of thrombolytic therapy (10-13). Warnings were sounded that beneficial 
effects of thrombolytic therapy had not been proven and that the expected 
benefits should be compared with the potential risks of the procedure in 
randomised clinical trials before its use could be recommended (14,15). For 
this reason a large randomised clinical trial was planned at the Thoraxcenter in 
Rotterdam. Before the trial started three pilot studies were performed (9, 16). 
Results of pilot studies 
The pilot studies were performed in 1980 and 1981. In six patients recanalisa-
tion was attempted with intravenous niphedipine and intracoronary 
nitroglycerine. The infarct related artery was occluded in five patients and 
recanalisation was achieved in one. In nine patients recanalisation was 
attempted with intracoronary urokinase (250,000 U). An occluded coronary 
artery was successfully recanalised in two out of eight patients (25%). More 
favourable results were obtained in a study with intracoronary streptokinase 
(250,000 U), in which 37 patients were enrolled. Four patients died from 
irreversible cardiogenic shock during acute cardiac catheterisation. One pa-
tient with a large anterior infarction developed severe bradycardia followed by 
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asystole when after left ventriculography right coronary arteriography was 
performed prior to the initiation of thrombolytic therapy. Two patients with an 
occluded left anterior descending artery suddenly developed severe hypoten-
sion and asystole during intracoronary infusion of streptokinase. Angiography 
revealed embolisation of a part of the thrombus from the left anterior descen-
ding artery into the left circumflex artery. The fourth patient was known with 
severe three vessel disease with an occluded left anterior descending artery. 
This patient suffered an acute inferior wall infarction during hospitalisation. 
During intracoronary infusion of streptokinase in the occluded right coronary 
artery severe hypotension developed, followed by electromechanical dissocia-
tion and death (9). In 27 of the remaining 33 patients an occluded infarct 
related artery was found which could be reperfused in 19 patients (70%). It 
was further observed in that study that the time interval between initiation of 
thrombolytic therapy and angiographic documentation of vessel patency was 
related to the delay between onset of chest pain and initiation of therapy. Lysis 
time was less than 30 minutes when thrombolytic therapy was started within 
three hours after onset of symptoms and considerably longer when treatment 
delay exceeded four hours. 
From these pilot studies several important lessons were learned. In the pilot 
studies the best results were obtained with intracoronary streptokinase in a 
dosage of 250,000 U. The preliminary results of the study with urokinase were 
disappointing. It appeared later, however, that the urokinase given contained 
mostly the low molecular weight form of urokinase with less activity than the 
high molecular weight form (17). Probably, the dosage given (250,000 U) was 
roughly equal to 100,000 Ploug Units, which can explain the low reperfusion 
rate observed (25% ). It was decided that streptokinase would be used in the 
randomised trial in a dosage of 4,000 U/min with a maximum of 250,000 U. 
Furthermore it was observed that the risks of acute angiography increased 
dramatically when contrast was injected into the non infarct-related artery or 
in the left ventricle before reperfusion was achieved, especially in patients with 
large anterior infarction. It was decided that angiography would begin with the 
infarct related coronary artery followed by intracoronary infusion of strep-
tokinase. Left ventricular angiography would only be performed in patients 
with a clinically stable condition at the end of the procedure who had a left 
ventricular enddiastolic pressure below 35 mm Hg. The pilot studies proved 
the feasibility of a randomised trial. Based on the observed relation between 
lysis time and treatment delay it was decided that only patients admitted to the 
hospital within four hours after onset of chest pain would be enrolled in the 
present study. 
Study design 
The purpose of the randomised trial was to analyse the difference between two 
strategies in the treatment of myocardial infarction. A strategy aimed at early 
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reperfusion, including angiography and administration of intracoronary strep-
tokinase, would be compared with conventional treatment of myocardial 
infarction without acute angiography and without administration of fibrinoly-
tic therapy. Consequently, this was an open study. The random assignment 
was known to the investigators and comparisons between the effects of both 
strategies could be made while the trial was still in progress. At the start of the 
trial the organisers realised that thrombolytic therapy was still in its infancy. It 
was expected that improvements of the intervention might arise during the 
trial. Therefore, modifications of the protocol would be allowed, if during the 
trial insights how to achieve optimal reperfusion would alter. The modifica-
tions in the protocol will be referred to as policy decisions. 
Patient selection and randomisation 
Patients were eligible for the trial if admitted to the hospital within four hours 
after onset of chest pain and with electrocardiographic signs typical of acute 
myocardial infarction: ST segment elevation of at least 0.1 m V in one or more 
extremity leads, at least 0.2 m V in one or more precordial leads, or at least 0.2 
m V ST segment depression in one or more precordial leads compatible with 
posterior infarction. Several categories of patients were excluded from the 
trial: patients who had previously been treated with streptokinase, since its 
repeated use might cause allergic reactions; patients with enhanced risks of 
bleeding, such as patients over 70 years of age, patients with a history of 
gastrointestinal bleeding, gastric or duodenal ulcer, hematuria or cerebral 
vascular accident within the last three months, patients with recent trauma 
including prolonged cardiac resuscitation, and female patients currently 
menstruating or pregnant. Furthermore, patients with previous bypass surgery 
in a vessel corresponding to the infarct location were excluded since it might be 
uncertain in which vessel streptokinase should be infused. Finally, patients 
who had previously been admitted to the study and patients in whom in-
complete follow-up was anticipated were excluded from the study for 
methodological reasons. These exclusion criteria were rather strict since 
benefits of early thrombolytic therapy had not been proven. In summary, only 
patients with specific electrocardiographic signs of acute myocardial infarction 
without any indication of enhanced risks of complications were admitted to the 
study. Details about the treatment protocol are presented in chapter 4. Until 
May 1983 envelopes containing random treatment allocation were provided by 
the data centre and stored in the participating centres. Since June 1983 patients 
who met the inclusion criteria were registered by a central telephone answer-
ing service. The responsible physician provided administrative data including 
hospital name, patient initials, gender, date of birth, and clinical state. The 
answering service then opened a randomisation envelope and provided treat-
ment allocation. Informed consent was sought from patients allocated to 
thrombolytic therapy only. This method, proposed by Zelen (18), is useful in 
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the evaluation of a new therapy. Randomisation took place before informed 
consent had been obtained. Patients allocated to thrombolytic therapy were 
informed about the possible benefits of early reperfusion and about the risks 
and inconveniences of acute coronary angiography and were asked for con-
sent. Patients who refused consent were treated with conventional therapy, 
but included in the analysis according to original treatment allocation. 
Interim analyses and policy decisions 
Patient recruitment started June 1981 at the Thoraxcenter in Rotterdam. 
Preliminary data indicated that reocclusion of a coronary artery after success-
ful thrombolysis was related to the severity of the residual stenosis (19). In 
September 1981 it was decided that immediate PTCA might be attempted as 
part of the recanalisation procedure in patients with a residual diameter 
stenosis of 70% or more in the infarct related coronary artery after successful 
thrombolysis. 
In 1982 a second policy decision was taken that the trial would be extended 
with other hospitals to enhance patient recruitment. A consequence of this 
decision was that immediate PTCA would not be obligatory, since this pro-
cedure could be performed in only two hospitals. Participation in the trial was 
extended with three hospitals in 1983 (the Hospital of the Free University of 
Amsterdam, the Zuiderziekenhuis in Rotterdam and the University Hospital 
in Maastricht). A first interim analysis was performed in 1983, when 234 
patients were admitted to the trial and results were presented from the first 150 
patients admitted to the trial in the Thoraxcenter (20). These results indicated 
that final patency of the infarct related artery was obtained in 84% of the 
patients who underwent acute angiography, that thrombolytic therapy seemed 
to result in limitation of enzymatic infarct size measured by cumulative alpha-
hydroxybutyrate dehydrogenase release (see chapter 5) and that left ventricu-
lar ejection fraction measured by contrast angiography was higher in the 
thrombolysis group than in the control group (table; group I). Three months 
mortality was not significantly different between the two treatment groups. 
In 1983 other studies reported successful recanalisation by means of early 
intravenous infusion of streptokinase (21). Since it was the strategy of this trial 
to achieve optimal reperfusion, a third policy decision was taken in 1983 that 
acute catheterisation would be preceded by infusion of 500,000 U strep-
tokinase intravenously over 20 minutes, to be given immediately upon hospital 
admission. Analysis of the data had shown a treatment delay of 60 minutes or 
more between admission to the coronary care unit and initiation of intracoro-
nary infusion of streptokinase in the catheterisation laboratory. Furthermore, 
bleeding after intracoronary streptokinase had mainly been limited to the 
angiography puncture site and bleeding risks after pretreatment with in-
travenous streptokinase were considered acceptable. A second interim 
analysis was performed in 1984, in which the results were analysed from all 
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.j:>. Table 3.1 Interim analyses 
Group I 
Group II 
Group I+II 
Group III 
All 
Group I : 
Group II: 
Group III: 
Three months 
n final median HBDH (U/1) median LVEF (%) mortality (%) 
c T patency c T p c T p c T p 
--
74 76 84% 980 720 0.02 47 55 0.0002 14 11 0.6 
76 76 82% 1120 790 0.006 49 56 0.07 9 8 0.9 
150 152 83% 1040 760 0.0004 48 56 O.Dl 11 9 0.6 
114 117 87% 1270 780 0.02 47 54 0.0001 15 4 0.007 
264 269 85% 1100 770 0.0001 47 53 0.0001 13 7 0.02 
The first 150 patients admitted to the trial in the Thoraxcenter (1981 to 1983). 
135 patients admitted in 1983 in the other hospitals, and 17 patients admitted late 1983 in the Thoraxcenter. 
231 patients admitted in 1984 and 1985 in all participating centres. 
Abbreviations: n: number of patients; C: control group; T: allocated to thrombolytic therapy; HBDH: alpha-hydroxybutyrate dehydrogenase; 
LVEF: left ventriculair ejection fraction. 
patients admitted to the study before the pretreatment with intravenous 
streptokinase was added to the protocol (table; group I+ II). 
In 1984 it was decided that at least 200 more patients would have to be 
recruited after the addition of the intravenous pretreatment to the protocol. 
This number of patients was required to allow an analysis of the effects of this 
additional intervention. Late in 1984 the participation was extended with the 
University Hospital in Lei den. Patient recruitment ended March 15, 1985. The 
results of the trial are discussed in the next chapters. 
Data analysis 
Data were recorded with the Thoraxcenter Utility System (TUS), running 
under a DSM operating system on a PDP 11/70 computer. Parts of the data 
were converted to another PDP 11/70 computer running under a RSX opera-
ting system, on which access was available to a BMDP statistical software 
package. Data were expressed in most cases as median values with first and 
third quartiles, in some cases as means with standard deviation. Differences 
between groups were tested with Fisher's exact test, Mann Whitney's rank sum 
test or Student's T-test, when appropriate. Differences between survival 
curves were analysed with the Mantel-Cox test. Two-sided p values are 
reported. 
Discussion 
The strategy chosen for this trial was based on the comparison of two options 
in the treatment of acute myocardial infarction: an attempt at reperfusion of an 
occluded coronary artery or "standard" treatment without acute angiography. 
This resembles the decision the attending physician must make when a patient 
with acute myocardial infarction is admitted to the hospital. The decision 
whether or not to attempt reperfusion must be based on information available 
shortly after hospital admission (medical history, physical examination and 
electrocardiogram) and not on results of coronary angiography. So, the results 
of the present trial were analysed according to the intention-to-treat principle. 
In this trial informed consent was asked from patients allocated to thromboly-
tic therapy only. This differed from the "classical approach" whereinformed 
consent is asked prior to randomisation. However, it was considered unethical 
to discuss the potential benefits and risks of thrombolytic therapy with cri-
tically ill patients who would eventually not receive this therapy. The patients 
in the control group were treated according to the, at that time, standard 
therapy for acute myocardial infarction and no informed consent was asked for 
any new or "experimental" therapy. A consequence of this approach was that 
patients allocated to thrombolytic therapy who refused consent were treated 
conventionally but included in the analysis according to their original treat-
ment allocation. This method of randomisation does not lead to loss of 
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statistical power compared to the "classical approach" where informed con-
sent is asked before randomisation (22). It should be realised that exclusion 
from the analysis of patients who refused consent or in whom thrombolytic 
therapy was withheld for other reasons would introduce a bias into the data, 
since for example patients who refuse consent may well differ from patients 
who do give informed consent. In fact, two categories of patients often refused 
to undergo acute angiography: patients in whom chest pain had already 
markedly diminished and patients who felt very ill and "wanted to be left 
alone". 
Much knowledge about thrombolytic therapy and the optimal way to 
achieve reperfusion became available while the trial was in progress. This 
information could not be neglected and modifications of the protocol were 
introduced. However, the main strategy of the trial, a comparison between 
attempted reperfusion and conventional therapy, was maintained during the 
entire study. Also, the results of the interim analyses showed a high grade of 
consistency. In all subgroups final patency was achieved in more than 80% of 
the patients who underwent acute angiography, a 30% limitation of enzymatic 
infarct size by thrombolytic therapy was observed, left ventricular ejection 
fraction was higher in the thrombolysis group than in the control group, and 
three months mortality was higher in the latter. Thus, the results of the present 
trial were not modified by the successive policy decisions. Only the statistical 
significance of the results reached higher values when more patients were 
admitted to the trial. The inference drawn from the results of this trial is 
discussed in chapter 11. 
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CHAPTER4 
COOPERATIVE STUDIES 
Early Thrombolysis in Acute Myocardial Infarction: Limitation of 
Infarct Size and Improved Survival 
MAARTEN L. SIMOONS, MD, FACC, PATRICK W. SERRUYS, MD, 
MARCEL VAN DEN BRAND, MD, JAN RES, MD, FREEK W. A. VERHEUGT, MD, FACC, 
X. HANNO KRAUSS, MD, WILLEM J. REMME, MD, FRITS BAR, MD, CHRIS DE ZWAAN, MD, 
ARNOUD VANDER LAARSE, PHD, FRANK VERMEER, MD, JACOBUS LUBSEN, MD, 
for the Working Group on Thrombolytic Therapy in Acute Myocardial Infarction of the Netherlands 
Interuniversity Cardiology Institute* 
Rorterdam. The Netherlands 
The effect of thrombolysis in acute myocardial infarction 
on infarct size, left ventricular function, clinical course 
and patient survival was studied in a randomized trial 
comparing thrombolysis (269 patients) with conventional 
treatment (264 control patients). All 533 patients were 
admitted to the coronary care unit within 4 hours after 
the onset of symptoms related to the infarction. Baseline 
characteristics were similar in both groups. Informed 
consent was requested only of patients allocated to 
thrombolysis; no angiography was performed in 35. The 
infarct-related artery was patent in 65 patients and oc-
cluded in 169. Recanalization was achieved in 133 pa-
tients. The median time to angiographic documentation 
of vessel patency was 200 minutes after the onset of 
symptoms. 
The clinical course in the coronary care unit was more 
favorable after thrombolysis. Infarct size, estimated from 
myocardial enzyme release, was 30% lower after throm-
bolysis. In patients admitted within 1 hour after the onset 
of symptoms the reduction of infarct size was 51%, in 
those admitted between I and 2 hours it was 31% and 
in those admitted later than 2 hours it was 13%. Left 
Myocardial infarction in most patients results from a throm-
botic occlusion of a major coronary artery. Recently, Ren-
trop and other investigators (1-4) have demonstrated that 
rapid recanalization can be achieved by intracoronary in-
*A listing of Participating Centers and Collaborators is presented at 
the end of the text. 
From the Thoraxcenter, Erasmus University, Rotterdam, The Neth-
erlands. 
Manuscript received July 23, 1985: revised manuscript received De-
cember 2. 1985. accepted December 13, 1985. 
Address for reprints: Maarten L. Simoons. MD. Thoraxcenter, BD 
434. Erasmus University. PO Box 1738. 3000 DR Rotterdam. The Neth-
erlands. 
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ventricular function measured by radionuclide angiog-
raphy before hospital discharge was better after throm-
bolysis (ejection fraction 48 ± 15%) than in control 
patients (44 ± 15% ). Similar improvement was ob-
served in patients with a first infarct only (thrombolysis 
50 ± 14%, control subjects 46 ± 15% ), in patients with 
anterior infarction (thrombolysis 44 ± 16%, control 
subjects 35 ± 14%) and in those with inferior infarction 
(thrombolysis 52 ± 12%, control subjects 49 ± 12%)_ 
Similar results were obtained by contrast angiography. 
Mortality was lower after thrombolysis. After 28 days 
16 patients allocated to thrombolysis and 31 control pa-
tients had died. One year survival rates were 91 and 
84%, respectively. On the other hand, nonfatal rein-
farction occurred more frequently after thrombolysis (36 
patients) than in control subjects (16 patients). Early 
thrombolysis by intracoronary streptokinase leads to a 
smaller infarct size estimated by enzyme release, pre-
serves left ventricular function at the second week and 
leads to improved 1 year survivaL 
(}Am Col/ Cardio/1986;7:717-28) 
fusion of streptokinase in approximately 80% of patients. 
Because early editorials called for caution (5-7), we initi-
ated in May I 981 a randomized trial to compare a straiegy 
aimed at early recanalization by intracoronary administra-
tion of streptokinase with conventional treatment in the coro-
nary care unit. The primary objective was to study the effect 
of the intervention on mortality and morbidity after myo-
cardial infarction. In addition we analyzed the effect of 
attempted thrombolysis on infarct size and left ventricular 
function measured by various methods. 
Because the aim of thrombolysis is rapid restoration <Jf 
blood flow to the jeopardized myocardium to preserve eel-
0735-1097/86/$3.50 
Table I. Distribution of Patients and Results of Angiography and Thrombolysis in the Four 
Participating Hospitals 
Control Thrombolysis No 
Coronary Patency+ 
Group Group Angiography* o~o •~o ·~· Thorax center 118 119 13 24 69 13 
St. Annada! 62 61 17 26 II 
Free University 46 47 10 19 
Zuiderziekenhuis 28 33 II 15 
Leiden University 10 3 4 
Total 264 269 35 65 133 36 
lntracoronary !50 !52 16 25 88 23 
thrombolysis 
Intravenous and 114 117 19 40 45 13 
intracoronary 
thrombolysis 
*Angiography was refused by or contraindicated in 35 patients. +The infarct-related vessel was open and 
remained open in 65 patients (0- OJ: recanalization of an occluded vessel was achieved in 133 patients 
(0- OJ. while the occlusion persisted in 36 patients (CP .._ Ol. Coronary angioplasty was attempted in 46 
patients and succeeded in 44. Note the greater fraction of patients with an open infarct-related vessel at 
angiography after pretreatment with intravenous streptokinase (40 [41 9cj of98 patients) than in patients without 
such treatment (25 [ 189c] of 136 patients). 
Table 2. Baseline Data in 533 Patients 
Number of patients 
Male 
Age (yrl (mean :::!::: SO) 
History 
Angina longer than 4 weeb. 
Angina Jess than 4 weeb. 
Previous myocardial infarction 
Previous bypass surgery 
Maintenance therapy 
None 
Anticoagulant thcr..tpy 
Beta-blockers 
Calcium antagonists 
Long-acting nitrates 
Digoxin 
Diuretic drug~ 
Therapy before admis:-.ion 
None 
Analge:-.ic:-. 
Antiarrhythmic agents 
Beta-blockers 
Calcium antagonists 
Nitrates 
Resuscitation 
Hemodynamic state 
Heart rate (beats/min) 
Systolic blood pressure (mm Hgl 
Diastolic blood pressure (mm Hg) 
Mild heart failure (no.) 
Acute congestive failure (no.) 
Shock (no.) 
Control 
Group 
264 
224 !85) 
55 ± 8 
74 128! 
91 134) 
60 123! 
8 !31 
143 1541 
II 141 
64!241 
31 1121 
47 !18! 
6 121 
16 161 
134 !51! 
57 (22) 
14!5) 
17 161 
24191 
87 !331 
5 (2) 
74 ± 16 
131 :::!::: 27 
84 :::!::: 20 
40 (!51 
2!11 
9 13) 
Thrombolysis 
Group 
269 
217 !811 
56 :::!::: 9 
69 126! 
89 1331 
56 !211 
5 121 
146 1541 
20 (7) 
62 1231 
31 I 121 
49 I lSI 
8 !31 
30 ill} 
133 1491 
57 !211 
II 141 
13 151 
28 (101 
79 1291 
7 131 
74 ± 17 
131 ± 30 
83 :!: 20 
40 (15) 
I 10.5) 
II 141 
The actual numbers in each group are presented: percentages are shown 
in parentheses. 
lular integrity and function, time must be a crucial factor 
limiting the salutary effects of thrombolysis. When it be-
came evident that preparation of the catheterization labo-
ratory and introduction of the catheter delayed streptokinase 
infusion by approximately I hour, pretreatment with intra-
venous streptokinase was given to patients who entered the 
trial after December 31. 1983 (4,8-10). The intake was 
completed in March 1985 after entry of 533 patients. Details 
of the design of the study and preliminary data were reported 
in 1982 ( 11-13). 
Recently. we reported ( 14) that short-term and I year 
survival rates were significantly improved after thrombo-
lysis. The data presented in this final report demonstrate 
that improved survival after early thrombolysis in acute 
myocardial infarction is indeed associated with a reduction 
of infarct size and with preservation of global left ventricular 
function. Furthermore. regional wall motion after throm-
bolysis appeared to be better than in the control group (15). 
Methods 
Patient selection. Patients were eligible for the trial if 
they were admitted to one of the participating coronary care 
units within 4 hours after the onset of chest pain lasting 20 
minutes or more and with electrocardiographic signs com-
patible with myocardial infarction (11-14). ST segment el-
evation of 0.2 mY or greater had to be present in one of 
the precordial leads or 0.1 mY in a limb lead, or both. 
despite treatment with oral or intravenous nitroglycerin or 
nifedipine. or both. In addition, patients were included with 
0.2 mY or greater ST segment depression in precordial 
leads. compatible with posterior wall infarction. 
19 
100 
Patency~ 
cath.labarrlval' * 
80 
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50 120 180 300 350 420 min 
Figure 1. Cumulative distributions of the intervals between the 
onset of symptoms and hospital arrival ( +-+ ). arrival in the 
catheterization laboratory (cath. lab) (.~-A) and angiographic 
confirmation of a patent infarct-related artery (0-0) when ap-
propriate. 
Exclusion criteria were: I) age ov~r 70 years: 2) previous 
treatment with streptokinase: 3) bypass surgery of the ves-
sels corresponding to the infarct location: 4) recent trauma 
including traumatic resuscitation: 5) a history of gastroin-
testinal bleeding, ulcer, hematuria or a cerebrovascular ac-
cident within 3 months: 6) pregnancy or menstruation: and 
7) mental confusion that precluded informed consent. 
Treatment protocol. Eligible patients who did not meet 
the exclusion criteria were registered by a central telephone 
answering service. The responsible physician provided ad-
ministrative data including hospital name, patient's initials, 
sex. date of birth and clinical state. The answering service 
then opened the randomization envelope and provided treat-
ment allocation. Informed consent was asked only of pa· 
tients allocated to thrombolytic treatment ( 16). Patients who 
refused consent were treated according to the conventional 
treatment protocol. but were included in the analysis ac-
cording to original treatment allocation. The study protocol 
was approved by the board of the Netherlands Interuniv-
ersity Cardiology Institute. 
In all patients treatment was directed to an "optimal" 
hemodynamic state characterized by sedation, a heart rate 
between 60 and 90 beats/min. systolic blood pressure be· 
tween I 00 and 140 mm Hg and absence of left ventricular 
failure. including pulmonary capillary wedge pressure less 
than 12 mm Hg when hemodynamic monitoring was used. 
Guidelines for treatment have been described in detail ( 17) 
and included the use of intraaortic balloon counterpulsation 
for treatment of can;liogenic shock. 
All patients were treated with intravenous heparin fol-
lowed by acenocoumarol (Sintrom) until hospital discharge. 
After discharge anticoagulant agents were continued only 
in patients with ventricular aneurysm, mitral incompetence 
or a large left ventricle with a poor contraction pattern. Beta-
receptor blockers were prescribed in the majority of patients 
starting between 7 and 14 days unless contraindications were 
present. Other therapy was prescribed as needed. 
Thrombolytic therapy. After giving informed consent, 
patients received intravenous nitroglycerin in a dose that 
reduced systolic blood pressure to I 00 to 120 mm Hg, as 
well as lidocaine. 2 mg/min, 5,000 U heparin, 250 mg 
acetylsalicylic acid and 100 mg prednisolone (13). Coronary 
angiography was performed with the Judkins technique. If 
the infarct-related artery was occluded, streptokinase was 
given at a rate of 4,000 U/min until all visible clot disap-
peared. Usually a maximum of 250,000 U was given. Sub-
selective catheterization of the occluded coronary branch of 
the left coronary artery or mechanical perforation of the clot 
was employed in a few patients. After completion of strep-
tokinase infusion, complete left and right coronary arteri-
Table 3. Degree of Obstruction* in the Coronary Arteriograms Before and After 
Attempted Reperfusion 
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Normal 
Less than 50% 
50 to 90% 
90 to 99% 
Occlusion 
Normal 
Less than 50% 
50 to 90% 
90 to 99% 
Occlusion 
First Angiogram After Streptokinao.;e 
Infarct-Related Artery Without Intravenous Streptokinase 
19 
Ill 
II 
25 
58 
40 
69 
22 
With Prior Intravenous Streptokinase 
28 
45 
18 
After Streptokinase Plus 
Coronary Angioplastyt 
26 
31 
56 
23 
19 
27 
37 
13 
*Visual analysis of the severity of the lesion in the infarct-related vessel. expressed as percent diameter 
steno~is. tPercutaneous transluminal coronary angioplasty was attempted in 27 patients without and in 19 
patients after pretreatment with intravenous streptokinase. 
Table 4. Clinical Course in Hospital 
Control 
Group 
No. of patients 264 
Hospital mortality (14 days) 26 
Recurrent infarction ( 14 days) 9 
Angina pectoris 55 
Hean failure (coronary care unit) 
Mild 55 
Severe 12 
Shock 24 
Dopamine/dobutamine 42 
treatment 
Respiratory support II 
lntraaortic balloon pump 10 
Heart failure during 53 
convalescence 
Ventricular fibrillation 61 
Pericarditis 46 
Bleeding 
Coronary angioplasty 
Bypass surgery 16 
Thrombolysis 
Group 
269 
14 
12 
57 
54 
10 
13 
26 
16 
37 
38 
19 
53 
59* 
29 
p Value 
0.05 
0.03 
0.05 
0.01 
0.0004 
0.0001 
Percutaneous transluminal angioplasty was performed more frequently 
in the thrombolysis group when the 46 patients with angioplasry imme-
diately after thrombolysis are included (*). Only p values of 0.05 or less 
are reported. 
ography was performed. In some of the patients with severe 
residual stenosis of the infarct-related coronary artery, per-
cutaneous transluminal coronary angioplasty was attempted 
as part of the recanalization procedure. Subsequently, ni-
troglycerin and lidocaine infusions were withdrawn. Admin-
istration of heparin was started as soon as measured recal-
cification time was less than 6 minutes. Starting in January 
1984 thrombolytic treatment was instituted immediately after 
informed consent was obtained witb injections of acetyl-
salicylic acid and prednisolone followed by 500,000 U strep-
tokinase intravenously over lO to 20 minutes. The patient 
100 % 
80 
50 
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was then prepared for cardiac catheterization and treated as 
described earlier. 
Post-therapy procedures. Serum alpha-hydroxybutyric 
dehydrogenase enzyme determinations were made on ad-
mission, every 12 hours during 2 days and then every 24 
hours until 5 days after admission. Cumulative release of 
alpha-hydroxybutyric dehydrogenase was calculated from 
these data as described earlier (!8). In two hospitals total 
lactate dehydrogenase was measured instead and converted 
to alpha-hydroxybutyric dehydrogenase by exchange of 
standards. 
Radionuclide angiography was carried out at the bedside 
on the first, second or third day after admission and repeated 
before hospital discharge and after 3 months. Gated images 
were obtained with 20 frames in each cycle after in vivo 
labeling witb 15 mCi technetium-99m. Data were analyzed 
by a fully automated computer program on a DEC-gamma 
II or an ADAC system ( 19) or with an MDS or Philips 
data analysis system. 
Before hospital discharge all patients in both groups were 
offered coronary arteriography. From the left cineventric-
ulogram in the right anterior oblique projection, left ven-
tricular ejection fraction and regional wall motion were mea-
sured (15). 
Follow-up. All patients were followed up at the out-
patient clinic for at least l year after admission. Recurrent 
myocardial infarction. angina pectoris, cardiac failure, by-
pass surgery and coronary angioplasty as well as prescribed 
medication were recorded. In addition. survival status was 
assessed for all patients at 6 month intervals: 
Statistical analysis. Data analysis was based on the 
"intention to treat" principle. Thus. patients who refused 
early angiography were analyzed as part of the thrombolysis 
group, according to the original treatment allocation. Dif-
ferences between the two groups were tested with the chi-
square test, Student's t test or Mann-Whitney test when 
appropriate. Two-sided p values are reported. 
,. tnrombolysts 
• controls 
Figure 2. Cumulative distributions of infarct size 
determined from serial alpha-hydroxybutyric dehy-
drogenase measurements in control patients ( e-e) 
and in patients allocated to thrombolysis (A-A). 
Patients who died before completion of the meas-
urements have been included as the largest infarct 
sizes (t) as discussed in the text. The median re-
duction of infarct size after thrombolysis is 30% 
(p = 0.0001 Mann-Whitney test). 
+---------~J~o~oo~--------~2~oo~o----------=Jo:'oo~---------~o 
HBDH u/l 
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more, similar results were obtained when the patients who 
died within 72 hours were not included in the analysis and 
when data from the five hospitals were analyzed separately. 
Median values for alpha-hydroxybutyric dehydrogenase in-
farct size in control and thrombolysis patients were I, I 00 
and 770 U/liter, respectively. In patients with a first infarct 
these values were 1,140 and 790 U/liter, respectively, in 
anterior wall infarction 1,280 and 840 U/liter, respectively 
and in inferior wall infarction 970 and 670 U/liter, respec-
tively. In Figure 3 alpha-hydroxybutyric dehydrogenase re-
lease is shown in relation to the interval between the onset 
of symptoms and hospital admission. In patients allocated 
to the control group, alpha-hydroxybutyric dehydrogenase 
release was independent of the interval between the onset 
of symptoms and admission. On the other hand, we found 
smaller enzyme release in patients allocated to thrombolysis 
within 2 hours after the onset of symptoms. These data 
indicate a 51% reduction of infarct size by thrombolysis in 
patients admitted within I hour, a 31% reduction of infarct 
size in those admitted between 1 and 2 hours and a 13% 
reduction in patients admitted between 2 and 4 hours after 
the onset of symptoms. 
Left ventricular function (Table 5). Left ventricular 
ejection fraction was measured by radionuclide angiography 
between day 2 and day 4 in 418 patients and before hospital 
discharge in 361 patients. Missing data were equally dis-
tributed between the two treatment groups and were due to 
death, transfer to other hospitals. patient refusal, unavail-
ability of the gamma camera or other administrative reasons. 
There was no change in global left ventricular ejection frac-
tion between the second day and hospital discharge in the 
control group. In the thrombolysis group left ventricular 
ejection fraction before discharge was 3.7 ± 9.0% higher 
than the first measurement. Accordingly. ejection fraction 
after 10 to 20 days was approximately 4% higher when 
thrombolysis was compared with conventional treatment. 
This difference was significant in the whole group, in pa-
tients treated with intracoronary thrombolysis only, in pa-. 
tients with a first infarction and in those with anterior in-
Table 6. Clinical Follow-Up 
Control Thrombolysis 
Group Group 
No. of patients 264 269 
Death 42 23 
Reinfarction 16 36 
Acute PTCA 46 
Late PTCNCABG 40 62 
farction. Similarly, a 6% greater ejection fraction was found 
during cardiac catheterization in the thrombolysis group. 
Again these differences were similar in patients with a first 
infarct only and in patients with anterior wall or inferior 
wall infarction on admission and in both treatment protocols 
(15). 
Follow-up (Tables 6 and 7). Clinical follow-up ranged 
from I to 48 months after admission. There was a 45% 
reduction of mortality after thrombolysis. This was offset 
by a higher incidence of late reinfarction and more frequent 
performance of late coronary angioplasty or bypass surgery 
after thrombolysis. The reduction in mortality was present 
in all subgroups, and it was similar in all five hospitals. 
The subgroup of patients without early angiography and 
those in whom recanalization failed fared worse than those 
in whom recanalization was achieved. On the other hand, 
there was only I death in 65 patients with a patent infarct-
related vessel at angiography and also I death in 46 patients 
in whom coronary angioplasty was performed immediately 
after thrombolysis. This particular patient underwent throm-
bolysis and angioplasty of the left anterior descending ar-
tery. Despite treatment with anticoagulant agents and ni-
fedipine, he developed postinfarction angina. After 7 days 
the artery was reoccluded at the same site and coronary 
angioplasty was repeated. After 31 days the patient devel-
oped a new anteroseptal infarction and died from intractable 
cardiogenic shock. 
Discussion 
The primary aim of the present study was the analysis 
of the effect of early thrombolysis on the clinical course 
and survival of patients with acute myocardial infarction. 
The results demonstrate that thrombolysis in the first hours 
after the onset of infarction can reduce myocardial damage 
and thus preserve part of the function of the left ventricle 
and improve patient survival. In one other randomized trial 
(20,21) there was a similar improvement in survival, al-
though left ventricular function and infarct size appeared 
No 
Thrombolysis 
Angiography* o~o e~o ·~· 35 65 133 36 
8 
4 21 
13 31 
18 28 
*Patients who were allocated to the thrombolysis group but did not undergo acute angiography. Major 
complications (mortality and nonfatal recurrent infarction) and coronary artery bypass surgery (CABG) or 
percutaneous transluminal coronary angioplasty (PTCA) in patients allocated to conventional treatment (control) 
or thrombolysis. Symbols as in Table 1. 
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Table 7. Mortality 
Total mortality 
I ntracoronary 
thrombo!y~is 
lntmvenous and 
intracoronary 
thromboly':.i:-. 
First infarct only 
Anterior wall infarction 
Inferior wall infun:tion 
Thomxcenter 
SL Annada! 
Free Univer:-.ity 
Zuiderziekt:nhui:-. 
Ldden University 
Control 
Group 
42 
23 
19 
26 
25 
17 
20 
Ill 
6 
6 
Thrombolysi~ No Thrombolysis 
Group Angiography o-o e-o 
·-· 23 
17 
II 
12 4 
II 4 
II 3 
4 
I 
Mortality in patients admitted before or since January 19X4 and mortality data in the tive panicipating 
ho~pital:-.. Patienh allocated to thrombolytic treatment an: grouped according to the re.,.ulb of the intervention. 
Note that similur trend':. an;: present in all ':.ubgroups. Symbols as in Table I. 
unaltered (22). while results of several smaller randomized 
trials were inconclusive (23-28). The difference between 
the results of the present trial and those of other studies can 
be explained hy differences in study design. by the shorter 
delay between the onset of symptoms and treatment and by 
its larger size. 
Study design. The study was designed to compare a 
new method of treatment (thrombolysis) with the accepted 
mode of therapy. Informed consent was asked only from 
patients allocated to angiography and thrombolysis as pro-
posed by Zelen ( 16). This design was chosen to prevent 
extensive discussions of the risk and potential benefits of 
acute angiography and thrombolysis in half of these criti-
cally ill patients who were eventually allocated to conven-
tional coronary care unit treatment. Data analysis was based 
on original treatment allocation. Therefore. the 35 patients 
who did not undergo acute angiography were analyzed as 
part of the thrombolysis group. This subgroup included a 
few patients in shock who refused the intervention ·"because 
they wanted to be left alone.·· This is reflected by the rel-
atively high mortality in this group (5 of 35 patients) n able 
6). Because similar patients must be part of the control 
group. removal of this subgroup from the intervention group 
would falsely favor the effect of thrombolytic treatment. 
Yet it is evident that these deaths are not related to the 
thrombolytic therapy. 
Possible limitations. The interpretation of this study might 
be questioned because of changes in the protocol in January 
!984. the inclusion of coronary angioplasty in some of the 
patients. missing data. the lack of coronary arteriography 
on admission in the control group and the absence of direct 
measurements of baseline left ventricular function. These 
points will therefore be discussed in detail. 
Because the aim of the trial was not to study the effect 
of intracoronary streptokinase itself, but rather to study the 
effect of early reperfusion. we decided to combine both 
intravenous and intracoronary thrombolysis in the later pa-
tients when it became apparent that the preparation of the 
catheterization laboratory. the introduction of catheters and 
the first angiogram delayed the administration of strepto-
kinase by approximately I hour. while several reports (8-10) 
indicated that recanalization occurred in a considerable num-
ber of patients with administration of intravenous strepto-
kinase. 
Direct perforation of the thrombus was attempted in 5 
patients and coronary angioplasty was performed in addition 
to the streptokinase infusion in 46 patients. This intervention 
was considered an integral part of the recanalization pro-
cedure because earlier observations indicated that patients 
with residual subtotal occlusion after thrombolysis are at 
increased risk for reocclusion. which would negate the effect 
of thrombolysis (3). Coronary angioplasty was not associ-
ated with complications. In fact. alpha-hydroxybutyric de-
hydrogenase release after coronary angioplasty was de-
creased and left ventricular ejection fraction was higher than 
in patients in whom only thrombolysis was carried out ( 15). 
Therefore. it is likely that the beneficial effects of throm-
bolysis in the present study would have been less apparent 
without additional coronary angioplasty. 
No patients were lost to follow-up with respect to mor-
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tality or major clinical events, which represent the major 
end points of the study. Missing data on left ventricular 
function were due to death of the patients, patient refusal, 
transfer to other hospitals, lack of technical facilities at the 
required time or intervening bypass surgery. It is unlikely 
that this would invalidate the results because missing data 
were equally distributed between the two groups and be-
cause similar differences were observed between patients 
allocated to thrombolysis and control patients in various 
subgroups. Also, there were no differences in baseline data 
between patients with or without measurements of left ven-
tricular function. 
In contrast with other trials (20-28). early angiography 
wa' not performed in our control group. Therefore. the 
coronary anatomy on admission could not be studied in these 
patients. This procedure was elected because acute angi-
ography is not a part of conventional management of myo-
cardial infarction. In fact, angiography might expose these 
patients to a small but pertinent risk, which could worsen 
prognosis in the control group ( 13). Similarly, determination 
of left ventricular function by radionuclide angiography was 
not attempted on admission because this would have delayed 
the intervention and thus diminish the possible salutary ef-
fects of recanalization: 
Angiography in acute myocardial infarction. Earlier 
data from pilot studies performed at the Thoraxcenter ( 13) 
indicated that the risk of mortality. directly related to intra-
coronary infusion of streptokinase in patients with acute 
myocardial infarction. might be as high as 5'/f. However. 
despite 5 deaths during the catheterization procedure, 14 
day mortality in patients allocated to thrombolysis was lower 
(14 deaths [5%[) than in the control group (26 deaths [10%[). 
In our experience the risk of the intervention is not so much 
associated with early angiography itself as with the actual 
recanalization. We thus agree with De Wood et al. (29). who 
reported that early angiography can be performed without 
excessive risk in patients with myocardial infarction. The 
82% incidence of coronary occlusion at angiography and 
the 79% recanalization rate in patients treated with intra-
coronary streptokinase in the present study are consistent 
with other reports on early angiography and intracoronary 
thrombolysis ( l-4.20.23-28). 
Myocardial enzyme release. Total alpha-hydroxybu-
tyric dehydrogenase release in 72 hours was calculated as 
a measure of infarct size using a two compartment model 
(30). This model takes into account the fractional catabolic 
rate or clearance of the enzymes from the blood and is 
insensitive to faster washout after reperfusion (30,31 ). Ear-
lier studies (32) demonstrated similar results when infarct 
size was estimated from different enzymes including crea-
tine kinase. creatine kinase-ME isoenzyme. alpha-hydroxy-
butyric dehydrogenase and aspartate aminotransferase. In 
the present study, alpha-hydroxybutyric dehydrogenase re-
lease was measured because it can be computed accurately 
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from samples taken at 12 hour intervals, whereas creatine 
kinase should be sampled more frequently. Furthermore, 
the error in the computed total enzyme release due to bio-
logic variations in the fractional catabolic rate of alpha-
hydroxybutyric dehydrogenase is smaller than for creatine 
kinase, creatine kinase-ME isoenzyme or aspartate ami-
notransferase (32). Although estimation of infarct size by 
enzyme release is controversial, earlier studies (18) dem-
onstrated a relation between total alpha-hydroxybutyric de-
hydrogenase release and the clinical sequelae of myocardial 
infarction. Furthermore, an autopsy study (33) in 84 patients 
who died of acute myocardial infarction demonstrated that 
peak levels of lactate dehydrogenase or thermostable lactate 
dehydrogenase correlated better with anatomic infarct size 
than did peak aspartate aminotransferase. Actually, the cor-
relation between thermostable lactate dehydrogenase and 
anatomic infarct size (r = 0.79) was similar to that in a 
recent study (34) comparing anatomic infarct size with peak 
creatine kinase (r = 0. 79) or total creatine kinase infarct 
size (r = 0.86). Other investigators have used peak creatine 
kinase values (20.23) or peak lactate dehydrogenase mea-
surements (27), which appeared not to be reduced after 
thrombolysis. In fact, peak creatine kinase in the Western 
Washington trial (20) was 30% higher in the streptokinase 
group than in control patients. However, such peak mea-
surements are not reliable estimates of myocardial enzyme 
release because enzyme washout is faster after reperfusion. 
In the present study we observed a faster washout of alpha-
hydroxybutyric dehydrogenase, lactate dehydrogenase and 
creatine kinase after thrombolysis. 
In our study a 30% median reduction of alpha-hydroxy-
butyric dehydrogenase release was observed in the throm-
bolysis group. This supports the hypothesis that myocardial 
tissue can be salvaged by early thrombolysis. The estimation 
of alpha-hydroxybutyric dehydrogena'e release from lactate 
dehydrogenase measurements in two hospitals did not affect 
the difference between the thrombolysis and control groups. 
because similar differences between these two groups were 
observed in all five hospitals. Although these methods have 
not been validated in patients after coronary reperfusion, it 
is unlikely that myocardial salvage is overestimated by com-
putation of alpha-hydroxybutyric dehydrogenase release. In 
fact. total creatine kinase release in dogs was approximately 
I 0% greater after reperfusion than without reperfusion at 
the same anatomic infarct size. whereas enzyme breakdown 
in the circulation was not affected by the presence of strep-
tokinase (35). If the data from such studies apply to alpha-
hydroxybutyric dehydrogenase release in patients with acute 
myocardial infarction. the actual salvage of myocardium 
would even be underestimated. The observed reduction of 
alpha-hydroxybutyric dehydrogenase release is in agreement 
with data reported by Anderson et al. (28). From their Figure 
6 we computed a 40% reduction of total lactate dehydro-
genase-! isoenzyme release in the thrombolysis group com-
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pared with conventionally treated patients. Thus both studies 
are consistent with a reduction of enzymatic infarct size 
after thrombolysis. 
Left ventricular function. Global left ventricular ejec· 
tion fraction was measured by contrast angiography and 
radionuclide angiography. Both methods showed a higher 
ejection fraction 2 weeks after thrombolysis than after con-
ventional therapy (15). This improvement was seen in in-
ferior wall as well as in anterior wall infarction and applied 
to patients with a first infarct as well as to those with re-
current infarction. Some differences between the two groups 
in left ventricular ejection fraction measured by radionuclide 
angiography were already apparent after 2 to 4 days (Table 
5), although these differences were of borderline signifi-
cance. Although no measurements of ejection fraction were 
performed on admission, we may presume that these data 
were similar in both groups because other baseline data were 
also evenly distributed. The data then indicate a gradual 
recovery of left ventricular function during the first 2 weeks 
after reperfusion (36). The differences in ejection fraction 
between the two groups of patients were small (4%). How-
ever, the global left ventricular ejection fraction is related 
to the function of both the infarcted myocardium and other 
areas. Thus, changes in the infarcted area may be under-
estimated because of compensatory changes elsewhere. The 
improvement in left ventricular function after thrombolysis 
is supported by analysis of regional wall motion and by the 
smaller end-diastolic and end-systolic volumes after throm-
bolysis, measured by contrast angiography (15). 
Earlier experiments have demonstrated salvage of myo-
cardial function after early coronary reperfusion in dogs 
(37-39). In addition, several studies reported a higher ejec-
tion fraction in patients with successful thrombolysis than 
in patients whose infarct-related coronary artery remained 
occluded (40-43) or in historical control patients (44). In 
other randomized trials, only Anderson et al. (28) reported 
a beneficial effect on ejection fraction after streptokinase 
treatment. Although the lack of a beneficial effect in other 
series may be due to the small number of patients studied, 
the different results between our trial and those of two other 
larger trials (20-23) can be explained by the longer delay 
until treatment in the latter studies because it is less likely 
that recanalization after 4 or 6 hours of occlusion will sal-
vage significant amounts of myocardium in the majority of 
patients (38,39). In fact, the data from the present trial 
indicate that a marked reduction of infarct size can be achieved 
only in patients admitted within 2 hours after the onset of 
symptoms. 
Clinical course and follow-up. Survival was improved 
significantly by early thrombolysis. Furthermore, there was 
a borderline significant reduction of heart failure and shock 
in patients allocated to thrombolysis. These data are in 
agreement with the observed reduction of infarct size and 
preservation of left ventricular function. Actually, the I year 
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survival rates are very similar to those reported by inves-
tigators in the Western Washington Trial (21), although 
these investigators did not find differences in intermediary 
measurements, such as infarct size or left ventricular func-
tion (20). 
Unfortunately, these beneficial effects of thrombolytic 
therapy on survival were offset by a higher incidence of 
reinfarction, particularly in patients with an inferior wall 
infarction (14). Because reinfarction occurred in some of 
the patients despite adequate anticoagulant therapy or after 
successful coronary angioplasty, further studies are war-
ranted to determine the optimal mode of treatment after 
thrombolysis. Bleeding after thrombolytic treatment oc-
curred frequently at puncture sites. but did not result in 
significant morbidity ( 45). 
Conclusions. The aim of recanalization in patients with 
acute myocardial infarction is rapid restoration of blood flow 
to the jeopardized myocardium to preserve viable myo-
cardial cells. Ultimately this should result in preservation 
of myocardial function and improved prognosis after the 
infarction. Although the measurements of infarct size and 
left ventricular function used in this study might be criti-
cized, the consistency of the observations supports the true 
benefits of early thrombolysis in patients with myocardial 
infarction. In contrast with other studies that either were too 
small (24-27) or initiated treatment later after the onset of 
symptoms (20-23), we demonstrated a 30% smaller infarct 
size estimated from myocardial enzyme release as well as 
preservation of left ventricular function documented by con-
trast angiography and radionuclide angiography in patients 
allocated to early thrombolytic therapy, as well as a reduc-
tion. of early and late mortality. Future studies should in-
vestigate whether intracoronary administration of a throm-
bolytic agent is indeed mandatory, or whether similar results 
can be obtained by intravenous infusion of newer throm-
bolytic drugs such as the tissue plasminogen activator (46-48). 
Finally, strategies should be developed for early recognition 
of the symptoms of myocardial infarction by the patient and 
for immediate intervention, because myocardial salvage is 
only attainable if myocardial blood flow is restored within 
the first few hours of infarction. 
Appendix 
Participating Centers and Collaborators 
Thoraxcenter, Erasmus University and University Hospital Dijk-
zigt, Rotterdam. Marcel J. B. M. vd Brand, MD, Pim J. de Feyter, MD, 
Paolo Fioretti, MD, Paul G. Hugenholtz, MD, Patrick W. Serruys, MD, 
Maarten L. Simoons, MD, William Wijns, MD. 
Department of Cardiology, Free University, Amsterdam. Machiei 
1. van Eenige, MSc, Jan C. 1. Res, MD, Jan P. Roos, MD, Freek W. A. 
Verheugt, MD, Frans C. Visser, MD, Ernst E. vd Wall, MD. 
Department of Cardiology, Zuiderziekenhuis, Rotterdam. Diederik 
C. A. van Hoogenhuyze. MD. X. Hanno Krauss, MD. WillemJ. Remme, 
MD. 
Department of Cardiology, St. Annadal HOspital, Maastricht. Frits 
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W. H. M. Bar. MD. Simon H. J. G. Braat, MD. Pedro Brugada. MD. 
K;.~.rd den Dulk. MD. Wim T. Hermens. MSc. Hein J. J. Wellens. MD. 
Chri:-. de Zwaan. MD. 
Department or Cardiology, University Hospital. Leiden. Berend 
Buis. MD. Jo:-. Engbers. MD. Amoud vd Laarse. PhD. 
Data processing center. Thoraxcenter, Erasmus University, Rot-
terdam. Sophie vd Doe:-.. Ron T. van Domburg. MSc. Jacobus Lubsen. 
PhD. Jan P. van Mantgem. MD. Karel J. de Neef. MD. Juan Planellas. 
MD, Frank Vermeer. MD. Anneke A. Wagenaar. loge C. J. Zorn. 
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CHAPTERS 
Effects of early intracoronary streptokinase on 
infarct size estimated from cumulative enzyme 
release and on enzyme release rate: A 
randomized trial of 533 patients with acute 
myocardial infarction· 
The effects of early intracoronary streptokinase (SK) on enzymatic infarct size and rate of 
enzyme release were studied in a randomized multicenter trial. A total of 533 patients with acute 
myocardial infarction (AMI) were allocated to either the SK treatment group (n = 269) or the 
conventional (control) treatment group (n = 264). Enzymatic infarct size was represented by the 
cumulative quantity of a·hydroxybutyrate dehydrogenase (HBDH) released by the heart per liter 
of plasma in the first 72 hours. Rate of enzyme release was represented by the ratio of HBDH 
quantities released in 24 hours and 72 hours. On an "intention to treat" basis, the SK group had 
a smaller (by 30%; p = 0.0001) median enzymatic infarct size and a higher (by 35%; p = 0.0001) 
median rate of enzyme release than the control group. Limitation of infarct size was less 
apparent in patients treated with intracoronary SK only (25%) than in patients treated with 
intravenous plus intracoronary SK {34%). Compared to the control group, the enzyme release 
rate in patients treated with intracoronary SK only was slightly less (34%) than that in patients 
treated with intravenous plus intracoronary SK (38%). Patients with a patent infarct-related 
coronary artery at acute angiography had a median infarct size which was 55% (p = 0.0001) 
smaller than the median infarct size of the control group, and the median rate of enzyme release 
was 38'% (p = 0.001) higher than the median release rate of the control group. Patients with 
successful recanalization during intracoronary SK infusion had a median infarct size which was 
31% (p = 0.002) smaller than the median infarct size of the control group and a median rate of 
enzyme release which was 42% (p = 0.0001) higher than the median release rate of the control 
group. Patients with persistent coronary occlusion in spite of thrombolytic therapy had a median 
infarct size which was 11% (NS) higher than the median infarct size of the control group, 
although the median rate of enzyme release was still 23% (p = 0.02) higher than the median 
release rate of the control group. It is concluded that thrombolysis in the early phase of AMI 
limits infarct size and that intracoronary SK treatment itself accelerates the process of enzyme 
release from infarcted myocardium, independent of the angiographic result. (AM HEART J 
1986;112:672.) 
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Both short- and long-term prognosis of patients who 
have had a myocardial infarction depends largely on 
"infarct size," or rather on the remaining function-
ing myocardial tissue.1-' Thus it is likely that limita-
tion of "infarct size" will lead to a better prognosis of 
infarct patients. Early recanalization of the occluded 
coronary artery in patients with acute myocardial 
infarction (AMI) has been proposed as a method for 
myocardial salvage.5• 6 We recently completed a 
study of 533 patients comparing early recanalization 
by intracoronary administration of streptokinase 
(SK) with conventional treatment. The results indi-
cate that early recanalization does indeed limit 
"infarct size" (estimated from serial enzyme deter-
minations), thereby preserving myocardial function 
(estimated by contrast angiography and radionu-
clide angiography). Finally, the 1-year survival rate 
in patients allocated to thrombolytic therapy was 
significantly improved compared to that of patients 
in the control group (91% vs 84% ).7·9 
This report further details the effects of thrombo-
lytic therapy on the estimated "infarct size" by 
calculation of total a-hydroxybutyrate dehydroge-
nase (HBDH) enzyme release and the effects of 
treatment on th.e rate of enzyme release. Limitation 
of infarct size was only apparent in patients with a 
patent infarct-related artery after the intervention. 
However, in contrast with earlier reports, 10·'3 the rate 
of enzyme release appeared to be accelerated by 
thrombolytic therapy independent of the angie-
graphic results. 
METHODS 
Patient selection. The study, sponsored by the Nether-
lands Interuniversity Cardiology Institute, was initiated in 
one hospital in 1981 and later extended to five hospitals.'· 
9
·" All patients admitted to the participating coronary 
care units were eligible for the trial if severe chest pain 
lasting more than 20 minutes was accompanied by ST 
segment elevation of 0.2 m V or greater in one or more 
precordial leads and/or 0.1 m V or greater in one or more 
limb leads. In addition, patients were included who had 
0.2 m V ST segment depression in precordial leads indica-
tive of posterior wall infarction. Patients up to the age of 
70 years were included if they were admitted to the 
coronary care unit within four hours after the onset of 
symptoms. Exclusion criteria were: previous treatment 
with SK, bypass surgery of the infarct-related vessel, 
recent trauma, traumatic resuscitation, gastrointestinal 
bleeding, gastric or duodenal ulcer, hematuria or cerebro-
vascular accident within 3 months, pregnancy or menstru-
ation, or inability to give informed consent. 
Eligible patients were registered by a telephone answer-
ing service which then provided treatment allocation. 
After randomization, informed consent was requested 
from patients allocated to the group receiving thrombolyt-
ic therapy only.15 Prior to cardiac catheterization patients 
received nitroglycerin, lidocaine (2 mg/min), heparin 
(5000 U), acetylsalicylic acid (250 mg), and prednisolone 
(100 mg) intravenously. Coronary arteriography was per-
formed with preformed catheters from the femoral 
approach. If the infarct-related artery appeared occluded, 
SK was administered intracoronarily at the rate of 4000 
U/min until all visible clots disappeared. Usually 250,000 
U was given. In patients with persistent occlusion, subsel-
ective infusion or mechanical perforation of the thrombus 
was attempted on occasion, while percutaneous translumi-
nal coronary angioplasty was performed in some of the 
patients with severe residual stenosis of the infarct-
related coronary artery.16 In order to reduce treatment 
delay, in patients admitted since January, 1984, 500,000 U 
of SK was administered intravenously, immediately after 
informed consent was obtained, as soon as possible, 
followed by intracoronary SK infusion during acute cardi-
ac catheterization. 7 
Measurement of serum enzyme activities. Samples of 
5 ml of venous blood were obtained at admission, directly 
after the SK infusion procedure (if allocated to study 
treatment), every 12 hours for the first 2 days, and daily 
for the following 3 days. The blood samples were all owe< l 
to clot, and the activities of HBDH in the serum were 
measured in the coronary care units of Rotterdam Tho-
raxcenter, Maastricht St. Annada! Hospital, and the Uni-
versity Hospital Leiden, and the activity of lactate dehy-
drogenase (LDH) in the serum was measured in the 
Rotterdam Zuiderziekenhuis and the Amsterdam Free 
University Hospital. Because erythrocytes contain high 
activity levels of LDH-1 and LDH-2, hemolytic samples 
were discarded, and new samples were ordered. 
Activity levels are expressed in micromoles of a-ketobu-
tyrate converted (HBDH) or micromoles of pyruvate 
converted (LHD) per minute or liter of serum at 37° C. 
The autoanalyzers which measured HBDH activities were 
calibrated daily such that the HBDH activity of a test 
serum (Autonorm H, batch 227, Nyegaard & Co, Oslo, 
Norway) equaled 430 U/L. So calibrated, the mean refer-
ence value of HBDH activity in serum is 83 U/L. From the 
autoanalyzers, which measured LDH activities, the serum 
LDH activities were converted to HBDH activities via the 
following formulas: Amsterdam Free University Hospital 
HBDH = 1.106 X LDH + 16 (r = 0.96), and Rotterdam 
Zuiderziekenhuis HBDH = 0.473 X LDH - 5 (r = 0.99). 
These formulas were obtained after LDH and HBDH 
measurement of 10 dilutions of an infarct serum diluted 
with a pasteurized plasma protein solution (Central Labo-
ratory of the Netherlands Red Cross Blood Transfusion 
Service, Amsterdam, the Netherlands) spanning an LDH 
range of 0 to 2660 U /L. 
Calculation of cumulative HBDH release. Previously 
the two-compartment model was presented17 with which 
the movements of liberated myocardial proteins to and 
from intravascular and extravascular spaces can be 
described. This model has now been verified for a great 
number of proteins, mostly enzymes. Briefly, this model 
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Table I. Median values (M) and first and third quartiles (Q1,Q3) of calculated and estimated cumulative HBDH 
release of patients allocated to thrombolytic therapy and to conventional treatment (control subjects) groups 
Streptokinase Control 
Patients n M 
448 patients with HBDHQ72 calculatedt 230 770 
495 patients with HBDHQ72 calculated 248 770 
(448) or estimated including 17 patients 
without AMI (Q72 = 40 U/L) and 30 
patients who died early (8 SK, 22 
control, Q72 = 6000 U/L)t 
29 patients with Q72 estimated by 14 860 
1.2 X Q48 
9 patients with Q72 estimated from 400 
CK(MB) curves 
All 533 patients with Q72§ 269 760 
*Mann· Whitney test. 
tlndicated by HBDHQ72. 
tlndicated by HBDHQ72A. 
§Indicated by HBDHQ72B. 
AMI =acute myocardial infarction. 
enables the calculation of the total quantity of enzyme 
which has entered the plasma up to timet (Q[t]) per liter 
of plasma. If the release of enzymes into plasma starts at 
timet= 0, Q(t) equals the quantity of enzyme present in 1 
L of plasma (C,[t]) plus the quantity of enzyme present in 
the extravascular compartment per liter of plasma (C,[t]) 
plus the quantity of enzyme that has been eliminated from 
1 L of plasma up to time t. Cumulative release of enzyme 
per liter of plasma up to time, t, Q(t), is represented by: 
Q(t) = C' ,(t) + C',(t) + FCR J C' ,(r)dr (equation 1), in 
which FCR is the fractional catabolic rate constant, and 
C' ,(t) and C' ,(t) are the enzyme concentrations at timet 
in plasma and the extravascular space, respectively. The 
accents added to C' ,(t) and C',(t) in equation 1 indicate 
that enzyme concentrations are corrected for the normal 
steady-state concentration (C,), that is, C' ,(t) = 
C,(t) -C,. 
This implies that Q(t) does not include normal steady-
state release of enzyme but only refers to the extra release 
of enzyme resulting from AMI. The term C',(t) can be 
calculate~ according to the formula: C' ,(t) = TER · 
e<-ERR·li.J e<ERR·•1 •. C',(r)dr (equation 2), in which 
TER and ERR represent the transcapillary escape rate 
constant and the extravascular return rate constant, 
respectively." With the use of fixed mean values for FCR, 
TER, and ERR being 0.015 hr-1, 0.014 hr-1, and 0.018 hr-', 
respectively, Q(t) was calculated from serial determina-
tions of serum HBDH activities and the normal steady-
state HBDH activity C, = 83 U/L. The total HBDH 
activity ultimately released by the infarcted myocardium 
is represented by HBDHQ72 as at 72 hours after onset of 
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Q, Q .• n M Q, Q, p* 
450 1230 218 1020 580 1630 0.0001 
410 1260 247 1100 580 1860 0.0001 
600 1500 15 1290 910 1850 0.0001 
200 500 1050 1250 0.0001 
400 1250 264 1140 630 1860 0.0001 
chest pain enzyme release rate is almost (~95%) complet-
ed by then." 
Calculation of HBDH release rate. As a measure of the 
rate with which enzymes are liberated from the myocardi-
um into the circulation, the ratio HBDHQ24/HBDHQ72 
is used, that is, the ratio of the quantities released in the 
first 24 hours and the first 72 hours. 
Statistical analysis. Differences between medians of 
two groups of data were tested with the Mann-Whitney 
rank-sum test. Differences with p values >0.05 (two-
sided) were considered not significant. 
RESULTS 
Between June, 1981, and March, 1985, a total of 
533 patients were entered into the study. Two 
hundred sixty-four patients were allocated to the 
conventional treatment group and 269 patients to 
the thrombolytic therapy group. In spite of treat-
ment allocation, no angiography was performed in 
35 patients. 7• 8 In 111 of 136 patients catheterized 
without intravenous SK the infarct-related vessel 
was occluded (82%) and recanalization was achieved 
in 79% of these. After prior intravenous SK the 
infarct-related vessel was patent in 40 of 98 patients 
(41% ). Ultimately the infarct-related artery was 
patent at admission or recanalized in 198 patients 
(85%). The median time between onset of symp-
toms !lld angiographic documentation of a patent 
infarct-related vessel was 200 minutes. 
Of 533 patients included in the study, measure-
ments of HBDH (or LDH) were complete in 448 
patients (84% ). The measurements were incomplete 
in 85 patients. In order to verify whether the results 
would be affected by missing data, HBDHQ72 was 
estimated from other data which were available for 
these 85 patients. Data were missing from 17 
patients who did not develop an infarct in spite of 
prolonged chest pain and significant ST segment 
elevation at admission. In these 17 patients creatine 
kinase (CK), CK-MB, HBDH, and other enzymes 
remained within reference ranges. Furthermore, 
data were necessarily incomplete in 30 patients who 
died early (within 72 hours) from large infarctions, 
characterized by pulmonary edema, cardiogenic 
shock, and a rapid rise of plasma enzymes to high 
levels. In the present analysis these patients were 
entered with values for HBDHQ72 which were 
arbitrarily set at 40 (for patients without infarct) 
and 6000 (for patients who died within 72 hours), 
respectively. The figures 40 and 6000 U!L corre-
sponded to the lowest and the highest values of the 
448 calculated infarct sizes. In 29 patients inade-
quate blood sampling prevented direct calculation 
of infarct size; however, HBDHQ72 could be approx-
imated by multiplication of calculated HBDHQ48 
by a factor of 1.2. This factor 1.2 was chosen because 
it was the value of the HBDHQ72/HBDHQ48 ratio 
;:-~ 218 control patients. Although in the patients 
allocated to the thrombolytic therapy group the 
mean ratio of HBDHQ72/HBDHQ48 was about 1.1, 
the factor 1.2 was used in all 29 patients in whom 
HBDHQ48 was present and HBDHQ72 was absent. 
Thus probably a small overestimation of infarct size 
was introduced in 14 patients allocated to the SK 
treatment group. In the nine patients in whom 
HBDHQ48 could not be calculated, HBDHQ72 was 
estimated via comparison of serum CK(MB) curves 
with serum CK(MB) curves of patients with calcu-
lated HBDHQ72. 
The data presented in Table I show that the 
median infarct size estimated from HBDHQ72 was 
25% lower in patients allocated to thrombolysis 
than in control patients. This difference in 
HBDHQ72 was hardly affected by the addition of 
the estimated data to the actual measurements: in 
fact, inclusion of estimated infarct sizes 
(HBDHQ72A and HBDHQ72B) increased these dif-
ferences to 30% and 33%, respectively. These dif-
ferences were similar among the five participating 
hospitals. Further analysis is based on both actual 
HBDH measurements (448 patients; HBDHQ72) 
and on data including patients without infarction 
and those who died early (495 patients; 
HBDHQ72A). Although much attention has been 
paid to the standardization of serum enzyme deter-
minations, it appears that median HBDHQ72 values 
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Fig. 1. Median value of enzymatic infarct size 
(HBDHQ72A) in patients allocated to thrombolytic ther-
apy (SK) is plotted against HBDHQ72A in patients 
allocated to conventional treatment (C) per participating 
center. Although an interdepartment variation is obvious, 
each center shows an almost identical result in terms of 
infarct size limitations of about 30%. 
varied per center. This was true for both patient 
groups (SK and control). Fig. 1 shows the median 
HBDHQ72A values in both patient groups per 
center. Although an interdepartment variation is 
obvious, each center shows an almost identical lower 
(by 30%) HBDHQ72 value in the SK group of 
patients than in control patients. 
Table II shows the medians and quartiles of 
calculated HBDH release (HBDHQ) after 24, 48, 
and 72 hours from the onset of infarction in patients 
in the control and SK groups. Evidently, after 24 
hours median HBDHQ values in both patient 
groups are almost identical, while cumulative 
HBDH release increases less during the following 2 
days in the SK group than in the control group. At 
72 hours from the onset of infarction, the median 
HBDHQ72 value of the SK group is 25% less than 
that of the control group (p = 0.0001). The differ-
ence in the time course of HBDH release between 
the two groups of patients is the result of a faster 
release of HBDH in the SK group than in the 
control group, as is reflected by the median 
HBDHQ24/HBDHQ72 which is 0.65-and 0.48 in the 
SK and control group, respectively (p = 0.0001). 
Table III shows that median HBDHQ72A values 
differ by 25% in favor of SK in the first 277 patients 
and by 34% in favor of SK in patients pretreated 
with intravenous SK. The HBDH release rate was 
34% and 38% higher in the SK group than in the 
control group for intracoronary SK and intravenous 
plus intracoronary SK treatment, respectively. 
Fig. 2 shows the median values as well as the first 
and third quartile values of HBDHQ72A and ratio 
HBDHQ24/HBDHQ72 in patients in the control 
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Table II. Median values (M) and first and third quartiles (Q1,Q3) of cumulative quantities of HBDH released per 
liter of plasma after 24, 48, 72, and 96 hours in patients allocated to thrombolytic therapy and to conventional 
treatment (control subjects) groups 
Streptokinase Controls 
n M Q, Q, n M Q, Q, p* 
HBDHQ24 252 460 260 780 236 490 300 730 NS 
HBDHQ48 245 680 420 1070 234 920 530 1390 0.003 
HBDHQ72 230 770 450 1230 218 1020 580 1630 0.0001 
HBDHQ96 187 780 450 1280 171 1050 620 1750 0.0006 
HBDHQ24/HBDHQ72 230 0.65 0.55 0.76 218 0.48 0.39 0.58 0.0001 
NS = not significant. 
*Mann-Whitney rank-sum test (two-sided). 
Table Ill. Median values (M) and first and third quartiles (Q1,Q3) of enzymatic infarct size (HBDHQ72A) and 
enzyme release rate (HBDHQ24/HBDHQ72) in patients allocated to thrombolytic therapy and to conventional 
treatment (control subjects)* 
Infarct size Streptokinase Control 
HBDHQ72A n M Q, Q, n M Q, Q, pf 
All patients 248 770 410 1260 247 1100 580 1860 0.0001 
lntracoronary SK 140 750 380 1220 137 1000 580 1700 0.001 
Intravenous + intracoronary SK 108 810 450 1320 110 1220 640 2010 0.001 
Enzyme release rate Streptokinase Control 
HBDHQ24/HBDHQ72 M Q, Q, n M Q, Q, Pt 
All patients 230 0.65 0.55 0.76 218 0.48 0.39 0.58 0.0001 
Intracoronary SK 127 0.67 0.57 0.76 121 0.50 0.39 0.61 0.0001 
Intravenous + intracoronary SK 103 0.65 0.53 0.76 97 0.47 0.40 0.54 0.0001 
"'Until 1984, SK was given intracoronarily only, and from January, 1984, on SK was given intravenously followed by intracoronarily. 
tMann-Whitney rank-sum test (two-sided). 
and SK groups. In addition, the SK group is subdi-
vided into four groups of patients: those without 
catheterization (35 patients), 65 with a patent 
infarct-related coronary artery at angiography, 133 
patients with actual recanalization by thrombolytic 
therapy, and 36 patients in whom the artery 
remained occluded (Fig. 2). 
Median infarct sizes of the patients without acute 
coronary angiography (910 U/L), as well as those of 
the patients in whom the infarct-related artery 
remained occluded (1220 U/L), were not significant-
ly different from those of control patients (1100 
U/L). In patients with recanalization during angiog-
raphy median infarct size was 760 U/L, which is 
31% lower than in control patients (p = 0.0001). 
The smallest infarcts were observed in 65 patients 
who already had a patent infarct-related artery at 
first angiography (median 500 U/L). In Fig. 2 the 
values of the ratio HBDHQ24/HBDHQ72 are pre-
sented, which are a measure of the rate of enzyme 
release. The control group and the patients in the 
SK group who did not undergo acute coronary 
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angiography had a relatively low median ratio 
HBDHQ24/HBDHQ72 (0.48 and 0.55, respectively) 
compared to patients with patent infarct-related 
coronary arteries (0.66), those with recanalization 
during angiography (0.68), and those with persistent 
occlusion (0.59). 
In order to study whether the severity of the 
remaining stenosis of the infarct-related artery had 
any effect on infarct size or rate of enzyme release, 
patients were subdivided according to the visual 
interpretation of the degree of stenosis after recana-
lization. The results in Fig. 2 show no effect of the 
degree of opening of the infarct-related artery on 
infarct size. 
Fig. 3 shows that in both anterior (including 
anteroseptal infarcts) and inferior (including poste-
rior) infarcts cumulative HBDH release was lower 
and HBDH release rate was higher in patients 
allocated to SK treatment compared to control 
patients. When both groups are compared, median 
values of HBDHQ72A differ by 34% (p = 0.007) and 
by 31% (p = 0.002) for patients with anterior and 
ENZYMATIC INFARCT SIZE RATE OF ENZYNE RELEASE 
""l 
1 0.6 II ~ 0.4 " ~ 0.2 o.o 
"' '" 
SK-ALI.OCA.TID PATIE.\15 SK-ALUXATED PATIEl1TfS 
no cnth. o--o .,._. no cath. o-o .-.-.o .._. 
t>S 133 3o l:S:S 36 
o----o ..____, o----o ....__._, 
rNS -, r:-:s-, rNS-, rNS --, 
""l "'l II I,:: ~ ~ B~ ~ O,b II ::;;:- 0.4 il-~ 400 ~ a.z 0 ' 0.0 \ stenosts ~90 ~90 >90 \ stenosis~90 >90 :":;90 
" 
31 71 31 71 
Fig. 2. Median values of enzymatic infarct size 
(HBDHQ72A) and rate of enzyme release (HBDHQ24/ 
HBDHQ72) in patients allocated to streptokinase (SK) 
and control (C) treatment groups, (top), in four categories 
of patients allocated to SK treatment group (middle), and 
in four categories of patients with patency of recanalized 
infarct-related coronary artery (bottom). The number of 
data per bar is indicated in the bar, and the number of 
patients per group is indicated below the bar. Levels of 
first and third quartiles are indicated. Statistical signifi-
cance of a difference between two medians is calculated by 
Mann-Whitney rank-sum test (two-sided). 
inferior infarcts, respectively. Median values of the 
HBDHQ24/HBDHQ72 ratio differ by 31% 
(p = 0.0001) and 38% (p = 0.0001) for patients with 
anterior and inferior infarcts, respectively. 
From a total of 533 patients randomized in the 
study, 65 (12%) patients have died within 1 year 
after onset of chest pain: 23 patients allocated to 
thrombolytic therapy and 42 control patients 
(p = 0.01). In Fig. 4 the number of patients from 
both groups in four classes of infarct size 
(HBDHQ72A ~ 600 U/L, 601 to 1200 U/L, 1201 to 
1800 U/L, and >1800 U/L) and the number of 
patients who have died within 1 year after onset of 
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Fig. 3. Median values of enzymatic infarct size 
(HBDHQ72A) and rate of enzyme release (HBDHQ24/ 
HBDHQ72) in patients having anterior infarction or 
inferior infarction allocated to streptokinse (SK) and 
control (C) treatment groups. The number of data per bar 
is indicated in the bar, and the number of patients per 
group is indicated below the bar. Levels of first and third 
quartiles are indicated. Statistical significance of a differ-
ence between two medians is calculated by Mann-Whit-
ney rank-sum test (two-sided). 
chest pain and per infarct size class per group are 
shown. This figure demonstrates that thrombolytic 
therapy is associated with both limitation of infarct 
size and an improved survival rate when compared 
to control patients. 
Of the 264 control patients and 269 patients 
allocated to the SK treatment group, angiographic 
data before discharge from the hospital were 
obtained from 125 and 129 patients with first AMI, 
respectively. Fig. 5 shows that in the SK group the 
median HBDHQ72 was 800 U/L, which was 33% 
lower (p = 0.0001) than that in the control group 
(1190 U/L). Furthermore, in the SK group median 
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Fig. 4. Mortality rates in four different classes of infarct 
size in patients allocated to thrombolytic therapy (SK) 
and in patients allocated to conventional treatment (C) 
groups. 
left ventricular ejection fraction at discharge was 
0.57, which was 14% higher (p = 0.0005) than that 
in the control group (0.50). 
DISCUSSION 
The aim of thrombolytic therapy is rapid restora-
tion of blood flow to the jeopardized myocardium in 
order to preserve cellular integrity and function or, 
in other words, "limitation of infarct size." Thus 
thrombolytic therapy must either prevent the 
infarction or lead to an infarct with a size smaller 
than would occur in the absence of thrombolysis-
induced reperfusion of the infarct-related coronary 
artery. 
Indirectly, limitation of infarct size by early intra-
coronary SK infusion has been demonstrated to 
occur since regional and global left ventricular func-
tion as well as the mortality rate were markedly 
improved in treated patients compared to conven-
tionally treated patients.'·• However, studies de-
signed to investigate direct effects of thrombolytic 
therapy in terms of infarct size limitation are scarce. 
Therefore, in the study on thrombolytic therapy 
conducted by the Netherlands Interuniversity Car-
diology Institute, measurement of enzymatic infarct 
size was incorporated. In 495 of 533 patients (93%) 
enrolled in the study quantitative information on 
infarct size (HBDHQ72A) was obtained. This study 
demonstrates that early thrombolysis does limit 
infarct size estimated by myocardial HBDH release. 
As expected, the smallest median HBDH infarct size 
was observed in patients with an open artery at 
angiography and, to a lesser extent, in patients with 
an occluded artery which later recanalized. Patients 
with a persistent occlusion in spite of thrombolytic 
therapy had the same infarct size as patients in the 
control group. 
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IN PATIENTS WITH FIRST AMI 
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Fig. 5. Relation between left ventricular ejection frac-
tion (L VEF) determined before discharge from coronary 
care unit and enzymatic infarct size (HBDHQ72A) in 254 
patients with first AMI allocated to streptokinase (SK) or 
control (C) treatment group. Per treatment group median 
values and first and third quartiles are presented. Statis-
tical significance of a difference between two medians is 
calculated by Mann-Whitney rank-sum test (two-sided). 
The method used to calculate infarct size in the 
present study is applicable to several cytoplasmic 
enzymes liberated from infarcted myocardium. 19·22 
Based on the assumption that different cytoplasmic 
(iso) enzymes are liberated from necrotic myocytes 
simultaneously, the different serum (iso)enzyme 
curves can be fully described by differences in their 
concentrations in normal myocytes and differences 
in fractional catabolic rate. Calculation of cumula-
tive released quantities of these (iso)enzymes results 
in identical overlapping curves when activities are 
expressed in gram equivalents of myocardium." 
Thus the different cytoplasmic (iso)enzymes are 
released to the same extent percentagewise from 
the infarcted tissue. In infarcted animal hearts23·25 
and in infarcted human hearts26 the extent to which 
the infarcted myocardium looses its enzymes is 
approximately 80% to 85%. 
The two-compartment model employed enables 
calculation of the cumulative activity released from 
the infarcted myocardium into the plasma space for 
each cytoplasmic (iso)enzyme. The method has 
proved its value for assessing myocardial damage 
induced by surgical and cardioplegic procedures27•29 
and for assessing the relationship between enzymat-
ic infarct size and the occurrence of pump failure, 
EOG changes, conduction and rhythm disturbances, 
global left ventricular function, wall motion abnor-
malities, and 1-year survival rate.17 Shell et al.30 in 
1971, published a different method for calculating 
enzymatic infarct size, which has since then been 
used by a large number of investigators. This meth-
od is confined to CK and CK-MB, and is based on a 
one-compartment modeL As in the early reports 
they mention a recovery rate of 30% of the CK (or 
CK-MB) activity,30 and since 1975 only 15%,31 the 
cumulative CK(-MB) activity calculated on the 
basis of serial serum CK(-MB) activities has to be 
multiplied by 1/0.3 (early) or by 1/0.15 (since 1975) 
to obtain the activity of CK(-MB) released by the 
heart. The remaining part of the released CK(-MB) 
is degraded locally in the heart according to the 
authors." The factor representing recovery of CK 
liberated by necrotic myocytes in the circulation 
appears to be sensitive to the occurrence of reperfu-
sion of infarcted myocardium. Roberts and Ishika-
wa" showed that two different relationships exist 
between accumulated CK release expressed in CK 
gram-equivalents of infarcted myocardium and ana-
tomic infarct size during unperfused infarction and 
during infarction followed by early reperfusion. 
From reperfused myocardium greater CK release 
per gram of anatomic infarct size has been observed 
than from unreperfused myocardium. 
Tamaki et al.,34 who also used the method of Shell 
et al.,30 observed that in patients with AMI success-
fully treated with intracoronary urokinase more 
CK-MB was released per equivalent infarct volume 
estimated by myocardial emission tomography with 
thallium-201 than in patients with AMI with unsuc-
cessful thrombolysis. The discrepancies mentioned 
by these authors may reflect different recovery 
fractions of the enzyme in both situations, since CK 
as well as CK-MB are relatively unstable (iso) 
enzymes compared to aspartate aminotransferase 
and LDH (see also reference 25). However, the 
infarct size calculated by the method of Shell et al. 30 
in patients with AMI correlated well with anatomic 
infarct size in patients who died from AMI,35 left 
ventricular ejection fraction in patients with first 
AMI,36•37 and long-term survival rates.l-4. 38 Erhardt" 
reported that in 43 patients with AMI the peak 
serum levels of LDH and heat-stable LDH (repre-
senting the combined activities ofLDH-1 and LDH-
2) were well correlated (r = 0.73 and r = 0.79, 
respectively) with anatomic infarct size, measured at 
postmortem examination. Anderson et al./3 who 
measured serial activities of several (iso)enzymes in 
serum, calculated the integrated concentrations of 
serum LDH and serum LDH-1, and did not find 
significant differences between the SK group and 
the control group. However, recalculation of 
released quantities of LDH and LDH-1, by means of 
the method used in the present study, yielded a 
smaller infarct size after thrombolysis of 20% and 
40% with LDH and with LDH-1, respectively. This 
is in agreement with the better left ventricular 
ejection fraction after thrombolysis reported by 
Anderson et al." Enzyme release rates (Q24/Q72) 
were 0.49 and 0.77 measured with LDH and 0.46 and 
0.70 measured with LDH-1 for control and SK-
treated patients, respectively, which are indeed sim-
ilar to the results of the present study. 
Another advantage of calculation of infarct size 
from HBDH rather than from CK values is that 
HBDH-infarct size can be incorporated easily and 
routinely in trials on infarct size limitation as serum 
HBDH has to measured only twice a day during the 
first 2 days and once a day during the following 3 
days at low cost. No assumption regarding the 
HBDH release function (f[t]) is incorporated in the 
calculation. Thus factors which increase (e.g., SK) or 
decrease (e.g., beta blockers) the HBDH release rate 
do not influence any parameter involved in the 
calculation. The quantity of the release as well as the 
rate at which HBDH is released are the outcome of 
the calculation, and can be used in rapidly releasing 
infarcts (reperfusion) as well as in slowly releasing 
infarcts (unreperfused infarcts) (see also reference 
22). 
The enzymatic method for quantitating myocar-
dial infarct size has one major drawback since 
. patients must survive the first 3 days to enable 
calculation of cumulative enzyme release. In order to 
prevent bias resulting from the higher mortality rate 
among patients in the control group, we included the 
patients who died early from extensive infarctions 
giving those a large value for HBDHQ72. Since this 
value was chosen arbitrarily non parametric statisti-
cal tests were used. Similarly, patients without 
infarction were included with a low value for 
HBDHQ72 (40 U/L). 
Enzyme washout, as expressed as the HBDHQ24/ 
HBDHQ72 release ratio, was increased in all groups 
of patients after thrombolytic therapy. The latter 
finding is not completely understood. Shell et al.4° 
demonstrated that reperfusion of the infarcted myo-
cardium significantly augments the release rate of 
CK-MB, while Ong et al.41 reported that in patients 
with AMI not treated with thrombolytic agents a 
rapid release rate of CK-MB correlated with 
improvement of global left ventricular function and 
regional left ventricular wall motion. These reports 
suggest that a rapid enzyme release rate is a mani-
festation of recanalization, either spontaneous or 
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CHAPTER6 
Value of Admission Electrocardiogram in Predicting 
Outcome of Thrombolytic Therapy 
in Acute Myocardial Infarction 
A Randomized Trial Conducted by The Netherlands 
Interuniversity Cardiology Institute 
FRITS W. BAR, MD, FRANK VERMEER, MD, CHRIS DE ZWAAN, MD, 
MERCEDES RAMENTOL, MD, SIMON BRAAT, MD, MAARTEN L. SIMOONS, MD, 
WIM T. HERMENS, PhD, ARNOUD VAN DER LAARSE, PhD, 
FREEK W.A. VERHEUGT, MD, X. HANNO KRAUSS, MD, 
and HEIN J.J. WELLENS, MD 
To determine the value of the admission 12-Iead 
electrocardiogram to predict infarct size limitation 
by thrombolytic therapy, data were analyzed in 488 
of 533 patients with acute myocardial infarction 
(AMI) from a randomized multicenter study. All pa-
tients had typical electrocardiographic changes di-
agnostic for an AMI and were admitted within 4 
hours after the onset of chest pain; 245 patients 
were allocated to thrombolytic treatment and 243 to 
conventional treatment. Cumulative 72-hour release 
into plasma of myocardial a-hydroxybutyrate dehy-
drogenase (HBDH) was used as a measure of in-
farct size. In general, the amount of infarct limitation 
due to thrombolytic therapy was proportional to the 
size of the area at risk. Patients with new a waves, 
high aRS score and high ST -segment elevation or 
depression had the largest enzymatic infarct size in 
both treatment groups, irrespective of location of the 
AMI. Compared with conventionally treated patients, 
patients with anterior AMI treated with streptokinase 
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had significant infarct size limitation ( 480 U/liter 
HBDH, 37%), and limitation was most prominent in 
those with a waves (820 U/liter HBDH) or high ST 
elevation (750 U/liter HBDH). Infarct size limitation 
in inferior AMI was less impressive (330 U/liter 
HBDH, 33%) and patients with high ST-segment el-
evation ( 460 U/liter HBDH) or marked contralateral 
ST-segment depression (430 U/liter HBDH) had the 
most notable infarct limitation. Independent of inter-
val between onset of chest pain and admission, in 
both types of AMI no significant infarct limitation 
was seen in patients with low ST elevation in the 
absence of Q waves, while in those with high ST el-
evation, in the presence but especially in the ab-
sence of a waves, thrombolytic therapy was effec-
tive. Thus, thrombolytic therapy is most potent in 
patients with AMI admitted early after onset of chest 
pain who have electrocardiographically a large in-
farcted or ischemic area. 
(Am J Cardiol1987;59:6-13) 
Data from the study conducted by the Netherlands 
Interuniversity Cardiology Institute and by others in-
dicate that in patients treated with streptokinase, re-
duction of the mortality rate1· 5 and preservation of left 
ventricular function4· 7 is related to limitation of enzy-
matic infarct size, which was estimated to be 30o/o.8 
However, such treatment carries a risk of bleeding and 
increased need for blood transfusion. 9 It would be of 
great clinical value to be able to identify patients 
with acute myocardial infarction (AMI) most likely to 
benefit from thrombolytic therapy at the time of ad-
mission using the 12-lead electrocardiogram and time 
of onset of chest pain. In a retrospective manner the 
present analysis was done to define such subgroups of 
patients. 
Methods 
Study design: The study design has been de-
scribed.3 Briefly, patients admitted to the coronary 
care unit with an AMI were randomized to conven-
tional treatment (control subjects] or thrombolytic 
therapy. Inclusion criteria were: age 70 years or youn-
ger; typical chest pain for more than 20 minutes; ad-
mission to the coronary care unit within 4 hours of 
onset of symptoms; no contraindications to streptoki-
nase therapy; and electrocardiographic changes diag-
nostic of AMI (;:::0.1 mV of ST-segment elevation at 
the J point in ;:::1 extremity lead or ;:::o.2 mV in ;:::1 
precordial lead, or ;:::0.2 m V of ST -segment depression 
in ;:::1 precordial lead, indicating posterior wall in-
farction]. 
Informed consent was sought from patients allocat-
ed to thrombolytic therapy only.1° Conventional thera-
PY was given to patients in the control group. This 
included, in all patients, Thalamonal® (droperidol, 
fentanyl] and heparin followed by acenocoumarol 
(Sintrom®) administration until hospital discharge. 
Other drugs were given when indicated.11 Patients 
who received thrombolytic therapy but who refused 
consent were treated according to the conventional 
treatment protocol. but evaluated according to their 
original treatment allocation (intention to treat].'0 At 
first, patients who received thrombolytic therapy were 
treated with intracoronary streptokinase only. In later 
patients a combination of intravenous and intracoro-
nary streptokinase was given because thrombolytic 
therapy appeared to be delayed by approximately 1 
hour, which was needed for preparation of the cathe-
terization. Furthermore, other studies12•13 suggested 
that the initial patency rate would increase to approxi-
mately 50o/o of patients. Intravenous streptokinase was 
given immediately after informed consent in a dosage 
of 500,000 U infused within 20 minutes. In patients in 
whom the infarct-related vessel was occluded or the 
open artery contained thrombus, intracoronary strep-
tokinase was given up to a maximal dosage of 250,000 
U in 1 hour. 
Electrocardiographic criteria used for QRS pa-
thology and ST-segment changes: For the present 
analysis 2 sets of criteria for QRS pathology were used. 
Further, the sum of ST-segment elevation and the sum 
of ST-segment depression were studied. QRS com-
plexes were judged abnormal by the following criteria: 
(1] Extremity leads-Q wave more than 25o/o of the R 
wave or width of Q at least 0.04 second (lead III is 
excluded]. (2) Lead V1-Q wave was diagnosed if a 
QIR complex was seen. An isolated QS complex in 
lead V1 was interpreted as normal. (3) In leads V2 to 
V3-a Q wave was always interpreted as abnormal. (4) 
Lead V 4-the Q wave was abnormal when it was more 
than 0.1 mV deep or the Qin lead V4 was larger than in 
V5, or the Q was at least 0.02 second wide. (5) In lead 
V5-the Q wave was considered abnormal if more 
than 25o/o of the R wave, larger than the Q wave in V6 
or at least 0.04 second wide. (6) Lead V6-Q wave more 
than 25o/o of the R wave or Q wave at least 0.04 second 
wide. 
In addition, the QRS scoring system proposed by 
Wagner et al14 was applied. Patients with complete 
right bundle branch block or left axis deviation were 
not excluded. In these cases points attributed to height 
of the R wave in leadsV1 and V2 or the S wave in leads 
V4-V6 were neglected. Patients with a QRS score of 2 
or less according to the criteria were not considered to 
have Q signs of AMI. Patients with previous AMI were 
excluded when presence or absence of Q waves and 
height of QRS score was determined because these 
electrocardiographic abnormalities have no relation to 
the current AMI. 
ST-segment elevation and depression were mea-
sured at the J point. We calculated sum of the eleva-
tions and depressions in the anterior and inferior leads 
(Table I]. Leads I, aVL, V5 and V6 were assigned to the 
inferior leads in case of inferior or posterior AMI, 
provided that anterior infarction was absent15; other-
wise these 4 leads were combined with the anterior 
leads. Based upon location of the ST-segment eleva-
tion on the electrocardiogram at the time of random-
ization, we separated our patients into 2 categories: 
those with anterior AMI (n = 220) and those with infe-
rior AMI (n = 268) (Table I). For practical reasons 
degree of elevation or depression was measured in 
millimeters instead of millivolts (10 mm = 1 mV) 
(Fig. 1). 
Sum of ST-segment elevation and depression was 
separated into 2 categories of equal size: In anterior 
AMI, ST-segment elevation was S12 mm or >12 mm 
and ST -segment depression S2 mm or >2 mm. In infe-
rior AMI, ST elevation was S6 mm or >6 mm and ST 
depression in S4 mm or >4 mm. Electrocardiograms 
were read independently by 2 experienced electrocar-
diographers. In case of differences in interpretation, 
TABLE I Location of Anterior and Inferior Electrocardiographic 
Abnormalities 
ST elevation 
Sum (mm) deter-
mined in leads 
Contralateral 
ST depression 
Sum (mm) deter-
mined in leads 
Q wave 
Anterior 
Leads 
Inferior 
Leads 
V 1-V" ll,lll.aVF 
-if ST elevation\ /-if ST elevation 
v,-v,. ll,lll.aVF 
I,AVL,v5.V6 
-if no ST / '- -if ST depression 
abnormalities "'-v 1-V" 
in other leads 
v,-v, ll,lll.aVF 
(J,aVL,V5 ,V6 ) (l,aVL,V,V,) 
v,-v6 ll,lll.aVF 
V,-V6 ll,lll,aVF 
v,-v,. ll,aVF 
{l,aVL,V5,V6) (l,aVL,V5 ,V6) 
Anterior infarct: ST elevation in 1 or more of the leads V 1-V ,., and I, aVL, 
V 5 , V 6 (if ST elevation in V 1-V,. or no ST abnormalities in other leads). 
Inferior infarct ST elevation in 1 or more of the leads II, Ill, aVF and I, 
aVL, V5, V6 (if ST elevation JJ, JIJ, aVF or ST depression V 1-V,.). 
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FIGURE 1. Twelve-lead electrocardiogram of a patient having an 
acute inferoposterior infarct (1 mV: 10 mm). The a wave In lead II 
is approximately 40 ms, while the a in lead a VF Is more than 25% ot 
the R wave. According to the QRS scoring system the Q wave In 
lead Ills ~30 ms, the Q wave in lead aVF is ~40 ms and the R-wave 
duration in lead V1 is ~40 ms and in lead V2 ~50 ms, resulting in 5 
points. ST segment elevation-lead II, 2 mm; Ill, 4 mm; aVF, 3 mm; 
V 8, 1 mm; sum ST elevation, 10 mm; contralateral ST depression: 
lead V1, 3 mm; V2, 5 mm; V3, 3 mm; sum ST depression, 11 mm. 
they agreed after discussion. Adequate electrocardio-
graphic tracings were available in 488 of 533 patients. 
Forty-five patients were excluded from the present 
analysis as explained in the Results section. 
Enzymatic infarct size determination: Myocardial 
a-hydroxybutyrate dehydrogenase [HBDH] levels 
were measured on admission, every 12 hours during 
the first 2 days and then once daily up to the fifth day 
after admission. Enzymatic infarct size was deter-
mined from the cumulative release of HBDH within 72 
hours after onset of symptoms, which reflects at least 
95o/o of the total HBDH release.8•16 Missing values for 
HBDH release were substituted on the basis of clinical 
data [death] or other enzymatic data as described 
elsewhere.8 
Left ventricular function: Radionuclide left ven-
tricular ejection fraction was measured before hospi-
tal discharge. If radionuclide angiographic ejection 
fraction before discharge was missing, earlier or later 
nuclear studies or angiographic left ventricular ejec-
tion fraction was used, as described before. 5 Patients 
with previous AMI were excluded from analysis. 
Statistical analysis: Because missing data on enzy-
matic infarct size were arbitrarily set at 6,000 or 40 
U/liter, nonparametric tests were used for analysis. 
Differences between groups were tested with the Fish-
er exact test or the Mann-Whitney rank sum test when 
appropriate. Two-sided p values are reported. Multi-
variate linear regession analysis was performed to pre-
dict the effect of thrombolytic therapy on enzymatic 
infarct size and left ventricular ejection fraction. 
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Results 
One hundred fifty-two of the first 302 patients were 
randomized to intracoronary streptokinase therapy 
and 150 patients to conventional treatment. Of the next 
231 patients, 117 were assigned to intravenous and 
intracoronary streptokinase therapy. Gender (83% 
men), age (mean 55 years) and a history of infarction 
(22%) were equally distributed between control and 
thrombolysis groups. 
Median interval between onset of symptoms and 
hospital admission was 90 minutes. Randomization 
was done at 115 minutes and patients receiving strep-
tokinase arrived in the catheterization laboratory 165 
minutes after symptom onset. Infusion of intracoro-
nary streptokinase was initiated 195 minutes [range 55 
to 375) after the onset of chest pain. In patients in 
whom the occluded vessel reopened during the inter-
vention, recanalization was achieved after a median of 
30 minutes.3 
The electrocardiogram at the time of randomization 
was suitable for the present analysis in 488 of 533 
patients. Forty-five patients were excluded: The re-
viewers judged the electrocardiograms of 40 patients 
inadequate for the present analysis, although the phy-
sician who admitted the patient to the trial interpreted 
the electrocardiogram as typical of AMI; the electro-
cardiographic diagnosis "true posterior infarct" 
depended on subjective interpretation. Therefore, 6 
patients with ST-segment depression in leads V1-V2 
only were excluded. Also, 4 patients were excluded 
because of complete left bundle branch block, Wolff-
Parkinson-White syndrome or third-degree atrioven-
tricular block with ventricular escape rhythm. In 30 
patients the electrocardiogram did not fulfill the crite-
ria of ST-segment el-evation. The electrocardiogram of 
5 patients could not \Je retrieved. 
The 488 patients available for analysis had baseline 
characteristics similar to those of the total group of 
533 patients. Two hundred forty-five patients were 
allocated to thrombolysis and 243 to conventional 
treatment. In 212 of the 245 patients allocated to strep-
tokinase therapy, acute coronary angiography was 
performed. Thirty-three patients refused the interven-
tion or were subsequently found to have a contraindi-
cation. At the end of the procedure patency was 85% 
after intracoronary and 86% after intravenous plus 
intracoronary streptokinase therapy. 
Infarct size and electrocardiogram: Patients treat-
ed with intracoronary streptokinase and those treated 
with intravenous plus intracoronary streptokinase 
showed no significant differences in enzymatic infarct 
size [Table II]. Also, location of AMI was equally dis-
tributed. Therefore, we present results as from 1 
group. Median enzymatic infarct size [cumulative 
HBDH release in 72 hours) was significantly smaller in 
the thrombolysis group for both anterior and inferior 
AMI than in the conventionally treated group [Table 
II]. Overall, infarct size was smaller with inferior AMI 
than with anterior AMI. 
Streptokinase treatment resulted in significant lim-
itation of infarct size irrespective of electrocardio-
graphic findings [Fig. 2). However, enzymatic infarct 
TABLE 11 Treatment Allocation, Location of Myocardial 
Infarction and Cumulative Enzyme Release (Median HBDH 
U/liter) 
Thrombolysis Control 
HBDH HBDH 
All 245 760 243 1,170 
JC group 133 760 134 1,100 
IV+ IC group 112 770 109 1,270 
Anterior infarct 115 820 105 1,300 
Inferior infarct 130 670 138 1,000 
p Value 
0.0001 
0.0001 
0.0001 
0.0001 
0.0001 
HBDH = a-hydroxybutyrate dehydrogenase; IC = intracoronary; IV = in-
travenous; n = number of patients. 
size was largest in patients with Q waves, a QRS score 
above 2, high ST-segment elevation and high ST de-
pression, independent of infarct location. Of all sub-
sets of patients with anterior infarction, the most nota-
ble enzymatic infarct size limitation was achieved 
when the electrocardiogram showed Q waves (820 
U/liter) or high ST-segment elevation (750 U/liter). In 
contrast to patients with anterior AMI, myocardial sal-
vage by streptokinase was less striking in patients with 
inferior AMI; infarct limitation was highest in the 
presence of high ST-segment elevation (460 U/liter) or 
depression ( 430 U /liter). 
ANTERIOR INFARCT 
'ii. CONTROL 
In anterior AMI the combination of 2 electrocardio-
graphic criteria (ST-segment elevation and Q waves) 
showed only very minor infarct limitation as a result of 
streptokinase treatment in patients with little ST ele-
vation in the absence of Q waves (Fig. 3). The other 
combinations yielded statistically significant lower en-
zyme levels in the thrombolysis than the control group. 
In inferior AMI all 4 combinations had lower infarct 
size in the treated group; however, differences were 
not statistically significant. 
Infarct size and left ventricular ejection fraction 
relative to electrocardiogram and interval between 
onset of pain and admission: To assess left ventricular 
function, radionuclide or contrast angiographic ejec-
tion fraction was determined in 460 patients.5 Median 
left ventricular ejection fraction was 43o/o in the con-
ventionally treated group and 50% in the thrombolysis 
group (p = 0.0001). 
In univariate analysis the effects of thrombolytic 
therapy appeared to be related to degree of ST eleva-
tion, presence or absence of Q waves (Fig. 2) and delay 
between onset of symptoms and admission.4•5 Multi-
variate linear regression analysis was performed. The 
results of the linear regression on enzymatic infarct 
size and left ventricular ejection fraction are present-
ed in Table III. In patients with anterior AMI the ef-
fects of thrombolytic therapy were modified by the 
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STREPTOKINASE HBDH 
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0 STREPTOKINASE 
U/L 
STt>2 
N=63 N"'47 N=52 N=58 N-=70 N.,49 N"'45 N=56 
P< 0.02 P<0.001 P<0.001 P< 0.03 
ORS"" ORS"" 
NO a• SCORE>; 2 SCORE >2 
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P<0.01 
*OLD INFARCTS ARE EXCLUDED 
N·~ N•73 
P< 0.02 
FIGURE 2. Relation between median enzymatic Infarct size (HBDH) and the electrocardiographic findings In patients with an anterior 
infarction (/eft) and an inferior Infarction (right). Numbers of patients, median HBOH values and p value of differences In Infarct size 
between conventionally treated patients and those treated with thrombolysis are given. Vertical lines In the bars represent first and third 
quartiles. Third quartile of control patients having anterior infarct: ST-segment elevation >12 mm, 3,270 U/llter; ST-segment depression >2 
mm, 2,400 U/liler; Q waves: 2,420 U/liter; and QRS score >2, 2,530 U/llter. 
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P< 0.01 
N-35 N=32 N=12 N .. 6 N~45 N-48 N .. 14 N-22 
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"'OLD INFARCTS ARE EXCLUDED 
FIGURE 3. Relation between median enzymatic infarct size and 
combination of presence or absence of a waves and low or high ST-
segment elevation in anterior and inferior Infarction. Control pa-
tients with anterior Infarction had following third quartlles: No a 
waves+ ST elevation >12 mm, third quartile 3,310 U/liter; a waves 
+ ST elevation >12 mm, third quartile 2,630 U/liter. For further 
explanation see Figure 2. 
degree of ST elevation (p = 0.02 in covariance analy-
sis), presence or absence of Q waves (p = 0.02) and 
admission delay (p = 0.2). In patients with inferior 
infarction these effect modifications were apparent, 
but did not reach statistical significance. A decision 
tree is presented in Figure 4, based on the results of the 
regression analysis on enzymatic infarct size. 
Patients with anterior infarction (Fig. 4, left), little 
ST-segment elevation and no Q waves had only mini-
mal infarct limitation after streptokinase administra-
tion. This was independent of admission delay. All 
other combinations showed smaller infarct size after 
thrombolysis. The most impressive infarct limitation 
was found in patients with high ST-segment elevation 
in the absence of Q waves (Table III). To a lesser 
degree also in inferior AMI (Fig. 4, right), patients with 
high ST elevation in the absence of Q waves benefited 
most from thrombolytic therapy. The only other com-
bination with important limitation of infarct size was 
early admission, high ST elevation and Q waves. All 
other comparisons yielded only small differences in 
enzyme levels between patients treated with thrombo-
lysis and those treated conventionally. 
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Discussion 
The present analysis of data shows that thromboly-
tic therapy is most effective in terms of infarct size 
limitation in a subset of patients admitted early after 
onset of chest pain with signs of a large infarction 
(development of Q waves) or extensive ischemic area 
(high ST-segment elevation or marked ST depression). 
These observations are relevant for the clinical deci-
sion as to whether the patient should or should not 
receive thrombolytic treatment. Such an analysis has 
not been undertaken. Results of some studies'-2.17-19 of 
streptokinase therapy in patients with AMI agree with 
our results3-7 that thrombolytic therapy preserves left 
ventricular function or reduces mortality, but Rentrop 
et aJ2° could not show a positive effect of this type of 
treatment. The disparities in outcome of thrombolytic 
therapy can partially be explained by the small num-
ber of patients in most studies. 
Enzymatic infarct size: In most trials peak CK-MB 
or lactic dehydrogenase enzyme levels for determina-
tion of infarct size were used1.20 This is another reason 
for the discrepancy in outcome of streptokinase trials. 
As pointed out by van den Laarse eta! and others,B.l6.21 
peak enzyme levels cannot be used for that purpose. In 
contrast, cumulative HBDH release in the first 72 
hours correlates well with left ventricular ejection 
fraction, development of heart failure, arrhythmias 
and intraventricular conduction disturbances, 16 and 
in-hospital death and death in the first year after 
AMI4 - 6·8 Erhardt22 found good correlation between 
peak thermostable lactic dehydrogenase release in 
plasma, which is identical to HBDH,8 and postmortem 
determined infarct size. We therefore selected for our 
study the cumulative release of myocardial HBDH in 
72 hours. 
Electrocardiogram: In many studies the electrocar-
diographic inclusion criteria have not been described, 
except for the remark that the electrocardiogram was 
typical for AMI. ST-segment elevation provides infor-
mation on severity of ischemic injury, while Q waves 
are markers for infarct size.14·23 Therefore, in some 
studies,1·17·20 patients with QRS changes such as Q 
waves or loss of R wave in the infarcted area were 
excluded because the investigators believed that Q 
waves precluded salvage of myocardial tissue by 
thrombolysis. This conclusion appeared to be contra-
dictory to the present observation that important sal-
vage occurred in patients with Q waves. 
ST segment: High ST-segment elevation and 
marked ST-segment depression on the admission elec-
trocardiogram were related to infarct size. These pa-
tients had also largest infarct limitation after thrombo-
lytic therapy. This was true for both anterior and 
inferior AMI. Berland et aJ24 reported similar findings 
in patients with inferior infarction. 
The electrocardiogram during AMI can change 
dramatically within a short period. Because ST-seg-
ment abnormalities may vary considerably over time, 
in some patients the classification of the sum of ST 
elevation or depression would have been different if 
the electrocardiogram of randomization had been re-
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FIGURE 4. Decision trees for anterior myocardial Infarction (MI) (teff) and Inferior Infarction (right). Patients are categorized according to 
time between onset of chest pain and admission (delay) and 2 electrocardiographic findings (degree of ST elevation and presence or 
absence of Q waves). Differences In enzymatic Infarct size between the conventionally treated patients and those who received 
thrombolytic therapy are expressed in 3 groups: <250 U/liler, 260 to 500 U/llter, and >500 U/liler. Patients with anterior infarction treated 
with streptokinase have significantly lower enzyme levels, except for those with low ST elevation and absence of Q waves. Patients with 
high ST elevation and absence ot Q waves benefit most. Patients with inferior Infarction have similar findings. Patients admitted early, with 
high ST elevation and Q waves also have significantly lower enzyme levels In the thrombolysis group. Finally, thrombolysis Is more 
effective In patients with a short admission delay. 
corded earlier or later. This is particularly important in 
patients already admitted to the hospital, who have a 
severe anginal attack with prominent ST-segment 
changes. Seventy of our patients were already in hos-
pital. Even after correction of the effect of short inter-
val between onset of chest pain and randomization, 
this group of 70 patients showed smaller enzymatic 
infarct size than expected from the height of ST-seg-
ment elevation, compared with patients admitted to 
the coronary care unit after myocardial infarction. It 
suggests that the degree of ST-segment elevation is 
higher in the hyperacute phase than in a later period 
of AMI. Patients with a myocardial infarction admit-
ted from outside the hospital usually did not show 
much variation of the ST segments, being in a more 
stable electrocardiographic situation because of the 
delay caused by the admission. Foerster et aJ25 showed 
that the degree of ST-segment elevation in patients 
with AMI is stable 1 to 4 hours after the onset of chest 
pain. 
Q wave: Important myocardial salvage by throm-
bolytic therapy was found in patients with new patho-
logic Q waves, indicating that exclusion of such 
patients from thrombolytic therapy is incorrect. In pa-
tients with anterior AMI with Q waves, we found an 
important limitation of infarct size, by 820 U/liter 
HBDH (47% ). Early Q waves may not indicate definite 
loss of myocardial tissue because patients with exten-
sive ischemia can show transient Q waves because of 
conduction delay in that zone.26 Cessation of ischemia 
TABLE Ill Enzymatic Infarct Size, Radlonucllde Left Ventricular 
Ejection Fraction, Electrocardiogram and Time Delay Between 
Onset of Chest Pain and Admission: Results from Multivariate 
Regression Analysis 
Median HBDH (U/Iiter) 
Delay ST Elevation Q Waves c T Diff Ef• 
Anterior Infarct 
<2 hours Low 970 740 230 
Low + 1,410 590 820 16 
High 1,940 720 1.220 17 
High + 2,070 1.330 740 15 
2-4 hours Low 880 1.110 -230 -4 
Low + 1.330 960 370 
High 1.860 1,090 770 
High + 1.990 1.700 290 
Inferior Infarct 
<2 hours Low 830 580 250 
Low + 720 480 240 
High 1.330 860 470 
High + 1,450 1.110 340 
2-4 hours Low 860 750 110 
Low + 750 650 100 
High 1,360 1.030 330 
High + 1,480 1,310 170 
"Differences between thrombolysis and control group. 
C = conventionally treated; Diff = difference between conventional and 
thrombolysis group; EF = lett ventricular ejection fraction; H~DH = a-hy-
droxybutyrate dehydrogenase. 
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by reopening the occluded coronary artery may pre-
vent further damage in that area. Even after 2 hours 
thrombolytic therapy limited infarct size in the anteri-
or wall, suggesting that large infarcts are still evolving. 
The criteria we used for pathologic Q waves were 
strict. However, results did not differ if the QRS scor-
ing system proposed by Wagner et al'4 was applied. 
This system was developed for infarct size estimation 
in patients with completed myocardial infarction, but 
appears to be helpful in AMI as well. No or minimal 
infarct limitation by thrombolytic therapy was found 
in patients without Q waves in combination with low 
ST-segment elevation. This was independent of time 
between onset of chest pain and admission. Such a 
finding suggests that the occluded artery reopened be-
fore treatment, preventing occurrence of high ST -seg-
ment elevation and Q waves, when beneficial effect of 
thrombolysis on infarction size can no longer be ex-
pected. Another explanation could be that such pa-
tients suffer only from a small infarct, in which case 
the effect of thrombolytic therapy is minor and not 
statistically significant. 
Importance of time between onset of chest pain 
and admission: In the reported studiest-3.17-zo interval 
from onset of chest pain to intervention varied from 3 
to 18 hours. An inverse relation between duration of 
occlusion and subsequent ventricular function has 
been shown in animal experiments.27 In humans, this 
relation was not always found.19·28 Most studies report-
ed, however. that reperfusion within 4 hours after the 
onset of symptoms resulted in improvement of left 
ventricular function18·29 or a decrease in mortality rate, 
as shown in the GISSitriaJ.2 In the present trial, throm-
bolysis was started relatively early after onset of symp-
toms (median 195 minutes), while recanalization was 
achieved within 4 hours in most patients. This is prob-
ably the most important explanation as to why, in our 
study, streptokinase had such a beneficial effect. As 
expected from animal studies,27 we found prominent 
infarct size limitation in most patients arriving at the 
hospital within 2 hours after onset of chest pain. As 
shown by Simoons et al,4 in patients allocated to con-
ventional treatment, HBDH release was independent 
of the interval between onset of symptoms and hospi-
tal admission. On the other hand, infarct size was re-
duced with 51 o/o in thrombolysis patients admitted 
within 1 hour, 31 o/o in those admitted between 1 and 2 
hours, and only 13% in those arriving 2 to 4 hours after 
the start of complaints. In the patients coming to the 
coronary care unit between 2 and 4 hours after onset of 
chest pain, subgroups could be identified that did not 
show limitation of infarct size even after successful 
reperfusion. This indicates that a time limit of 4 hours 
is too long for some patients. Although it was apparent 
that time after onset of chest pain is an important de-
terminant of the outcome of successful thrombolytic 
therapy, the exact time of onset of pain may be difficult 
to define. Especially in patients with several attacks of 
pain, time of onset of myocardial infarction cannot be 
determined accurately. Accepting these uncertainties, 
we found that in patients arriving at the coronary care 
unit between 2 and 4 hours after onset of chest pain, 
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thrombolytic therapy was less successful than in those 
admitted earlier. After AMI Q waves develop over 
time. In contrast to this, ST elevation is highest early. 
after the onset of AMI. In patients arriving 2 to 4 hours 
after the start of complaints with high ST -segment ele-
vation and absence of Q waves, streptokinase was still 
effective. Incorrect judgment of the time of onset of 
AMI may explain why these patients still have such 
significant infarct size limitation. 
Another argument for the validity of the electrocar-
diographic criteria was the correlation between medi-
an HBDH values and left ventricular ejection fraction 
in patients with anterior infarction (Table III). This 
correlation did not hold for patients with inferior in-
farction, because the distance of the infarcted area to 
the collimator is much greater than in anterior infarc-
tion. As discussed by Wackers,30 the contribution of 
the posteroinferior wall to ejection fraction will be 
less, resulting in overestimation of ventricular wall 
motion. 
It was mentioned earlier that 33 of 245 patients 
refused the intervention or were subsequently found 
to have a contraindication for thrombolysis. They were 
evaluated according to their original treatment alloca-
tion.10 These 33 patients influence negatively the 
results of thrombolysis. If they would have been ex-
cluded, therapeutic success in terms of infarct size 
limitation would be greater. 
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CHAPTER 7 
THERAPY AND PREVENTION 
CORONARY THROMBOLYSIS 
Which patients benefit most from early 
thrombolytic therapy with intracoronary 
streptokinase? 
FRANK VERMEER. M.D., MAARTEN L. SIMOONS, M.D .. FRITS W. BAR, M.D., 
JAN G. P. TUSSEN. M.S .. RoN T. VAN DOMBURG, M.S., PATRICK W. SERRUYS, M.D., 
FREEK W. A. VERHEUGT, M.D .. JAN C. J. RES, M.D .. CHRIS DE ZWAAN, M.D .. 
ARNOUD VANDER LAARSE, PH.D., X. HANNO KRAUSS, M.D .. JACOBUS LUBSEN, PH.D., 
AND PAUL G. HuGENHOLTZ, M.D. 
ABSTRACT The effect of thrombolysis in acute myocardial infarction on enzymatic infarct size. left 
ventricular function. and early mortality was studied in subsets of patients in a randomized trial. Early 
thrombolytic therapy with intracoronary streptokinase (!52 patients) or with intracoronary streptoki-
nase preceded by intravenous streptokinase ( 117 patients) was compared with conventional treatment 
(264 patients). All 533 patients were admitted to the coronary care unit within 4 hr after onset of 
symptoms indicative of acute myocardial infarction. Four hundred eighty-eight patients were eligible 
for this detailed analysis. and 245 of these were allocated to thrombolytic therapy and 243 to conven-
tional treatment. Early angiographic examinations were performed in 212 patients allocated to throm-
bolytic therapy. Patency of the infarct-related artery was achieved in 181 patients (85%). Enzymatic 
infarct size. as measured from cumulative a-hydroxybutyrate dehydrogenase release. was smaller in 
patients allocated to thrombolytic therapy (median 760 vs 1170 U/liter in control patients, p = .0001). 
Left ventricular ejection fraction measured by radionuc!ide angiography before discharge from the 
hospital was higher after thrombolytic therapy (median 50% vs 43% in control patients. p = .0001 ). 
Three month mortality was lower in patients allocated to thrombolytic therapy (6% vs 14% in the 
control group, p = .006). With the use of multivariate regression analysis. infarct size limitation, 
improvement in left ventricular ejection fraction. and three month mortality were predicted by sum of 
the ST segment elevation. time from onset of symptoms to admission, and Killip class at admission. 
Thrombolysis was most effective in patients admitted within 2 hr after onset of symptoms and in 
patients with a sum of STsegment elevation of 1.2 mV or more. On the other hand, no beneficial effects 
of streptokinase on enzymatic infarct size. left ventricular function, or mortality were observed in the 
subset of patients with a sum ofSTsegment elevation of less than 1.2 mV who were admitted between 2 
and 4 hr after onset of symptoms. 
Circulation 74, No. 6, 1379-1389, 1986 
IN APPROXIMATELY 80% to 90% of patients with 
acute myocardial infarction, intracoronary infusion of 
streptokinase given in the first hours after onset of 
chest pain leads to thrombolysis and recanalization of 
the occluded coronary artery.,_, 
angiographically proven obstruction, without .major 
complications. The high patency rate after thromboly-
sis was associated with limitation of infarct size, high-
er left ventricular ejection fraction (L VEF), and im-
proved survival in comparison with these variables in 
conventionally treated patients. The design of this 
study. clinical course in the hospital, complications of 
early catheterization, limitation of enzymatic infarct 
size, and improvement in left ventricular function and 
survival during the follow-up period have been de-
scribed elsewhere .... , 
The multicenter randomized trial conducted by the 
Netherlands Interuniversity Cardiology Institute dem-
onstrated early recanalization in 79% of patients with 
From the Working Group on Thrombolytic Therapy in Acute Myo. 
cardia! Infarction of the Netherlands Interuniversity Cardiology Insti-
tute. Participating centers and collaborators are listed before the refer-
ences. 
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Box 19I8. 6201 BX Maastricht. The Netherlands. 
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The aim of the present analysis was to define subsets 
of patients that benefitted most from early recanaliza-
tion. Special attention was paid to patient characteris-
tics available early after hospital admission, such as 
history, the delay between onset of symptoms and ad-
mission, the extent of myocardial ischemia as reflected 
by the sum of ST segment elevation (lST) on the 
electrocardiogram (ECG), and the hemodynamic state 
of each patient. 
Patient selection and methods 
Patients were eligible for the trial if they were admitted to one 
of the participating coronary care units within 4 hr after the 
onset of chest pain and with electrocardiographic signs typical 
of acute myocardial infarction: ST segment elevation of at least 
0.1 mY in one or more extremity leads orthat of at least 0.2 mY 
in one or more precordial leads. or ST segment depression of at 
least 0.2 mY in one or more precordial leads. compatible with 
posterior wall infarction.4 Exclusion criteria were age over 70 
years. previous treatment with streptokinase, recent trauma (in-
cluding prolonged resuscitation). enhanced risk of bleeding, 
pregnancy. bypass surgery of a vessel corresponding to the 
infarct location, and mental confusion that precluded the patient 
from giving informed consent. Patients who met the inclusion 
criteria were registered by a central telephone answering service 
and were allocated either to thrombolytic therapy or to conven-
tional treatment. Informed consent was obtained from patients 
allocated to thrombolytic therapy only. Patients who refused 
consent or patients in whom thrombolytic therapy was withheld 
for other reasons received conventional treatment, but were 
included in the analysis according to original treatment 
allocation. 8 
Early coronary angiographic examinations were performed 
only in patients allocated to thrombolytic therapy. after in-
formed consent had been obtained (figure I). If the infarct-
related coronary artery appeared to be occluded, intracoronary 
streptokinase was given at a rate of 4000 U/min, until all visible 
clots had disappeared or the total of250,000 U of streptokinase 
had been given. In the second part of the study cardiac catheter-
ization was preceded by infusion of 500,000 U of streptokinase 
over 20 min, administered intravenously to reduce treatment 
delay. After catheterization patients allocated to thrombolytic 
therapy were treated according to the same treatment protocol as 
the control group. 
Serum a-hydroxybutyrate dehydrogenase (HBDH) levels 
were determined upon admission, every 12 hr for 2 days. and 
then daily up to the fifth day. Cumulative HBDH release was 
calculated from these data as described before!· 10 Radionu-
c!ide angiography was performed I to 3 days after admission. 
before discharge. and again after 3 months. Cardiac catheteriza-
tion was offered to all patients before discharge. All patients 
were followed at the outpatient clinic for at least I year after 
admission. 
For identification· of subgroups the following data. available 
at the moment of randomization, were considered: (I) history 
(age, gender, previous myocardial infarction. history of angina 
pectoris. time from onset of symptoms to admission). (2) results 
of physical examination (heart rate, blood pressure, Killip 
class), (3) electrocardiographic findings (location of the infarct, 
extent of ST segment elevation and depression). 
All ECGs were reviewed independently by two experienced 
cardiologists. Consensus about the interpretation was always 
reached. The location of the infarct was defined as anterior if 
there was ST segment elevation in leads V 1 to V 4, and as inferior 
if there was ST segment elevation in leads II, Ill. and a YF. In 
the case of ST segment elevation in leads I, aYL. Y5 , and Y6• 
the location of the infarct was defined as anterior. unless ST 
segment elevation was also present in leads 11.111, and aYF, or 
ST segment depression was present in leads V 1 to V 4 • In the 
latter case the location of the infarct was defined as inferior. The 
2ST on the ECG was defined for anterior infarcts as the sum of 
ST segment elevation in leads I. aYL. andY 1 toY 6 and that for 
inferior infarcts was defined as the sum of ST segment elevation 
in leads I, II, Ill. aYL, aYF, Y5, and Y6 and ST segment 
depression in leads Y 1 to Y 4• 
Statistical analysis. Missing data for cumulative HBDH re-
lease and L YEF were supplemented by various means. as de-
scribed in the results. Because arbitrarily chosen values for 
cumulative HBDH release and L VEF were used for some of the 
patients, nonparametric statistical tests were used. Differences 
between groups were tested with the Fisher exact test or the 
Mann-Whitney rank-sum test when appropriate. Two-sided p 
values are reported. Linear regression analysis was used to 
select the significant and clinically relevant predictors of enzy-
matic infarct size. LYEF. and 3 month mortality. A BMDP 
statistical software package was used. Baseline variables shown 
by univariate analysis to be related to cumulative HBDH release 
were entered stepwise into the regression model. Factors that 
modified the effects of thrombolytic therapy were included as 
interaction factors. 11 The same procedure was used to predict 
L YEF and 3 month mortality. 
Results 
Five hundred thirty-three patients were admitted to 
the trial between June 1981 and March 1985. Two 
ADMISSION CCU 
SYMPTOMS < 4H 
TYPICAL ECG 
1 
RANDOM I ZA Tl ON 
/~ 
CONVENTIONAL INFORMED CONSENT 
CARE C!V+)JC STREPTOKINASE 
~/ 
CUMULATIVE ENZYME RELEASE 
l 
CONTRAST ANGIOGRAPHY 
RAD!ONUCL!DE ANGIOGRAPHY 
1 
LONG TERM FOLLOW UP 
FIGURE 1. Flow chart of the study protocol. Informed· consent was 
obtained from patients allocated to thrombolytic therapy only. Patients 
who refused consent received conventional treatment, but were includ-
ed in the analysis according to original treatment allocation. CCU = 
coronary care unit; H = hours. 
49 
hundred sixty-four patients were allocated to con-
ventional treatment and 269 to thrombolytic therapy; 
152 of these were allocated to treatment with intracor-
onary streptokinase and 117 to intracoronary strepto-
kinase preceded by intravenous streptokinase. 
Forty-five patients were excluded from the present 
analysis because the ECG obtained at admission to the 
trial could not be interpreted in accordance with the 
definitions presented above. These patients were even-
ly distributed between the two treatment groups. Nine-
teen patients were excluded because they did not have 
the required amount of ST segment elevation on the 
ECG and 17 were excluded because they had only ST 
segment depression. Two patients with third-degree 
atrioventricular block and ventricular escape rhythm, 
one patient with left bundle branch block, and one 
patient with preexcitation due to an abnormal atrioven-
tricular conduction pathway were also excluded. The 
ECGs from five patients could not be retrieved for 
review. 
Table I lists the baseline and follow-up data from 
the patients admitted to the trial, including 488 patients 
included in this analysis and 45 patients excluded. One 
year follow-up was complete in all patients. All base-
line characteristics were equally distributed between 
the two treatment groups. Patients allocated to throm-
bolytic therapy had lower cumulative HBDH release. 
TABLE I 
Baseline and follow-up data 
Baseline data 
No. of patients 
Males 
Age (median) 
Previous myocardial infarction 
Anterior infarction 
In hospital at onset of symptoms 
Killip class III/IV on admission 
LST (mV) 
Median time since onset of symptoms (min) 
Follow-up data 
Median cumulative HBDH release (Ufl) 
Median radionuclide angiographic LVEF on day 10--20 (o/c) 
Median contrast angiographic LVEF on day 10-40 (%) 
Total 3 month mortality 
Total 1 year mortality 
higher L VEFs as measured by radionuclide and con-
trast angiography, and improved survival compared 
with patients allocated to conventional treatment ..... 
From here on results are presented for patients includ-
ed in this analysis only. 
Early angiographic examinations were performed in 
212 patients allocated to thrombolytic therapy (figure 
2). Among patients treated with intracoronary strepto-
kinase only, the infarct-related vessel was patent on the 
first angiogram in 22 of 118 patients ( 19%) and paten-
cy was achieved in 100 patients (85%). In the group 
pretreated with intravenous streptokinase initial vessel 
patency was observed in 39 of 94 ( 41%), and final 
patency was achieved in 81 patients (86%). 
Effect of thrombolytic therapy on enzymatic infarct size. 
Enzymatic infarct size was measured by cumulative 
HBDH release in the first 72 hr after onset of symp-
toms in 414 patients. To eliminate bias caused by mis-
sing data, infarct size was estimated in 7 4 patients. 
Twenty-seven patients who died within 72 hr all had 
extensive myocardial infarction and were assigned to 
the largest infarct category and I 0 patients without 
significant enzyme elevation were assigned to the 
group with the smallest infarct size. In 29 patients 
infarct size was estimated from cumulative HBDH re-
lease in the first 48 hr, and in eight patients it was 
estimated from cumulative creatine kinase release. 
Patients included in Patients excluded from 
this analysis this analysis 
T c T c 
245 243 24 21 
197 204 20 20 
57 56 61 55 
45 54 II 6 
116 105 13 II 
29 41 10 3 
10 11 
1.2 1.3 0.2 0.1 
95 85 50 90 
760 1170 720 560 
50 44 42 45 
56 48 50 42 
15 (6%) 33 (14%) 4 (17%1 I (5%) 
22 (9%) 41 (17%) 4 (17%) 2 (10%) 
All baseline characteristics were distributed evenly among groups. Patients allocated to thrombolytic therapy had smaller 
enzymatic infarct size. higher L VEF. and improved survival compared with control patients. 
T = allocated to thrombolysis group~ C = control group. 
50 
100% 
0 - 0 
75% 
50% Ill - 0 
25% 
Ql - Ill 
0% 
83 118 
IC 
94 
IV+IC sr ... L 2 
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32 
ShL 2 
2-4H 
66 
ST<L 2 
"'2H 
31 
ST<L 2 
2-4H 
FIGURE 2. Results of early angiography in subsets of patients. Early catheterization was offered to patients allocated to 
thrombolytic therapy only. Final patency rate was lower in patients admitted 2 to 4 hr after onset of symptoms than in patients 
admitted within 2 hr after onset of symptoms. ST = sum ofST segment elevation on the ECG at admission (mV); H = hours: 0-0 
= infarct-related vessel patent at first angiogram; •-o = infarct-related vessel opened during intracoronary infusion of 
streptokinase; •-• = infarct related vessel remained occluded. 
Median cumulative HBDH release was I I 70 U/Iiter 
in patients allocated to conventional treatment, and 
760 U/liter in patients allocated to thrombolytic ther-
apy (p = .0001). The difference in cumulative HBDH 
release between the two treatment groups (410 U/liter) 
represents limitation of infarct size by thrombolytic 
TABLE 2 
therapy. The largest differences in enzymatic infarct 
size were found in patients with high ~ST (table 2). 
The relationship between time from onset of symptoms 
to hospital admission and enzymatic infarct size is also 
given in table 2. Patients admitted to the hospital be-
fore onset of symptoms were considered a special 
Cumulative HBDH release, LVEF. and 3 month mortality in subsets of patients eligible for this analysis 
HBDH (median. U!l) LVEF (median. %) Mortality (%) 
T c T c p value T c p value T c Risk difference 
All 245 243 760 I 170 0.0001 50 43 0.0001 14 -8 (-13. -2) 
Streptokinase ic only 133 134 760 1100 0.0001 50 41 0.0001 12 -4(-12.3) 
Streptokinase iv + ic 112 109 770 1270 0.0001 50 44 0.006 4 15 -II (-20, -3) 
Anterior infarct 116 105 820 1300 0.0001 44 32 0.0001 18 -10 (-20, -2) 
Inferior infarct 129 138 670 1000 0.0001 55 49 0.0001 10 -6 (-12, I) 
In hospital at onset of symptoms 29 41 400 970 0.004 56 44 0.004 12 -9 (-23. 6) 
Admitted within 60 min 45 54 620 1310 0.0001 51 42 0.0006 4 18 -14 (-27. -I) 
Admitted 61-120 min 99 90 760 1160 0.0003 50 41 0.002 6 II -5 (-14. 3) 
Admitted 121-240 min 72 58 970 1320 0.06 47 49 0.5 14 -6 (-18. 6) 
LSTO.I-0.6mV 36 38 500 780 0.005 57 50 0.03 -5(-17.5) 
LST 0.7-1.1 mY 80 58 590 820 0.05 51 44 0.03 12 -5(-16.6) 
LST 1.2-1.7 mY 61 68 800 1280 0.003 50 46 0.07 12 -4 (-15, 8) 
LST >1.7 mY 68 79 1120 1770 0.0001 44 37 0.003 20 -14 ( -26, -4) 
FirstMI 200 189 780 1150 0.0001 52 46 0.0001 -3 (-8, I) 
Previous MI 45 54 710 1250 0.03 40 33 0.06 20 41 -21 (-38, -2) 
Killip class I or II 235 232 760 1140 0.0001 50 43 0.0001 5 II -6 (-II, -I) 
Killip class III or IV 10 II 1440 33!0 0.02 38 27 0.1 20 64 -44 (-73. -I) 
Two-sided p values (Mann-Whitney rank-sum test) or risk differences with 95% confidence interval are reponed. Thrombolytic therapy led to 
limitation of enzymatic infarct size. improvement in LVEF and reduction in 3 month mortality in all subsets of patients. Most prominent differences 
were in patients with high :EST. in patients in Killip class III or IV at admission, and in patients with an anterior infarct. 
MI = myocardial infarction; other abbreviations are as in table I. 
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group. For patients admitted to the hospital after onset 
of symptoms there was no relationship between dura-
tion of symptoms and enzymatic infarct size in the 
control group, but limitation of infarct size by throm-
bolytic therapy decreased as the delay between onset of 
symptoms and admission lengthened. Limitation of 
infarct size was greater in patients with an anterior 
infarct (480 U/liter) than in patients with an inferior 
infarct (330 U/liter). Patients in Killip class III or IV at 
admission had extensive myocardial infarction and in 
these patients there was a substantial limitation of en-
zymatic infarct size by thrombolytic therapy. 
Effect of thrombolytic therapy on left ventricular fnnc-
tion. L VEF was measured by radionuclide angiography 
I to 3 days after admission, before discharge, and 
again after 3 months, and by contrast angiography I 0 
to 40 days after admission. Radionuclide angiographic 
L VEF before discharge was used to assess the im-
provement in left ventricular function induced by 
streptokinase (336 patients). If data on radionuclide 
angiographic L VEF before discharge were missing, 
measurements obtained after 3 months (56 patients), 
after I to 3 days ( 62 patients) or of contrast angio-
graphic LVEF (six patients) were used. A LVEF ofO% 
was assigned to 24 patients who died within I 0 days 
after admission without undergoing angiography. Me-
dian L VEF was 43% in the control group and 50% in 
the streptokinase group (p = . 000 I). The largest dif-
ferences in median L VEF between the two treatment 
groups were found in patients with an anterior infarct. 
in patients admitted within 2 hr after onset of symp-
toms, and in patients in Killip class III or IV at admis-
sion (table 2). 
Effect of thrombolytic therapy on 3 month mortality. 
Three month mortality was higher in patients allocated 
to conventional treatment (14%) than in patients allo-
cated to thrombolytic therapy (6%, p = .006). This 
difference in mortality was expressed as a negative risk 
difference (6% - 14% = - 8%) produced by throm-
bolytic therapy. The largest reduction in 3 month mor-
tality was observed in patients admitted within I hr 
after onset of symptoms, in patients with lST greater 
than I. 7 m V, in patients pretreated with intravenous 
streptokinase, in patients with previous myocardial in-
farction, and in patients in Killip class III or IV at 
admission (table 2). 
Multivariate analysis. Multivariate regression analy-
sis was used to define the relative contributions of 
baseline factors to the effect of thrombolytic therapy 
on enzymatic infarct size, L VEF, and mortality. In the 
27 patients who died within 72 hr, a cumulative HBDH 
release of 3500 U/liter was used in the computations. 
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In stepwise regression analysis the following baseline 
variables appeared to be relevant predictors of cumula-
tive HBDH release, LVEF, and 3 month mortality: 
kST, allocation to thrombolytic therapy, location of 
the infarct, and Killip class at admission. The effect of 
thrombolytic therapy was modified by 1ST, delay in 
admission, and Killip class on admission. Other fac-
tors, including age, gender, history of angina, partici-
pating center, and allocation to intracoronary strepto-
kinase or intravenous and intracoronary streptokinase 
did not contribute to the prediction of cumulative 
HBDH release, L VEF, or 3 month mortality when the 
above-mentioned variables were included in the re-
gression model. 
The results of the regression analysis are given in 
table 3. At the top, the coefficients for the baseline 
variables predicting cumulative HBDH release, 
LVEF, and 3 month mortality are given. The bottom of 
table 3 gives additional values for predictive variables 
for patients allocated to thrombolytic therapy, indica!-
ing the limitation of enzymatic infarct size, the im-
provement in LVEF, and the reduction in 3 month 
mortality as a result of thrombolytic therapy. From the 
coefficients for the variables used in the regression 
analysis, the predicted effect of thrombolytic therapy 
on enzymatic infarct size, L VEF, and mortality can be 
calculated. For example, a patient with an anterior 
infarction was admitted I hr after onset of symptoms 
TABLE 3 
Regression coefficients for the multivariate regression models pre~ 
dieting enzymatic infarct size, LVEF, and mortality 
HBDH LVEF Monality 
(U!l) (%) (%) 
Intercept A 450 57 -4 
~ST (each mY) 600 (70) -6 (I) 9 (3) 
Admission delay (each hour) -10 (60) 0 (1) 0 (2) 
In hospital -300 (150) I (3) -1 (6) 
Killip class ill or IV 1230 (230) -13 (4) 49 (9) 
Previous MI 200 (80) -12 (2) 8 (3) 
Location Anterior 240 (70) -10 (1) 5 (3) 
Additional value of predictive variables for patients allocated to 
thrombolytic therapy 
Thrombolytic therapy 
~ST (each m V) 
Admission delay (each hour) 
In hospital 
Killip class ill or IV 
Standard error of the estimate 
-300 (220) 
-200 (100) 
100 (80) 
130 (240) 
-630 (340) 
740 
9 (4) 
2 (2) 
-3 (3) 
I (4) 
2 (6) 
13 
3 (8) 
-8 (4) 
2 (3) 
-3 (9) 
-33 (13) 
28 
Standard errors for the regression coefficients are given in parentheses. 
M1 = myocardial infarction. 
"(Hypothetic) Val outcome variable if all independent variables are 0. 
See text. 
with a :SST of 1.5 m V. He was in Killip class II and 
had suffered a previous myocardial infarction. If he 
were not treated with streptokinase, predicted enzy-
matic infarct size would be 450 U/liter + 1.5 X 600 
U/liter (:sST) - 10 U/liter (admission delay) + 200 
U/liter (previous myocardial infarction) + 240 U/liter 
(anterior location) = 1780 U/liter. If the same patient 
were treated with streptokinase, enzymatic infarct size 
would be 1780 U/liter - 300 U/liter (allocation to 
thrombolytic therapy) - 1.5 X 200 U/liter (:SST) + 
100 U/liter (admission delay) = 1280 U/liter. Predict-
ed limitation of enzymatic infarct size by thrombolytic 
therapy would be 1780 U/liter- 1280 U/liter = 500 
U/liter (95% confidence interval 360 to 640 U/liter). 
Similarly, predicted L VEF would be 26% and risk of 
mortality 22% if the patient were not treated with 
thrombolytic therapy, while predicted L VEF would 
increase to 35% and risk of mortality would be reduced 
to 15% after treatment with streptokinase. The expect-
ed improvement in L VEF induced by thrombolytic 
therapy would be 9% (95% confidence interval 7% to 
11 %), and the risk difference for mortality -7% (95% 
confidence interval -2% to -12%). 
The expected limitation of infarct size, improve-
ment in LVEF, and reduction in mortality can be ex-
pressed as a function of :SST and time from onset of 
symptoms to admission. Corrections must be made for 
2. 0 
ST 
mY 
1.0 
NO LIMITATION OF INFARCT SIZE 
BY THROMBOLYTIC THERAPY 
patients in hospital at the time of onset of symptoms 
and patients in Killip class III or IV at admission. The 
predicted effect of thrombolysis on enzymatic infarct 
size is a limitation with 300 U/liter + 200 U/liter for 
each millivolt of :SST - I 00 U/liter for each hour 
delay between onset of symptoms and admission (fig. 
ure 3). The predicted improvement in LVEF as a result 
of thrombolysis is 9% + 2% for each millivolt of :SST 
- 3% for each hour after onset of symptoms. The risk 
difference for mortality after thrombolytic therapy is 
3% - 8% for each millivolt of :SST + 2% for each 
hour between onset of symptoms and admission. 
Since these computations are somewhat cumber-
some, four subgroups of patients that can easily be 
recognized in clinical practice were defined: patients 
with :SST less than I .2m V, those with :SST of 1.2 m V 
or more, those with times from onset of symptoms to 
admission of less than 2 hr, and those with times from 
onset of between 2 and 4 hr. Patency rate at the end of 
the procedure was high in all these subsets of patients. 
although somewhat lower (68%) in patients with :SST 
less than I. 2 m V who were admitted between 2 and 4 
hr after onset of symptoms (figure 2). Limitation of 
infarct size by thrombolytic therapy was greatest in 
patients with :SST of 1.2 mV or more and in patients 
admitted within 2 hr after onset of symptoms (figure 
4). Improvement in LVEF was seen only in patients 
0 w 1~ 100 MIN 240 
TIME FROM ONSET OF SYMPTOMS TO ADMISSION 
FIGURE 3. Limitation of infarct size by streptokinase. Results of the multivariate regression model. Predicted limitation of 
infarct size is a function ofi.ST and time from onset of symptoms to admission. ST = sum of ST segment elevation on the ECG 
at admission (mV). 
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FIGURE 6. Three month mortality, expressed as a percentage. in four subsets of patients in both treatment groups. Reduction in 
three month mortality was most prominent in patients with 1ST of 1.2 mY or more. ST = sum of ST segment elevation on the 
ECG at admission (mV). 
treatment groups was not altered by the use of another 
L VEF measurement in the patients in whom radionu-
clide angiography was not performed before dis-
charge. The 24 patients who died within 10 days after 
admission without angiography (22 of them died with-
in 72 hr after admission) were included to prevent the 
bias described above in the discussion of cumulative 
HBDH release. To these patients a L VEF of 0% was 
assigned; no apparent differences with respect to the 
prediction of L VEF were found in the regression anal-
ysis when L VEF values of I 0% or 20% were assigned 
to these patients. 
The effects of thrombolytic therapy on limitation of 
enzymatic infarct size, improvement in LVEF, and 
reduction in mortality were related to the same inde-
pendent factors. No relevant changes in the value of 
these independent factors were found when the regres-
sion analyses were repeated without the inclusion of 
estimates for missing data on cumulative HBDH re-
lease and L VEF. 
Pretreatment with intravenous streptokinase. During 
the course of this trial on early reperfusion by intrave-
nous streptokinase other studies have been reported. 13 
Since it was our aim to achieve reperfusion as quickly 
as possible, pretreatment with intravenous streptoki-
nase was added to the protocol for patients allocated to 
thrombolytic therapy since January 1984. Earlier anal-
ysis suggested that, although intravenous pretreatment 
resulted in a larger fraction of patients with a patent 
infarct-related vessel at the first angiographic exami-
nation (figure 2), effects on infarct size and left ven-
tricular function were similar with and without pre-
treatment. 6• 10 Accordingly, inclusion of pretreatment 
56 
in the regression model did not improve the prediction 
of cumulative HBDH release, LVEF, or 3 month mor-
tality when the other predictors were included in the 
modeL Due to the low number of patients pretreated 
with intravenous streptokinase (n = 94), no conclu-
sions can be drawn about the merits of this additional 
therapy from our data. 
Comparison with other trials. Other randomized tri-
als 17- 26 of intracoronary streptokinase have not shown 
consistent limitation of infarct size, improvement in 
left ventricular function, or reduction in early mortal-
ity. This discrepancy with our data can now be ex-
plained by the delays in admission and the different 
inclusion criteria in those trials. Time is a crucial factor 
in thrombolytic therapy after acute myocardial infarc-
tion. In nonrandomized trials it has been reported that 
recanalization leads to limitation of infarct size pro-
vided therapy is started within 4 hr after onset of symp-
toms, 27• 28 although beneficial effects of intracoronary 
streptokinase have been reported in individual patients 
treated up to 18 hr after the onset of chest pain. 29 In the 
present study beneficial effects of streptokinase in pa-
tients admitted between 2 and 4 hr after onset of chest 
pain were observed only in those with extensive myo-
cardial ischemia, as reflected by a high ~ST, and in 
patients in Killip class III or IV at admission. Although 
recanalization was also observed in a high percentage 
(68%) of patients with low ~ST, this did not lead to 
limitation of enzymatic infarct size, improvement in 
LVEF, or reduction in mortality. 
In the Western Washington trial, 17- 20 mean time to 
initiation of streptokinase infusion was 276 min, and 
patients with newly fonned Q waves or receiving 
maintenance therapy for congestive heart failure were 
excluded. A significant reduction in early mortality 
was reported, although no beneficial effect on infarct 
size by thallium imaging or on left ventricular function 
was observed. Apparently this study included many 
patients who would not benefit from thrombolytic ther-
apy according to our analysis, while patients with ex-
tensive ischemia leading to left ventricular failure, 
who might have benefitted from thrombolytic therapy, 
were excluded. In two other studies the infusion of 
streptokinase started on average more than 5 hr after 
the onset of symptoms and patients with signs of car-
diogenic shock were excluded. 2 1. 22 No improvement in 
left ventricular function or reduction in mortality was 
observed. which is consistent with our observations. 
Among three relatively small studies beneficial effects 
of thrombolytic therapy were observed in only one, in 
which the mean time between onset of symptoms and 
admission was 160 min. 2,_26 In most of these studies 
patients with new! y formed Q waves or signs of cardia-
genic shock were excluded, and these groups of pa-
tients were shown to benefit greatly from thrombolytic 
therapy in the present trial. 30 
ST segment elevation as predictor of the effects of throm-
bolytic therapy. In the regression analysis enzymatic 
infarct size was strongly related to 2ST. although ST 
segment elevation may vary considerably over longer 
periods of time in patients with acute myocardial in-
farction."· 32 The highest ST segment elevation is usu-
ally found within I hr after the onset of symptoms. In a 
group of patients V(ho are already in the hospital before 
the onset of symptoms infarct size may be overestimat-
ed by 2ST. This explains why "in hospital at the onset 
of symptoms" was included as an independent variable 
in the regression model. In patients admitted after the 
onset of symptoms no correction was necessary for the 
gradual decrease in ST segment elevation with time. 
Contrary to other observations. 33 we noted that pa-
tients with inferior infarction and precordial ST seg-
ment depression generally had larger infarctions than 
patients without precordial ST segment depression. 
The regression coefficient for the total ST segment 
elevation was equal to the regression coefficient for the 
total precordial ST segment depression. so both were 
combined. Contralateral ST segment depression was 
not related to enzymatic infarct size in patients with 
anterior infarction, and therefore was not included in 
the regression model. 
Which patients benefit most from thrombolytic therapy 
by intracoronary streptokinase? Thrombolytic therapy 
with intracoronary streptokinase led to significant 
limitation of infarct size. improvement in left ventricu-
Iar function. and reduction in mortality in patients with 
extensive myocardial ischemia, that is. in patients with 
a high 2ST, when thrombolytic therapy was started in 
the first few hours after onset of symptoms. Data from 
the GISSI trial34 and the ISAM study35 also indicate 
that beneficial effects from intravenous streptokinase 
dominate in patients admitted within 3 hr after onset of 
symptoms. Thus. it can now be recommended that 
thrombolytic therapy be offered to patients admitted 
within the first few hours after the onset of symptoms. 
and only to those patients who show extensive ST 
segment elevation on the ECG. Further studies pres-
ently underway both in the United States and in Europe 
should determine the relative values of intravenous and 
intracoronary treatment and of the use of streptokinase 
or other thrombolytic agents such as recombinant tis-
sue-type plasminogen activator. 
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CHAPTERS 
Cost benefit analysis of early thrombolytic therapy with 
intracoronary streptokinase 
12 month follow-up report of the randomised multicentre trial conducted by the 
Netherlands Interuniversity Cardiology Institute. 
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Cardiology Institute, The Netherlands: 
In slightly different version accepted for publication in Br Heart J. 
Summary 
Costs and benefits of early thrombolytic therapy with intracoronary strep-
tokinase in acute myocardial infarction were compared in a randornised trial. 
All hospital admissions were recorded and functional class was assessed at 
visits to the out-patient clinic during 12 months follow-up of 269 patients 
allocated to thrombolytic therapy and 264 to conventional treatment. Mean 
survival during the first year was calculated for patients with inferior and with 
anterior infarction and adjusted for impaired quality of life in case of 
symptoms or hospital admission. In patients with inferior infarction mean 
survival was 337 days (out of 365 days) for patients allocated to thrombolytic 
therapy and 327 days for controls (p = 0.4). Quality adjusted survival was 7 
days longer in the thrombolysis group (307 v 300 days in controls). In patients 
with anterior infarction mean survival was 35 days longer in the thrombolysis 
group compared with the control group (p = 0.02) and quality adjusted 
survival was 38 days longer (304 v 266 days in controls; p = 0.002). 
Life expectancy was calculated for all patients. The gain in life expectancy 
by thrombolytic therapy was 0. 7 years for patients with inferior infarction, 2.4 
years for patients with anterior infarction, and 3.6 years for the subset of 
patients with large anterior infarction who were admitted within two hours 
after onset of symptoms. Costs of medical therapy, including hospital stay, 
cardiac catheterisations, coronary angioplasty, and bypass surgery in the first 
year follow-up were higher in patients allocated to thrombolytic therapy 
(Dfl. 7,000 in inferior and Dfl. 9,000 in anterior infarction) than in conven-
tionally treated patients. The additional costs per year of life gained were 
Dfl. 10,000 in inferior infarction, Dfl. 3,800 in anterior infarction, and only 
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Dfl. 1,900 in patients with large anterior infarction, admitted within two hours 
after onset of symptoms. Intracoronary thrombolysis can be recommended as 
a cost effective therapy in patients with extensive antero-septal infarction. 
Introduction 
In the randornised trial conducted by the Netherlands Interuniversity Cardiol-
ogy Institute, patency of the infarct related coronary artery was achieved in 
85% of the patients treated with intracoronary streptokinase. This was associ-
ated with limitation of enzymatic infarct size, improvement of global and 
regional ieft ventricular function, and improved survival ( 1-5). However, non-
fatal reinfarction occurred more frequently and percutaneous transluminal 
coronary angioplasty or coronary artery bypass grafting were required more 
often in patients allocated to thrombolytic therapy than in the control group 
(1,2). The improved survival after early thrombolytic therapy on one hand, 
together with the higher incidence of non-fatal complications in these patients, 
makes it difficult to assess the true value of thrombolytic therapy in acute 
myocardial infarction. In order to obtain a complete picture of total mortality 
and morbidity the functional status of each patient was recorded at regular 
intervals during one year follow-up. Also the total medical costs were recorded 
in each patient. From these data mean survival was calculated and adjusted for 
impaired quality of life in case of symptoms or hospital admission. Further-
more the "additional costs" of thrombolytic therapy per "year of life gained" 
were computed. In patients with anterior infarction quality adjusted survival 
appeared to be significantly better in patients allocated to thrombolytic 
therapy. On the other hand, differences between both groups were limited in 
patients with inferior infarcts. 
Patient selection and methods 
Five hundred and thirty three patients entered the trial as described earlier (1). 
Patients were eligible for the trial if admitted to one of the five participating 
coronary care units within four hours after onset of chest pain and with 
electrocardiographic signs typical for acute myocardial infarction. Two 
hundred and sixty four patients were allocated to conventional therapy, 269 to 
thrombolytic therapy of whom 152 to intracoronary streptokinase and 117 to 
intracoronary streptokinase preceded by intravenous streptokinase. Informed 
consent was asked from patients allocated to thrombolytic therapy only. 
Patients who refused consent or patients in whom thrombolytic therapy was 
withheld for other reasons received conventional treatment, but were included 
in the analysis according to original treatment allocation (6). Acute coronary 
angiography was performed in 234 patients allocated to thrombolytic therapy. 
If the infarct related coronary artery appeared to be occluded, intracoronary 
streptokinase was given, usually 250,000 U. In the second part of the study 
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angiography was preceded by intravenous administration of 500,000 U strep-
tokinase in order to reduce treatment delay. In 46 patients with severe residual 
stenosis of the infarct related coronary artery coronary angioplasty was 
attempted as part of the recanalisation procedure. After catheterisation pa-
tients allocated to thrombolytic therapy were treated according to the same 
treatment protocol as the control group (1). 
All patients were followed at the out-patient clinic for at least one year after 
admission. The following data were recorded: 
- Functional class on the day of each visit to the out-patient clinic, according 
to the criteria of the New York Heart Association (7). 
- All hospital admissions, including day of admission, day of discharge, and 
reason for admission. 
- Functional class before hospital admission and functional class at discharge. 
- If a patient died: day and cause of death and functional class prior to death. 
From these data the functional status was defined for each patient at weekly 
intervals as the lowest of the following six mutually exclusive classifications: 
- Class I (criteria New York Heart Association), not hospitalised 
- Class II (criteria New York Heart Association), not hospitalised 
- Class III (criteria New York Heart Association), not hospitalised 
- Class IV (criteria New York Heart Association), not hospitalised 
- Hospitalised 
- Deceased. 
Changes of functional class were assumed to have occurred halfway between 
two subsequent visits to the out-patient clinic unless known otherwise. Mean 
number of days spent in each category was calculated for all patients. Mean 
survival was calculated for each group of patients as the mean time elapsed 
between admission to the study and death or end of follow-up (one year). 
Survival was adjusted for impaired quality of life by discount factors for days 
spent in Class II-IV or in hospital, as described under results (8). Costs of 
medical therapy the first year after acute myocardial infarction were calcula-
ted, taking into account the number of days in hospital, the increased costs for 
stay in a coronary care unit or surgical intensive care unit, costs- of acute 
coronary angiography including thrombolytic therapy with or without coro-
nary angioplasty, costs of elective coronary angiography, elective coronary 
angioplasty, and bypass surgery. 
Differences between groups were tested with Fisher's exact test, Mann 
Whitney's rank sum test, or Student's t-test when appropriate. Two sided p 
values are reported. 
Results 
One year follow-up was complete in all 533 patients admitted to the trial, 
duration of follow-up ranged from 1 to 4 years (mean 2 years). Baseline 
characteristics were distributed evenly between both treatment groups (table 
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Rj Table 8.1. Baseline and follow-up data 
All patients Inferior MI Anterior MI 
c T p c T p c T p 
Number of patients 264 269 148 139 116 130 
Males 224 217 123 110 101 107 
Previous myocardial infarction 60 56 31 28 29 28 
Median admission delay (minutes) 90 90 90 90 90 90 
Median cumulative HBDH release (U/1) 1100 770 0.0001 970 670 0.007 1280 840 0.005 
Mean angiographic LVEF (day 10-40, %) 47 53 0.0001 49 57 0.0001 43 50 0.002 
Total one year mortality 43 26 0.03 17 12 0.4 26 14 0.01 
Recurrent myocardial infarction 14 36 0.001 9 26 0.001 5 10 0.3 
C =control group; T =thrombolysis group; HBDH =alpha hydroxybutyrate dehydrogenase; LVEF =left ventricular ejection fraction. Two 
sided p values (Mann-Whitney's rank sum test or Fisher's exact test) are reported from follow-up data. 
1). Patients allocated to thrombolytic therapy showed a 30% limitation of 
enzymatic infarct size (median a-hydroxybutyrate dehydrogenase release 770 
VII v 1100 U/1 in controls, p = 0.0001), higher left ventricular ejection fraction 
by contrast angiography (53% v47%, p = 0.0001), improved one year survival 
(90% v 84%, p = 0.03), and a higher incidence of non-fatal reinfarction (13% 
v 5%, p = 0.001). Mean hospital stay during the first year was similar in both 
treatment groups, although coronary angioplasty and bypass surgery were 
performed more frequently in the thrombolysis group (table 2). 
Table 8.2. Hospital admissions, hospital stay, PTCA, CABG, and cardiac catheterisations in 
patients with inferior and anterior infarction, and in the subgroup of patients with anterior 
infarction, admitted to the hospital within 2 hours after the onset of symptoms with extensive 
myocardial ischemia (see results). 
Anterior 
infarction 
lST;?;1.2mV 
Inferior Anterior admitted 
within 2 hrs 
c T c T c T 
Number of patients 148 139 116 130 50 45 
Catheterisation + Sk 107 88 29 
Catheterisation + Sk + PTCA 17 29 12 
Elective catheterisation 120 99 85 100 35 38 
Recurrent MI 9 26 5 10 2 4 
Late PTCA 7 9 6 14 2 8 
CABG 21 22 11 22 1 4 
Other hospital admissions 41 39 33 36 18 16 
Days in hospital (general ward) 2521 2310 2041 2190 791 689 
Days in CCU 491 523 367 456 164 133 
Days in surgical ICU 42 44 22 44 2 8 
MI = mycardial infarction; Sk = streptokinase; PTCA = percutaneous transluminal coronary 
angioplasty; CABG = coronary artery bypass grafting; CCV = coronary care unit; ICU = 
intensive care unit; l ST = total ST segment elevation on the ECG made at admission to the trial. 
The proportion of patients in each functional class at weekly intervals during 
one year follow-up is presented for patients with inferior infarction in figure 1. 
Patients allocated to thrombolytic therapy showed improved survival, com-
pared with the control group as is evident by the larger area occupied by the 
survivors. Mean survival and average number of days spent in each category 
were calculated (table 3). Mean survival at one year follow-up after inferior 
infarction was 10 days longer in the thrombolysis group compared to the 
control group (p = 0.4), although less days were spent without symptoms (225 
v 232 days in controls). In patients with anterior infarction differences in 
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survival between the two treatment groups were more pronounced than in 
inferior infarction. Mean survival was 35 days longer in the thrombolysis group 
(p = 0.02), with more days without symptoms (239 v 183 days in controls, p = 
0.002), as illustrated by the larger area of class I after thrombolysis in figure 2. 
CONTROLS INFERIOR STREPTO INFERIOR 
100% 
DECEASED 
II1-IV 
80% 
60% 60% 
CLASS I 
40% 40% CLASS I 
20% 20% 
0%~---.----.----.--~ 0%W----,----.----.--~ 
3 6 9 12 3 6 9 12 
MONTHS MONTHS 
Figure 8.1. Proportion of patients with inferior infarction in each functional class during the first 
year after myocardial infarction. In hospital is presented by the shaded area. NYHA class III and 
IV are combined. 
To weigh the opposite differences in mortality and morbidity, especially in 
patients with inferior infarction, quality adjusted survival was calculated by 
means of an estimation of the impairment of quality of life in case of symptoms 
or hospital admission. Quality of life without symptoms (class I) was given 
100%. Quality of life in class II was estimated as 90%, in class III or IV as 70%, 
and in hospital as 30% (8). Following these estimations quality adjusted mean 
survival for patients with inferior infarction was 307 days (out of 365 days) in 
the thrombolysis group and 300 days in the control group (table 3). In patients 
with anterior infarction quality adjusted survival was 38 days longer in the 
thrombolysis group than in controls (p = 0.008). 
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CONTROLS ANTERIOR STREPTO ANTERIOR 
100% 100% DECEASED 
DECEASED 
I II-IV 
80% 80% 
II I-IV 
60% 60% 
CLASS I 
40% 40% 
CLASS I 
20% 20% 
0%~---.----.----r--~ O%w_ __ _,----,----.--~ 
3 6 9 12 3 6 9 12 
MONTHS MONTHS 
Figure 8.2. Proportion of patients with anterior infarction in each functional class during the first 
year after myocardial infarction. See legend figure 8.1. 
Costs of medical therapy the first year after myocardial infarction were based 
on the price level of 1984 at the University Hospital Dijkzigt in Rotterdam. 
Included were days spent in hospital (Dfl. 600/day), days in a coronary care 
unit (Dfl. 1,500/day), days in a surgical intensive care unit (Dfl. 2,500/day), 
costs of acute cardiac catheterisation including thrombolytic therapy 
(Dfl. 6,200) and coronary angioplasty (Dfl. 11,900), costs of elective 
catheterisation (Dfl. 2,600), elective coronary angioplasty (Dfl. 8,300) and 
bypass surgery (Dfl. 14,000). Total costs of medical therapy the first year after 
myocardial infarction averaged Dfl. 20,000 for inferior infarction and 
Dfl. 19,000 for anterior infarction in the control group, and Dfl. 27,000 for 
inferior infarction and Dfl. 28,000 for anterior infarction in patients allocated 
to thrombolytic therapy. The higher costs of patients allocated to thrombolytic 
therapy were mainly due to the acute catheterisation. 
Life expectancy was calculated by the DEALE method (9,10). Mortality 
rate was assumed to be 6% per year for patients alive at the end of follow-up. 
This assumption was based on long term prognosis after myocardial infarction 
as observed in several large studies (11-14). Thrombolytic therapy increased 
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Table 8.5. Calculation of costs per year of life gained in various groups of patients 
Mean life expectancy Costs Costs per year 
c T c T of life gained 
Inferior infarction 16.3 years 17.0 years Dfl. 20,000 Dfl. 27,000 Dfl. 10,000 
Anterior infarction 
(all patients) 14.1 years 16.5 years Dfl. 19,000 Dfl. 28,000 Dfl. 3,800 
Anterior infarction 
(admission :,;;; 2 hours 12.7 years 16.3 years Dfl. 17,000 Dfl. 24,000 Dfl. 1,900 
and :SSt;;, 1.2 mV) 
Anterior infarction 
(admission 2-4 hours 15.1 years 16.6 years Dfl. 21,000 Dfl. 31,000 Dfl. 6,700 
or :SST< 1.2 mV) 
In this analysis all hospital admissions were recorded and functional class was 
defined for each patient at regular intervals during one year follow-up, 
according to the method proposed by Olsson et al. (18). This enabled us to 
compare differences in mortality and morbidity between the two treatment 
groups. Although the assessment of impairment in the quality of life when 
angina pectoris or heart failure occurs is dependent on the patient's opinion, 
quality of life can be measured in an objective manner from the ability to carry 
on normal activity (8) as estimated by the Karnofsky Performance Status 
Scale. It is evident that in patients with anterior infarction thrombolytic 
therapy improved both life expectancy and quality of life, independent of the 
method chosen for quality adjustment, while the salutary effects of thromboly-
tic therapy in inferior infarction remained small. Total duration of hospital 
stay appeared to be equal in both treatment groups. However, admissions in 
the thrombolysis group were more often related to ischemia (reinfarction and 
additional revascularisation procedures as coronary angioplasty or bypass 
surgery), while in the control group more admissions were due to symptoms of 
heart failure. This confirms the more severe impaired left ventricular function 
in conventionally treated patients. 
The true "costs" of thrombolytic therapy include the acute intervention as 
well as the higher incidence of reinfarction and additional revascularisation 
procedures. Therefore total costs in the first year were calculated. It should be 
noted that the number of days "in hospital" (table 3) was based on a weekly 
assessment of functional status. This overestimated actual hospital stay which 
was 21 days in both treatment groups. Calculation of total costs was based on 
actual hospital stay, catheterisations, coronary angioplasty, and bypass sur-
gery during follow-up. Although thrombolytic therapy reduced the occurrence 
of ventricular fibrillation, cardiogenic shock, and heart failure (1), workload 
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on the coronary care unit was not affected. The increased workload due to the 
administration of thrombolytic therapy was balanced by the lower incidence of 
complications in the coronary care unit (19). Therefore the average costs for 
stay on the coronary care unit were used. Medication was not taken into 
account since this did not differ between the two treatment groups. 
Total costs per patient during one year follow-up appeared to be higher after 
thrombolytic therapy, mainly due to the costs of acute angiography and 
subsequent coronary angioplasty or bypass surgery. Evenso, the cost benefit 
analysis of intracoronary thrombolytic therapy with streptokinase is very 
favourable when compared with other established medical therapies. For 
example costs for one year increase in quality adjusted life expectancy after 
bypass surgery as calculated by Weinstein varied from Dfl. 20,000 to 
Dfl. 75,000 (20) while the costs for treatment of moderate diastolic hyperten-
sion were Dfl. 30,000 to Dfl. 90,000 per year oflife gained (21). The excellent 
cost benefit ratio for thrombolytic therapy is related to the fact that it requires 
but a single intervention at the time of hospital admission, with considerable 
salutary effects, in particular in patients with a large anterior infarction. The 
treatment can thus be limited to a well defined and easily recognised group of 
patients, while hypertension therapy must be given to large numbers of 
patients over a long period of time in order to prevent or delay a relatively 
small number of cardiovascular events. 
A disadvantage of intracoronary thrombolytic therapy is the need for acute 
angiography. It should be noted however, that the costs of equipment and 
personnel for 24 hours angiography service were included in the analysis. It is 
as yet unknown how the cost benefit ratio of intracoronary thrombolysis 
relates to intravenous thrombolysis. Intravenous administration of strep-
tokinase is initially less expensive, but also considerably less effective than 
intracoronary treatment both in achieving patency, in salvage of myocardial 
function (22) and in mortality reduction (17). Careful analysis of follow-up 
data of trials with intravenous streptokinase (17,22), intravenous tissue-type 
plasminogen activator (23-25) and intracoronary treatment with or without 
immediate coronary angioplasty should enable physicians and health authori-
ties to decide upon the most cost effective method for thrombolytic treatment. 
From presently available data intracoronary thrombolysis can be recom-
mended as a cost effective therapy in patients with extensive anterior myocar-
dial ischemia (15, 26) admitted early after the onset of symptoms of myocardial 
infarction. 
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CHAPTER9 
Value of PTCA performed immediately after successful 
thrombolysis with intracoronary streptokinase 
A matched pair analysis of the effect of PTCA in the randomized multicentre 
trial of intracoronary streptokinase conducted by the Interuniversity Cardiol-
ogy Institute the Netherlands. 
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Abstract 
Acute PTCA following successful thrombolysis with streptokinase was per-
formed in 46 patients out of 533 patients enrolled in a multicentre randomized 
trial comparing a strategy aimed at early reperfusion with conventional 
therapy in patients with acute myocardial infarction. Additional effects of 
PTCA were compared with successful thrombolysis alone in a matched pair 
analysis. The indication for PTCA was significant residual obstruction after 
thrombolysis with insufficient distal run-off, as visualized during catheteriza-
tion. Thirty six pairs of patients were formed who were identical with respect 
to the infarct related coronary artery, presence or absence of previous myocar-
dial infarction, total ST segment elevation on the ECG at admission to the 
trial, and delay between onset of symptoms and hospital admission. All further 
hospital admissions were recorded and functional class was assessed at visits to 
the out patient clinic during three years follow-up. PTCA after successful 
thrombolysis did not lead to additional limitation of infarct size. However, 
improvement in L VEF, measured by radionuclide angiography, was 8% in the 
PTCA group vs 2% after successful thrombolysis alone (p = .005). Recurrent 
infarction within three years was 14% in the PTCA group versus 30% in the 
thrombolysis group (p = .05). In the PTCA group more time was spent 
without symptoms of angina or heart failure (mean 128 weeks out of 156 
weeks) than in the thrombolysis group (102 weeks; p = .03). Prevention of 
recurrent ischemia by early PTCA was observed to the same extent in patients 
with anterior infarction and with inferior infarction. 
It is concluded that immediate PTCA after successful thrombolysis prevents 
recurrent ischemia and improves quality of life. Thus PTCA can be recom-
mended as an early procedure in patients who demonstrate a residual stenosis 
of 70% or more in the infarct related coronary artery with a poor distal run-off. 
72 
Introduction 
A strategy aimed at early recanalization of an infarct related coronary artery 
with intracoronary streptokinase (1-5) will result in salvage of myocardial 
tissue (6-8), preservation of left ventricular function (9-10), and improved 
survival (5, 11-12). However, in many patients a severe stenosis of the infarct 
related artery remains after successful thrombolysis. This artery may reoc-
clude in part of the patients and abolish the initial beneficial effects of throm-
bolytic therapy. Indeed, non-fatal reinfarction occurred more frequently in 
patients allocated to thrombolytic therapy than in conventionally treated 
patients (5, 12). In order to prevent reocclusion, but also to optimize coronary 
flow to the jeopardized myocardium, acute PTCA has been advocated by 
several authors (13-17), and the efficacy of PTCA early after thrombolytic 
therapy is currently investigated in randomized clinical trials (18-20). The 
purpose of the present analysis was to evaluate the influence of PTCA per-
formed immediately after successful thrombolysis in part of the patients in the 
randomized trial conducted by the Interuniversity Cardiology Institute the 
Netherlands (ICIN), on left ventricular function, re-infarction, reocclusion, 
and on the necessity of subsequent revascularization procedures such as 
re-PTCA or coronary artery bypass grafting. In order to eliminate a possible 
selection bias, patients who underwent acute PTCA were compared with a 
matched group of patients with similar baseline characteristics in whom the 
lesion in the infarct related coronary artery was suitable for PTCA but who 
were admitted to those hospitals where PTCA could not be performed as part 
of the recanalization procedure. 
Patient selection and methods 
Patient selection and methods of the trial conducted by the ICIN have been 
described extensively before (5,14). Thrombolytic therapy was given after 
informed consent and consisted of intracoronary administration of strep-
tokinase in the catheterization laboratory, usually 250,000 U. In patients 
admitted to the trial since January 1984 this was preceded by intravenous 
administration of 500,000 U streptokinase given upon admission, in order to 
reduce treatment delay. The indication for PTCA was significant residual 
obstruction after thrombolysis with insufficient distal run-off as visualized 
during catheterization. In addition all patients received acetyl salicylic acid 250 
mg intravenously and heparin 20,000 U/24 hours followed by oral coumadin 
until hospital discharge.Niphedipine,(10 mg four times daily)was given to most 
patients after PTCA. 
Total ST segment elevation was calculated as the sum of ST segment 
elevation in standard and precordial leads, as described before (11). Global 
left ventricular ejection fraction (L VEF) was measured by radionuclide 
angiography 1 to 3 days after admission and again after 10 to 20 days. All 
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patients were followed at regular intervals at the out-patient clinic for 20 to 60 
months (mean 38 months) after admission. All hospital admissions were 
recorded and functional class was assessed according to the criteria of theN ew 
York Heart Association (NYHA). 
From these data the functional status was defined for each patient at weekly 
intervals as the lowest of the following five mutually exclusive classifications: 
- Class I (NYHA), not hospitalized 
- Class II (NYHA), not hospitalized 
- Class III or IV (NYHA), not hospitalized 
- Hospitalized 
- Deceased. 
Mean number of weeks spent in each category was calculated for all patients. 
Mean survival was calculated as the mean time elapsed between admission to 
the study and death or end of follow-up (three years). 
Matching 
The patients in whom immediate PTCA was attempted (PTCA group) were 
matched with patients allocated to thrombolytic therapy in those participating 
centres where PTCA could not be performed as part of the recanalization 
procedure (Sk-only group). Matching was performed according to the follow-
ing rules: 
- Coronary angiograms of all patients successfully treated with intracoronary 
streptokinase and admitted to those participating centres where acute 
PTCA was not performed were reviewed by three cardiologists to assess 
whether the lesion in the infarct related coronary artery had been suitable 
for PTCA. Consensus about the suitability for PTCA was always reached. 
Only patients in whom the lesion was judged to have been suitable for 
PTCA were included in the next step of the matching procedure. 
- All patients were grouped with regard to the infarct related coronary artery 
and the presence or absence of previous myocardial infarction. 
- Within each group pairs of patients were selected with least difference in 
admission delay (maximum difference 30 minutes) and secondly least 
difference in total ST segment elevation (maximum difference 0.6 mV) on 
the ECG made at admission to the trial. Admission delay and total ST 
segment elevation were chosen as matching parameters since they deter-
mined the outcome of thrombolytic therapy as reported earlier (11). 
In order to ascertain that differences between the PTCA group and the Sk -only 
group were not due to differences between the various hospitals, two matched 
control groups of patients allocated to conventional therapy were constructed. 
One control group was formed from patients allocated to conventional therapy 
in the hospitals where acute PTCA was performed (matched control group I), 
and the other from patients allocated to conventional therapy in hospitals 
without acute PTCA (matched control group II). Matching for these groups 
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Table 9.1. Baseline characteristics 
Matched groups Matched control 
All groups 
c TPTCA PTCA Sk-only CI en 
No of patients 264 269 46 36 36 36 36 
Males 224 217 39 29 29 28 26 
Previous infarction 60 56 12 4 4 4 4 
Anterior infarction 116 130 29 22 22 22 22 
Age (median) 56 57 59 59 56 52 55 
Admission delay (median; min) 90 90 90 90 105 90 100 
l ST (median; mV) 1.2 1.1 1.3 1.2 1.1 1.2 1.3 
Abbreviations: 
C: control group; T: allocated to thrombolysis; min: minutes; Sk: streptokinase; PTCA: percutaneous translumi-
naCcoronary angioplasty; CI: matched control group from hospitals with acute PTCA; CII: matched control 
group from hospitals with Sk-only; l ST: total STsegment elevation on the electrocardiogram made on admission 
to the trial. 
Baseline characteristics were distributed evenly between the four matched groups. 
was done according to the same rules as described for the PTCA group and the 
Sk-only group. Patients in the control groups with anterior infarction on the 
ECG were compared with patients in the thrombolysis group where the lesion 
was located in the left anterior descending artery, and patients with inferior 
infarction were compared with patients with a lesion in the right coronary 
artery. 
Statistical analysis 
Differences between groups were tested with Fisher's exact test or Student's T 
test when appropriate. Two sided p-values are reported. 
Results 
A total of 533 patients were admitted to the trial. Acute angiography was 
performed in 234 out of 269 patients allocated to thrombolytic therapy, 20 
patients refused the intervention, and in the remaining 15 patients thromboly-
tic therapy was withheld for other reasons ( 5). PTCA was performed as part of 
the recanalization procedure in 46 patients admitted to two of the five par-
ticipating hospitals, the Thoraxcenter in Rotterdam (44 out of 106 patients) 
and the Academic Hospital in Leiden (2 out of 9 patients) (6). PTCA was not 
successful in two patients since the artery reoccluded immediately after the 
procedure. Patency of the infarct related coronary artery as shown at angiogra-
phy was achieved in 98 patients admitted to one of the three participating 
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Table 9.2. Results of coronary angiography (n = 234) 
Matched groups 
PTCA Sk-only PTCA Sk-only 
Number of patients 46 188 36 36 
Infarct related artery 
LAD 29 74 22 22 
RCA 15 74 14 14 
LCX 2 38 0 0 
bypass 0 2 0 0 
Patency at the end of the 
procedure 
occluded 2 34 2 0 
91-99% 4 89 4 27 
50-90% 4 54 4 8 
<50% 36 11 26 1 
Patency at second angiography 
patent 31 113 25 23 
occluded 6 27 4 5 
unknown 9 48 7 8 
Abbreviations: 
PTCA: percutaneous transluminal coronary angioplasty; Sk: streptokinase; LAD: left anterior 
descending artery; RCA: right coronary artery; LCX: left circumflex artery. 
PTCA led to a significant decrease in residual stenosis of the infarct related coronary artery. 
centres where acute PTCA was not performed. Coronary angiograms were 
available for review from 86 of these 98 patients. The lesion in the infarct 
related coronary artery was on review judged to have been suitable for PTCA 
in 62 patients. These 62 patients were matched with the 46 patients in whom 
acute PTCA was actually carried out. Thirty six pairs of patients were formed 
following the matching rules as described in the methods section. Ten patients 
in whom acute PTCA was performed could not be matched because no pairs of 
patients could be formed which were identical with regard to the infarct related 
coronary artery and the presence or absence of previous myocardial infarc-
tion. Baseline characteristics were distributed evenly between the four 
matched groups (table 1). 
Coronary angiography 
Acute PTCA was performed more often when the lesion was located in the left 
anterior descending artery (29 out of 55 patients in the two hospitals with acute 
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Table 9.3. Patency of the infarct related coronary artery at second angiography (10-40 days) in 
patients with successful thrombolysis (n = 198) 
All patients Matched groups 
PTCA Sk-only PTCA Sk-only 
Number of patients 44 154 36 36 
LAD 
patent 22 45 16 17 
occluded 1 5 1 2 
unknown 4 12 5 3 
RCAorLCX 
patent 9 57 7 8 
occluded 5 14 4 2 
unknown 3 21 3 4 
Abbreviations: See table 2. 
Reocclusion rate was not influenced by PTCA. 
PTCA; 53%) than in the right coronary artery (15 out of 40 patients; 38%) or 
the left circumflex artery (2 out of 19 patients; 11% ). Acute PTCA led to a 
significant decrease in residual stenosis (p = .001), although immediate reoc-
clusion was observed in two patients (table 2). Reocclusion, defined as an 
occluded infarct related coronary artery at second angiography in patients with 
successful thrombolysis, was observed in 9 out of 57 patients (16%) in the two 
matched groups (table 3). Reocclusion rates were high when the lesion was 
located in the right coronary artery or left circumflex artery ( 6 out of 21 
patients; 28%) and lower in case of a lesion in the left anterior descending 
artery (3 out of36 patients; 8%). Reocclusion rates were identical in the PTCA 
group and the Sk-only group (18% versus 14%). 
Infarct size and left ventricular function 
Enzymatic infarct size, measured by cumulative alpha-hydroxybutyrate 
dehydrogenase (HBDH) release (7) was 30% lower in patients allocated to 
thrombolytic therapy (median 770 U/1) than in the control group (median 1100 
U/1, p = .0001). However, cumulative HBDH release in the PTCA group 
(median 760 U/1) did not differ from that in the Sk-only group (median 740 
U/1). Improvement of left ventricular ejection fraction, measured by ra-
dionuclide angiography (6, 10) as well as by contrast angiography (9), was 
observed after thrombolytic therapy. Mean radionuclide LVEF after 1 to 3 
days was 41% in the PTCA group and 48% in the Sk-only group. Mean L VEF 
after 10 to 20 days was 49% in the PTCA group and 50% in the Sk-only group. 
77 
In order to obtain a complete picture of total mortality and morbidity in the 
PTCA group and the Sk-only group the proportion of patients in each func-
tional class at weekly intervals during three year follow-up was calculated and 
is presented in figure 3. From these data the mean number of weeks spent in a 
functional class or in hospital were derived (table 5). In the PTCA group more 
weeks were spent without symptoms (128 versus 102 weeks in the Sk-only 
group; p = .03). Consequently, fewer weeks were spent in the PTCA group 
with symptoms of angina pectoris or heart failure (16 versus 37 weeks in the 
Sk-only group; p = .04). Mean survival during three year follow-up and time 
spent in hospital did not differ significantly between the PTCA group and the 
Sk-only group. 
STREPTO + PTCA STREPTO ONLY 
60% 60% 
CLASS I 
40% 40% CLASS I 
20% 20% 
6 12 18 24 30 36 6 12 18 24 30 36 
MONTHS MONTHS 
Figure 9.3. Proportion of patients in each functional class during the first three years after 
myocardial infarction. NYHA class III or IV and in hospital are combined and presented by the 
shaded area. 
The same effects of PTCA were observed in patients with anterior and with 
inferior infarction. In patients with anterior infarction on average 122 weeks 
were spent without symptoms in the PTCA group versus 97 weeks in the 
Sk-only group. In patients with inferior infarction these figures were respec-
tively 139 and 111 weeks. We reported earlier that patients admitted to the 
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hospital within two hours after the onset of myocardial infarction with high ST 
segment elevation (1.2 m V or more) on the ECG made at hospital admission, 
benefitted most from thrombolytic therapy (11). This particular subgroup (28 
patients) again showed the largest benefit of PTCA after thrombolysis, on 
average 128 weeks were spent without symptoms in the PTCA group versus 87 
weeks in the Sk-only group (p = .04), while little benefit was observed in 
patients "'_ith low ST segment el~vation or longer treatment delay. 
Table 9.5. Mean number of weeks spent in the different functional classes or in hospital 
Class I 
Class II 
Class III-IV 
In hospital 
Mean survival 
Matched groups 
PTCA Sk-only 
128 102 
15 29 
1 8 
4 5 
148 weeks 144 weeks 
PTCA performed as part of the recanalization procedure after successful thrombolysis resulted in 
more weeks without symptoms of angina or heart failure than successful thrombolysis alone. 
Discussion 
Several recent studies including the present trial demonstrated that throm-
bolytic therapy with streptokinase, begun within a few hours after the onset of 
myocardial infarction, can lead to limitation of infarct size and improved 
survival ( 4, 5, 21). However, a rather high incidence of late reocclusion (10 to 
28%) or reinfarction (7 to 15%) has been reported after successful throm-
bolysis (15, 16, 22). The present analysis indicates that PTCA performed 
immediately after successful thrombolysis and supported by pharmacotherapy 
with acetyl salicylic acid, coumadin, and niphedipine, effectively reduced the 
degree of residual stenosis and presumably thereby prevented recurrent 
myocardial infarction, although it did not result in additional limitation of 
infarct size. A peculiar finding is that late angiography did not demonstrate a 
significant difference in reocclusion rates (18% in the PTCA group versus 14% 
in the Sk-only group). 
In the present study PTCA was performed only in two of the five centres 
participating in the ICIN trial (the Thoraxcenter in Rotterdam and the Univer-
sity Hospital in Lei den) (5-12). PTCA was performed without delay; if techni-
cally and organisationally feasible, in fact in 46 patients. The decision to 
perform PTCA was based on video-screen images of the coronary angiogram. 
Earli~r we reported a more favourable clinical course in patients who under-
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went immediate PTCA in comparison with those without this additional 
intervention (9). However, since the results of the PTCA group might easily be 
biased by selection, a matched pair analysis was performed. Because benefi-
cial effects of thrombolytic therapy are strongly influenced by the extent of 
myocardial ischemia upon admission (as reflected by total ST segment eleva-
tion) and by the rapidity of lysis onset (8, 11), these baseline characteristics 
were included in the matching procedure. In fact, the two matched groups 
turned out to be almost identical with regard to the most important prognostic 
factors. 
It was found that reocclusion rates were higher when the lesion was located 
in the right coronary artery or in the circumflex artery than in the left anterior 
descending artery (table 3). The same observation was made in the ISAM 
study (22), and other smaller studies (15-16, 23-24). Surprisingly, we observed 
no reduction in reocclusion rate after acute PTCA despite its marked effect on 
the severity of the residual stenosis. Reocclusion rate after thrombolytic 
therapy is related to the degree of residual stenosis (23), but after PTCA it is 
probably more related to the anatomy of the residual lesion. Furthermore, 
many changes in coronary blood supply will have occurred (such as forma-
tion of collaterals) between the time of initial PTCA and late reobstruction 
explaining the apparent difference between increased reocclusion rate and 
decreased reinfarction rate. Also the pharmacotherapy (aspirin, niphedipine 
and heparin) may have influenced the outcome in an unpredictable manner. In 
the larger prospective studies of Erbel (25) and O'Neill (26, 27) acute PTCA 
led to reduction in reocclusion rates, but not as much as might be expected 
when the severity of the residual stenosis were the only important factor. 
Temporary occlusion of a coronary artery leads to a depression in left 
ventricular function that may persist for several days, as is known from animal 
experiments and human observations (28-30). The left ventricular ejection 
fraction measured 1 to 3 days after the onset of myocardial infarction probably 
reflects the initially depressed state of left ventricular function. Thrombolytic 
therapy leads already to an improvement in left ventricular function when 
L VEF after 1 to 3 days is compared to L VEF at 10 to 20 days in the same 
patient (6, 10). This improvement in LVEF was more pronounced in the 
PTCA group than in the Sk-only group (figure 1), although L VEF after 10 to 
20 days was almost equal in these two groups. Clearly, recovery from the 
stunned myocardium plays a major role here. From the data presented it 
remains unclear whether PTCA additionally improves left ventricular function 
or may have led to an initially more pronounced although temporary depres-
sion of left ventricular function. We believe that the former explanation is 
correct since in the study of O'Neill et al. (26) a greater improvement in left 
ventricular function was observed in the PTCA group, in whom the first 
radionuclide angiogram was performed prior to the initiation of thrombolytic 
therapy, a procedure lacking in the ICIN study. 
Long term follow-up after successful thrombolysis followed by acute PTCA 
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compared favourably with successful thrombolysis alone, in that more patients 
were free of symptoms during three year follow-up while fewer patients 
suffered from reinfarction or required re-PTCA or bypass surgery (table 4 and 
5). Also, total morbidity was lower in the PTCA group (figure 3). These 
differences were not caused by the comparison of patients treated in different 
hospitals, since no differences were apparent between the two matched con-
trol groups (table 4). Although beneficial effects of thrombolytic therapy 
predominated in patients with (large) anterior infarctions (6, 11-12), PTCA 
performed immediately after successful thrombolysis reduced morbidity to an 
equal extent in patients with inferior infarction. In the subgroup of patients 
with high ST segment elevation, admitted to the hospital within two hours 
after onset of symptoms, thrombolytic therapy resulted in the largest reduc-
tion in three months mortality (7% compared to 16% in the control group) and 
in this particular subgroup acute PTCA resulted also in the largest improve-
ment in quality of life (128 weeks spent without symptoms versus 87 weeks in 
the Sk-only group), making these patients the ones who benefitted most from 
thrombolytic therapy and from acute PTCA. 
Beneficial effects of thrombolytic therapy are largely time dependent, thus 
thrombolytic therapy should be initiated as soon as possible after the onset of 
myocardial infarction (11, 21). The main effect of PTCA after successful 
thrombolysis is to complete reperfusion when thrombolysis alone is insuffi-
cient, and to prevent recurrent ischemia, especially reinfarction. As is evident 
from figure 2 many reinfarctions occur in the first weeks after thrombolysis. 
So, whereas currently PTCA is indicated on anatomical grounds only, it 
should probably be performed early, at least within the first days following 
successful thrombolysis. Currently, thrombolytic therapy is widely practised in 
community hospitals without catheterization laboratories or surgical standby. 
It appears that sufficient time can be gained by thrombolysis for transferral to 
another hospital where elective PTCA can be performed within the next days 
immediately following successful thrombolysis. 
Conclusions 
Acute PTCA performed immediately after successful thrombolysis improved 
quality of life during the first three years after myocardial infarction, although 
it did not lead to additional limitation of infarct size. The currently available 
data suggest that PTCA after successful thrombolysis should be attempted in 
all patients with a residual stenosis of 70% or more in the infarct related artery 
with poor run-off into the distal coronary artery bed and perhaps in all in 
whom signs of ischemia return. Such PTCA should be attempted immediately 
or within the first days after the onset of myocardial infarction. However, since 
the number of patients treated with PTCA in the present trial and in other 
trials reported sofar is relatively small, these conclusions must be presented 
with caution. Larger trials are presently underway, both in Europe and in the 
83 
United States, where the clinical course after acute PTCA and after delayed 
PTCA will be compared with thrombolytic therapy with recombinant tissue-
type plasminogen activator alone. It may be expected that those studies will 
provide additional data regarding the optimal and practical timing of PTCA 
and the selection of patients in whom this additional procedure should be 
recommended. 
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Chapter 10 
Summary of other reports from the trial 
In addition to the data presented in the chapters 4 to 9, other results of the trial 
have been analysed and presented in papers or abstracts. These reports are 
summarised in this chapter. 
Clinical course 
Patients allocated to thrombolytic therapy had a more favourable clinical 
course in hospital than the control group, except for a higher incidence of 
bleeding complications (chapter 4). This was equally true for patients alloca-
ted to intracoronary streptokinase only as for patients in whom angiography 
was preceded by intravenous administration of streptokinase (1, 2). Despite 
the more favourable clinical course in the thrombolysis group no significant 
differences were observed between patients allocated to thrombolytic therapy 
and the control group in hemodynamic measurements during the first 24 hours 
in the coronary care unit (3). The lower incidence of ventricular fibrillation in 
the thrombolysis group was remarkable, since a high incidence of reperfusion 
arrhythmias has been reported in animal experiments (4). In the thrombolysis 
group less patients had "spontaneous" ventricular fibrillation within 48 hours, 
but also the incidence of late ventricular fibrillation and ventricular fibrillation 
during treatment of cardiogenic shock was lower in these patients (5; table). 
The former may be due in part to treatment with lignocaine in the thrombolysis 
group, while the latter is in agreement with the reported limitation of infarct 
size and preservation of left ventricular function. 
Table 10.1 
Ventricular fibrillation 
n 
Total VF 
Primary VF (<48 hours)* 
Catheter induced VF 
Late VF (>48 hours) 
Shock+ VF 
* Median delay after symptoms 
86 
controls 
264 
60 (23%) 
24 ( 9%) 
9 ( 3%) 
10(4%) 
17 ( 7%) 
3 hours 
thrombolysis 
269 
36 (13%) 
13 ( 5%) 
15 ( 5%) 
2 ( 1%) 
6 ( 2%) 
2 hours 
Workload 
Thrombolytic therapy did not affect the workload of the nursing staff in the 
coronary care unit. CCU workload, calculated with the Therapeutic Interven-
tion Scoring System for 237 patients admitted to the Thorax center, was higher 
in the thrombolysis group on the day of hospital admission, but markedly 
lower on the second and third day after admission, due to fewer patients who 
required prolonged diuretic therapy and pulmonary catheters (6). On the 
other hand, workload was increased for the staff in the catheterisation labora-
tory, as reported earlier (7). The additional costs for this increased workload 
of the catheterisation staff were included in the cost benefit analysis (chapter 
8). 
Infarct size 
Myocardial perfusion at rest and during exercise was measured by 201-Tl 
scintigraphy three months after the myocardial infarction. In a quantitative 
analysis of circumferential profiles of the thallium scintigrams from 118 pa-
tients admitted to the Thoraxcenter the infarct area size appeared to be 13% 
smaller in the thrombolysis group (8). Scintigraphically measured infarct size 
correlated well with enzymatic infarct size since in the same group of patients a 
21% limitation of enzymatic infarct size was observed. Similar observations 
were made when thallium scintigrams of 236 patients with a first myocardial 
infarction from the five participating centres were analysed qualitatively (9, 
10). 
Left ventricular function 
Global left ventricular ejection fraction, measured by radionuclide angiogra-
phy, was significantly higher in the thrombolysis group at two days, two weeks 
and three months after admission (1i, 12). In addition, global and regional 
ejection fraction was assessed by contrast angiography in the right anterior 
oblique projection 10 to 40 days after admission. Global left ventricular 
ejection fraction was higher in the thrombolysis group (mean 53%) than in the 
control group (mean 47%; p = 0.0001), due to smaller end-systolic and end-
diastolic volumes in the thrombolysis group. Wall motion analysis showed 
depressed values of regional contribution to ejection fraction in the "infarct 
zone" with at second angiography subsidence of the initially augmented 
functioning of the"non-infarct zone" The latter phenomenon was particularly 
prominent in patients who underwent the combined procedure of recanalisa-
tion and angioplasty. Segmental function in the "infarct zone" was poorest in 
patients whose coronary artery could not be recanalised and significantly 
better in patients who underwent successful thrombolysis. The highest in-
crease (16%) in the value of the regional contribution to ejection fraction of 
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the "infarct zone" from the acute to the chronic stage was observed when 
angioplasty was performed as part of the recanalisation procedure (13, 14). 
Location of the lesion 
Final patency rate was high in all subsets of patients which were studied and 
appeared not to be related to the location of the lesion in the coronary artery 
(15). On the other hand, limitation of enzymatic infarct size was observed only 
in patients with a lesion in the left anterior descending artery or proximal in the 
right coronary artery and not in patients with a lesion in the left circumflex 
artery or distal in the right coronary artery ( 16). Patients with a lesion proximal 
in the right coronary artery could be distinguished from other patients with 
inferior infarction by ST segment elevation in lead V 4R on the admission 
electrocardiogram, as it was recorded from patients admitted to the University 
Hospital Maastricht and the Hospital of the Free University of Amsterdam 
(17). 
Residual ischemia 
In the majority of cases, a significant stenosis remained in the infarct related 
coronary artery after successful thrombolysis. This artery might reocclude in 
part of the patients and thus abolish the initial beneficial effects of thromboly-
tic therapy. Indeed, a high incidence of reocclusion of the infarct related artery 
or reinfarction within 30 days was observed after successful thrombolysis, 
namely 8% in patients with anterior infarction and 28% in those with inferior 
infarction (18). In the thrombolysis group more patients had to undergo 
coronary angioplasty or bypass surgery because of angina pectoris than in the 
control group (chapter 8). Coronary angioplasty, performed as part of the 
recanalisation procedure after successful thrombolysis in selected patients 
admitted to the Thoraxcenter or the University Hospital in Leiden, appeared 
to reduce reinfarction rates and led to a lower prevalence of angina pectoris 
when compared to successful thrombolysis alone, as assessed in the matched 
pair analysis (chapter 9). Surprisingly, exercise induced ischemia, assessed by 
201-Tl scintigraphy three months after admission, was less prominent in the 
thrombolysis group than in the control group (8-10). It seems likely that after 
three months patients allocated to thrombolytic therapy are no longer more 
prone to recurrent ischemia and recurrent myocardial infarction than patients 
in the control group. Indeed, the higher incidence of recurrent infarction and 
additional revascularisation procedures in the thrombolysis group was only 
observed in the first three months after admission with no relevant difference 
between the two treatment groups in the incidence of these events during later 
follow-up (ranging from 20 to 60 months with a mean follow-up of 38 
months). 
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Consistency of the results 
The results of this trial might be criticised because of the modifications in the 
protocol while the trial was in progress, which were described in chapter 3. The 
inclusion of the pretreatment with intravenous streptokinase and the addition 
of coronary angioplasty did not affect the outcome of the trial. As becomes 
evident from the results of the interim analyses (see table in chapter 3), 
beneficial effects of early thrombolytic therapy were demonstrated in all 
subsets of patients. Limitation of enzymatic infarct size and improvement in 
left ventricular function by thrombolytic therapy were observed in the first 150 
patients admitted to the trial in the Thoraxcenter, but also in patients admitted 
to the other hospitals, where immediate angioplasty was not performed as part 
of the recanalisation procedure. The additional value of acute angioplasty and 
the effects of the pretreatment with intravenous streptokinase were also 
analysed separately. In the latter subgroup the largest mortality reduction was 
observed (1). However, inclusion of the pretreatment in the multivariate 
regression model did not improve the prediction of the effects of intracoronary 
streptokinase on infarct size, left ventricular ejection fraction or three months 
mortality (chapter 7). Thus, it can be concluded that the better outcome of the 
patients allocated to thrombolytic therapy was for the greater part due to the 
effects of intracoronary streptokinase and cannot be ascribed only to effects of 
intravenous streptokinase or coronary angioplasty. 
The additional reports summarised in this chapter support the outcome of 
the trial. All findings are in agreement with a smaller infarct size in the 
thrombolysis group, namely less heart failure in the coronary care unit and 
thereafter, a lower incidence of ventricular fibrillation and less patients with 
symptoms of pericarditis. As a consequence, these patients required less 
attention from the nursing staff, once the intervention was completed. The 
observed limitation of infarct size, measured by cumulative enzyme release 
and by 201-Tl scintigraphy, led to better left ventricular function, analysed 
with radionuclide and with contrast angiography, and to improved survival in 
the thrombolysis group. It is this consistency in the results that supports our 
conclusion that early thrombolytic therapy with intracoronary streptokinase is 
indeed beneficial in patients with acute myocardial infarction. 
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CHAPTER 11 
Conclusions and recommendations 
Other studies with intracoronary streptokinase 
Effects of thrombolytic therapy with intracoronary streptokinase have been 
investigated in seven randomised clinical trials (1-8). Although successful 
recanalisation of an occluded coronary artery was observed in 60 to 80% of the 
patients, the majority of these studies did not demonstrate significant limita-
tion of infarct size, improvement in left ventricular function or reduction in 
mortality (table 1). This discrepancy with the data of the ICIN study can be 
explained by differences in study size, treatment delay and inclusion criteria. 
In the Western Washington Trial, the second largest study with 250 patients, 
mean treatment delay was 280 minutes and patients with newly formed Q 
waves and those receiving maintenance therapy for congestive heart failure 
were excluded (1, 2). Apparently, this study included many patients who 
would not benefit from thrombolytic therapy according to our analysis (e.g., 
patients with a small ischemic area admitted to the hospital more than two 
hours after onset of symptoms; chapter 7), while patients with extensive 
ischemia leading to new Q waves, who might have benefitted from thromboly-
tic therapy (chapter 6), were excluded. In the Western Washington trial no 
differences in infarct size (measured by thallium imaging in a subset of pa-
tients) or in left ventricular ejection fraction were observed between the two 
treatment groups. One year mortality was lower in the thrombolysis group 
(11% vs 19% in the control group, risk difference -8% ). This difference was 
statistically not significant (p = 0.08), although the figures are similar to those 
from our larger trial. The studies of Khaja (3), Leiboff (4), Raizner (5) and 
Rentrop (6) included relatively few patients and had a long treatment delay. 
Accordingly, it became unlikely that a significant difference in left ventricular 
ejection fraction or mortality would be observed. On the other hand, in the 
study of Anderson 50 patients were included with a mean treatment delay of 
240 minutes. Intracoronary streptokinase led to higher left ventricular ejection 
fraction and mortality reduction after 18 months follow-up (risk difference 
-11% ), albeit that the latter difference was statistically not significant due to 
the small size of the study. Infarct size, calculated at our institution from 
cumulative release of lactate dehydrogenase based on enzyme data provided 
by Anderson, appeared to be 40% smaller in the thrombolysis group than in 
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Table 11.1 Randomised clinical trials with intracoronary streptokinase N 
n treatment recanalisation limitation LVEF (%) duration of mortality (%) 
Study c T delay rate(%) infarct c T p follow-up c T RD (95% CI) 
(min) size (months) 
Anderson 26 24 240 75 50% 39 47 0.04 18 19 8 -11 (-30, 8) 
ICIN 264 269 195 79 30% 47 53 0.0001 26 19 11 - 8 (-13, -1) 
Kennedy 116 134 280 69 0 46 46 12 15 8 - 7 (-15, 1) 
Khaja 20 20 300 60 49 51 10 20 5 -15 (-35, 5) 
Leiboff 18 22 240 69 40 43 11 6 9 + 3 (-13, 20) 
Raizner 35 29 330 72 54 46 14 days 6 14 + 8 (- 7, 23) 
Rentrop 61 63 350 74 6 10 21 +11 (- 2, 23) 
Abbrevations: C: control group: T: thrombolysis group; min: minutes; 
L VEF: left ventricular ejection fraction 
RD (95% CI): risk difference with 95% confidence interval. 
the control group, which is in agreement with the infarct size limitation 
observed in the ICIN study (chapter 5). 
Studies with intravenous streptokinase 
Effects of intravenous streptokinase on early or late mortality have been 
studied in many large clinical trials. An overview of their outcome has been 
presented by Yusuf et al (9). Most of the earlier trials with intravenous 
streptokinase did not demonstrate a significant reduction in mortality and 
effects on patency rate, infarct size or left ventricular function were not 
studied. The negative outcome of these trials can be explained by the fact that 
patients were admitted up to 48 hours after onset of symptoms and the relation 
between treatment delay and mortality reduction was not studied. In his 
overview Yusuf combined the data from all published randomised trials with 
intravenous streptokinase and concluded that early mortality was reduced by 
15 to 20%. However, these conclusions are difficult to interpret, since one may 
not expect the same response to thrombolytic therapy in all groups of patients 
admitted up to 48 hours after onset of symptoms. Thus, this overview does not 
answer the question which patients with acute myocardial infarction are likely 
to benefit from intravenous streptokinase. 
Table 11.2 Effects of intravenous (GISSI trial) vs intracoronary (ICIN study) streptokinase on 
early mortality 
GISSI time to in hospital mortality (%) 
randomisation c T RD (95% CI) 
<3 hours 12 9 -3 (-4, -1) 
3-6 hours 14 12 -2 (-5, 0) 
6-9 hours 14 13 -1 (-5, 2) 
9-12 hours 14 16 +2 (-4, 8) 
All 13 11 -2 (-3, -1) 
ICIN time to hospital 14 days mortality (%) 
admission c T RD (95% CI) 
<2 hours 11 5 -6 (-12, -1) 
2-4 hours 6 6 0 (- 9, 9) 
All 10 5 5 (- 9, 0) 
Abbreviations: C: control group; T: allocated to thrombolytic therapy RD (95% CI) = risk 
difference with 95% confidence interval. 
The first convincing results of the efficacy of intravenous streptokinase have 
come from the GISSI trial, in which 11,712 patients were enrolled and reduc-
tion in early mortality by treatment with 1,500,000 U streptokinase was 
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~ Table 11.4 Guidelines for the indications for thrombolytic therapy in patients with acute myocardial infarction. 
Infarct location 
Anterior* 
Inferior* 
Lateral/posterior 
Admission delay 
~ 2 hours 
2-4 hours 
4-6 hours 
~ 2 hours 
2-6 hours 
0-6 hours 
Thrombolytic therapy to be considered in patients with 
all anterior infarcts 
large anterior infarcts, defined as total ST segment 
elevation (sum of leads I, aVL, V1 to V6);;;,: 1.2 mV 
unknown, probably only if total ST segment elevation>> 1.2 mV 
large inferior infarcts, defined as total ST segment 
elevation (sum of leads I, II, III, aVL, aVF, V5, V6) > 0.6 mY or 
total ST segment elevation+ depression (sum of leads V1 to V4);;;,: 1.2 mV or 
STsegment elevation;;;,: 0.1 mVin lead V4R 
unknown if minor benefits outweigh risks 
unknown; minor benefits possible 
* anterior infarcts defined as ST segment elevation;;;,: 0.2 mV in two or more precordial leads 
* inferior infarcts defined as ST segment elevation;;;,: 0.1 mV in two or more inferior leads 
Which patients are candidates for thrombolytic therapy? 
The interval between the onset of myocardial infarction and initiation of 
thrombolytic therapy largely influences the effects of reperfusion on infarct 
size, left ventricular function and mortality. Trials with a large time window 
produced negative results when thrombolytic therapy was compared to con-
ventional treatment (table 1). Indeed it can be stated that thrombolytic 
therapy is not indicated in patients with acute myocardial infarction when 
treatment delay exceeds six hours. From all patients admitted within six hours 
after onset of symptoms in the GISSI trial and the ISAM study, major benefits 
from thrombolytic therapy were only observed in patients treated within three 
hours after onset of symptoms. In the ICIN study, the amount of myocardium 
at risk was also taken into consideration. Beneficial effects of intracoronary 
streptokinase on infarct size, left ventricular function and three months morta-
lity were observed in patients admitted to the hospital within two hours after 
onset of symptoms and in patients with a large ischemic area (reflected by high 
degree of ST segment elevation on the admission electrocardiogram) admitted 
within four hours after onset of symptoms (chapter 7). However, improve-
ment of long term survival was observed only in patients with anterior infarc-
tion (chapter 8). In patients with inferior infarction mortality during long term 
follow-up appeared to be reduced by thrombolytic therapy only to a minor 
extent in the ICIN study (9% in the thrombolysis group vs 11% in the control 
group during one year follow-up) and in the ISAM study (10% in the thrombo-
lysis group vs 14% in the control group after a mean follow-up of 21 months), 
most likely due to the high incidence of recurrent infarction after thrombolysis 
in these patients. Based on these data, the following guidelines are presented 
for the use of thrombolytic therapy in patients with acute myocardial infarction 
and summarised in table 4. 
Anterior infarction (at least 0.2 mV ST segment elevation in two or more 
precordial leads). 
Beneficial effects have been demonstrated in patients admitted to the hospital 
within two hours after onset of symptoms and in patients with a large ischemic 
area (total ST segment elevation 1.2 m V or more) admitted within four hours 
after onset of symptoms. The largest benefit was observed in patients with 
extensive ischemia admitted within two hours after onset of symptoms. In 
other patients admitted within six hours after onset of symptoms it remains 
unclear whether benefits outweigh the risks of the procedure. 
Inferior infarction (at least 0.1 mV ST segment elevation in two or more 
inferior leads). 
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Beneficial effects seem likely in patients admitted within two hours after onset 
of symptoms with signs of extensive ischemia, which can be defined as: 
- total ST segment elevation in leads I, II, III, a VL, a VF, V5, V6 more than 
0.6 mV (chapter 6) or 
- total ST segment deviation (total ST segment depression in leads V1 to V 4 
added to the total ST segment elevation) at least 1.2 mV (chapter 7) or 
- presence of at least 0.1 mV ST segment elevation in lead V4R, indicating 
right ventricular involvement (25). 
In other patients admitted within six hours after onset of symptoms it seems 
unlikely that thrombolytic therapy will result in major benefit. It remains 
unclear whether a minor benefit, if present, will warrant the risks of the 
intervention, not to mention costs of acute angiography or subsequent 
procedures. 
Lateral or posterior wall infarction 
Major benefit from thrombolytic therapy was not demonstrated in the GISSI 
trial nor in the ISAM study. In the ICIN study patients with lateral infarction 
were combined with those with anterior infarction and patients with posterior 
infarction were combined with those with inferior infarction, but excluded 
from subgroup analyses (chapter 6 and 7). Minor benefit from thrombolytic 
therapy in part of these patients cannot be excluded. 
When these guidelines would have been followed in the present trial thrombo-
lytic therapy would have been offered to 325 patients out of the 533 patients 
(61%) that were in fact admitted to the study. In this subset of patients mean 
life expectancy was 14.5 years in the control group and 16.3 years in the 
thrombolysis group, based on the calculations as described in chapter 8. Total 
costs per year of life gained by thrombolytic therapy with intracoronary 
streptokinase averaged Dfl 5,000 for those patients in whom thrombolytic 
therapy is recommended in these guidelines. 
Value of adjuvant pharmacotherapy 
Thrombolytic therapy was in the present study accompanied by supportive 
pharmacotherapy with platelet aggregation inhibitors, heparin, oral anticoa-
gulants, lignocaine and corticosteroids (chapter 4). The exact value of this 
adjuvant therapy has not been established. The use of lignocaine can be 
favoured in order to prevent ventricular arrhythmias caused either by reperfu-
sion or by the myocardial infarction. The value of the short term corticosteroid 
therapy remains debatable, since in the GISSI trial, where no corticosteroids 
were given, severe allergic reactions were only observed in 0.1% of the 
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patients after treatment with streptokinase (10). The major problem lies in the 
prevention of reocclusion by pharmacotherapy. Even with the use of platelet 
aggregation inhibitors, heparin and oral anticoagulants a high incidence of 
reocclusion and reinfarction was observed in the present trial after successful 
thrombolysis, especially in patients with inferior infarction. Studies to define 
the optimal pharmacotherapeutic regimen to prevent reocclusion after suc-
cessful thrombolysis are urgently needed. The applicability of thrombolytic 
agents in patients with inferior infarction will depend on the possibilities to 
prevent reocclusion in these patients. 
Coronary angioplasty 
Immediate coronary angioplasty after perforation of the thrombus in the 
infarct related coronary artery by a guidewire has been proposed by Rentrop 
et al. as an alternate approach to the use of thrombolytic therapy in patients 
with acute myocardial infarction (26). In a small study reported by O'Neill et al 
(24) patency of the infarct related artery was achieved in 24 out of 29 patients 
(83%) by this method (table 3). However, the inevitably longer treatment 
delay will restrict the applicability of this approach to patients in whom 
intravenous thrombolytic therapy is contraindicated. After successful or at-
tempted thrombolysis coronary angioplasty may be of value in order to 
complete the reperfusion strategy. After successful thrombolysis severe steno-
sis may remain in the infarct related coronary artery. This artery may reoc-
clude and abolish the beneficial effects of reperfusion. Indeed, reinfarction 
rates observed in patients with a residual stenosis of 70% or more after 
successful thrombolysis were as high as 30% during three years follow-up with 
most of the reinfarctions occurring within three months (chapter 9). The 
additional value of coronary angioplasty in those patients has been reported by 
others (27-30) and was also demonstrated in the present study. Coronary 
angioplasty appeared to be of value both in patients with anterior and with 
inferior infarction. In patients with anterior infarction reocclusion rates were 
relatively low (8% at second angiography), but reocclusion might lead to large 
anterior reinfarctions, while in patients with inferior infarction reocclusion 
rates were higher (28% at second angiography) but the area at risk was on 
average smaller than in patients with anterior infarction (chapter 9). Conse-
quently, if acute angiography is not performed after attempted thrombolysis 
or when coronary angioplasty after successful thrombolysis is not feasible due 
to lack of surgical standby, coronary angiography should be carried out within 
the next days to assess the suitability for elective PTCA. When symptoms and 
signs of ischemia reappear this intervention should be carried out on a (semi-) 
urgent basis. 
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Recommendations 
In patients with acute myocardial infarction in whom thrombolytic therapy can 
presently be recommended (table 4), the optimal approach begins with intra-
venous administration of streptokinase (500,000 U) as early as possible, 
usually immediately upon hospital admission, followed by acute angiography 
and intracoronary administration of streptokinase. Only when signs of reper-
fusion have appeared prior to angiography such as sudden relief of chest pain 
with marked decrease of ST segment elevation, can angiography be delayed. 
When after intracoronary thrombolysis a residual stenosis of 70% or more in 
the infarct related artery with poor run-off into the distal coronary artery bed is 
seen, immediate PTCA is recommended. When acute PTCA is not feasible or 
when acute angiography has not been performed following intravenous throm-
bolytic therapy, coronary angiography within the next days remains indicated 
to assess the suitability for elective PTCA. 
Impact of these recommendations on health care 
Following the guidelines presented before (table 4), thrombolytic therapy can 
be offered to 15 to 20% of all patients admitted to the hospital with acute 
myocardial infarction (31). Even in large hospitals in the Netherlands the 
number of patients treated with thrombolytic therapy will then not exceed 100 
patients per hospital per year. When catheterisation laboratories are available 
on a 24 hour basis, total workload for their technical staff will only be increased 
to a minor extent. The costs for this increased workload were included in the 
cost benefit analysis (chapter 8) and the apparent benefits from thrombolytic 
therapy certainly warrant the additional costs (Dfl 5,000 per year of life 
gained) even in the present times when budgets available for health care are 
limited. However, many patients with acute myocardial infarction are admit-
ted to community hospitals with limited or no possibilities for acute angiogra-
phy. It is for this reason that Verstraete stated that intravenous thrombolytic 
therapy would be "the only way" (32). Furthermore, even if thrombolytic 
therapy would be restricted to intravenous administration in those hospitals, 
the number of subsequent catheterisations to be performed in adjacent large 
hospitals in order to assess the suitability for elective PTCA would lead to a 
major increase in workload in the catheterisation laboratories in those hospi-
tals. The new generation of more effective thrombolytic agents (rt-PA, rscu-
p A and APSAC) is currently being investigated in large clinical trials. Prelimi-
nary results have indicated that intravenous use of these agents does lead to 
successful thrombolysis in a higher percentage of patients than presently can 
be achieved with intravenous streptokinase (table 3). Part of these trials also 
adress the question whether PTCA is mandatory after successful thromboly-
sis, and whether this additional procedure should be performed immediately 
or can be deferred a few days. In our opinion the results of these trials will have 
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to be awaited before the required capacity of catheterisation laboratories can 
be estimated (see below). 
Questions for the future 
In this thesis the characteristics have been defined of those patients with acute 
myocardial infarction to whom early thrombolytic therapy would offer a major 
benefit. However, this concerns only 15 to 20% of all patients admitted to the 
hospital with acute myocardial infarction. It is still unclear whether early 
thrombolytic therapy will offer benefit to other patients with acute myocardial 
infarction. Presently, it seems unlikely that patients admitted to the hospital 
more than six hours after onset of symptoms will benefit from thrombolytic 
therapy, but effects of thrombolytic therapy should be investigated in other 
patients admitted within six hours after onset of symptoms than those in whom 
benefits were demonstrated (table 4). Especially patients admitted up to 24 
hours after onset of symptoms with extensive ischemia (usually located ante-
riorly) or with signs of cardiogenic shock constitute a group of high risk 
patients who might derive major benefit from thrombolytic therapy (33). On 
the other hand, patients with less extensive ischemia admitted early after onset 
of symptoms and even patients admitted with unstable angina might also 
benefit from thrombolytic therapy, but in these low risk patients the possible 
benefits must be carefully weighted against the risks of the intervention in 
terms of major bleeding, stroke and consequences of eventual reocclusion. 
The indications for thrombolytic therapy, especially in patients with inferior 
infarction, will also depend on the possibilities to prevent reocclusion. If our 
observation that coronary angioplasty following successful thrombolysis and 
supported by pharmacotherapy effectively reduces reinfarction rate is confir-
med in larger clinical trials (which are presently underway), more patients with 
acute myocardial infarction might be considered candidates for thrombolytic 
therapy. 
It is likely that in the near future the new generation of thrombolytic agents 
(rt-PA, rsu-PA and APSAC) will become first choice for the intravenous 
initiation of thrombolytic therapy. Then, the indications for either acute or 
delayed angiography might be different from the present ones. Cost benefit 
analyses will be required to assess the additional value of intracoronary 
thrombolysis and coronary angioplasty after intravenous administration of 
rt-PA, rscu-PA or APSAC. The required capacity of catheterisation laborato-
ries and facilities for coronary angioplasty and bypass surgery will depend on 
the results of those analyses. We expect that the guidelines presented in this 
thesis are applicable to all thrombolytic agents and that a stepwise approach 
including intravenous and possibly intracoronary treatment followed by coro-
nary angioplasty in selected patients will prove to be the optimal strategy. 
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Summary 
The purpose of this study was to analyse the effects of thrombolytic therapy 
with intracoronary streptokinase in patients with acute myocardial infarction. 
Five centres participated in the study, the Thorax center in Rotterdam (237 
patients), the Academic Hospital of the Free University of Amsterdam (93 
patients), the Zuiderziekenhuis in Rotterdam (61 patients), the Academic 
Hospital of the University of Limburg in Maastricht (123 patients) and the 
Academic Hospital of Leiden (19 patients). The study was conducted by the 
Interuniversity Cardiology Institute the Netherlands. A strategy aimed at 
early reperfusion, including acute coronary angiography and intracoronary 
administration of streptokinase, was compared to conventional therapy of 
myocardial infarction without acute angiography and without administration 
of fibrinolytic therapy. Patients were eligible for the study if admitted to the 
hospital within four hours after onset of symptoms and with electrocar-
diographic signs typical for acute myocardial infarction. Patients over 70 years 
of age and patients with enhanced risks of bleeding were excluded. 
A total of 533 patients were included in the study of which 264 were 
randomly allocated to conventional treatment and 269 to thrombolytic 
therapy. Informed consent was sought from patients allocated to thrombolytic 
therapy only. Final patency of the infarct related artery was achieved with 
intracoronary streptokinase (usually 250,000 U) in 198 out of 234 patients 
(85% ). In 98 patients angiography was preceded by intravenous infusion of 
streptokinase (500,000 U). Clinical course was better in the thrombolysis 
group, less patients had symptoms of cardiogenic shock or heart failure. Also, 
the incidence of ventricular fibrillation appeared to be lower in the throm-
bolysis group. Bleeding complications were mainly related to the angiography 
puncture site. Thrombolytic therapy led to a limitation of enzymatic infarct 
size, measured by cumulative release of alpha-hydroxybutyrate 
dehydrogenase (median 770 U/1 vs 1100 U/1 in the control group; p = 0.0001). 
Left ventricular ejection fraction measured by contrast angiography 10 to 40 
days after admission was higher in the thrombolysis group (median 53% vs 
47% in the control group, p = 0.0001). Furthermore, thrombolytic therapy 
improved one year survival (90% vs 84% in the control group; p = 0.03). 
However, thrombolytic therapy led to a higher incidence of non-fatal myocar-
dial infarction during the first year (13% vs 5% in the control group; p = 
0.001). 
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In multivariate regression analysis it was observed that beneficial effects of 
thrombolytic therapy were related to the delay between onset of symptoms 
and hospital admission, to the extent of myocardial ischemia, and to the 
development of new Q waves on the admission ECG. Patients with extensive 
ischemia, admitted to the hospital within 2 hours after onset of symptoms, 
derived most benefit from thrombolytic therapy. 
In a cost benefit analysis mortality and morbidity during one year follow-up 
were related to the costs of the procedure, of hospital admissions, and of 
additional interventions. In patients with inferior infarction thrombolytic 
therapy improved survival and quality oflife only to a minor extent. Total costs 
the first year averaged Dfl 20,000 for patients in the control group, and Dfl 
27,000 for patients allocated to thrombolytic therapy. Total costs per year of 
life gained by thrombolytic therapy were D£110,000. In patients with anterior 
infarction thrombolytic therapy improved one year survival (89% vs 78% in 
the control group; p = 0.01) and improved quality of life during the first year 
follow-up, in that on average more time was spent without symptoms of angina 
pectoris or heart failure. Total costs averaged Dfl 28,000 in the thrombolysis 
group and D£121,000 in the control group. Total costs per year oflife gained by 
thrombolytic therapy therefore were Dfl3 ,800. The subgroup of patients with 
anterior infarction with extensive ischemia, admitted within 2 hours after 
onset of symptoms derived the largest benefit from thrombolytic therapy and 
total costs per year of life gained were only D£11,900. 
The additional value of PTCA after successful thrombolysis was assessed in 
a matched pair analysis. Patients in whom PTCA was carried out as part of the 
recanalisation procedure were compared to patients with successful throm-
bolysis admitted to those hospitals where acute PTCA was not performed. 
PTCA performed immediately after successful thrombolysis additionally im-
proved quality of life during three years follow-up, in that on average 128 
weeks (out of 156 weeks) were spent without symptoms of angina pectoris or 
heart failure in the matched PTCA group and 102 weeks in a matched group of 
patients with successfull thrombolysis only (p = 0.03). 
Thrombolytic therapy can presently be recommended in patients with an-
terior infarction admitted to the hospital within two hours after onset of 
symptoms and in patients with a large ischemic area as reflected by total ST 
segment elevation of 1.2 m V or more on the admission electrocardiogram, 
admitted two to four hours after onset of symptoms. In patients with inferior 
infarction beneficial effects of thrombolytic therapy seem only likely in pa-
tients admitted within two hours after onset of symptoms with signs of exten-
sive ischemia on the admission electrocardiogram. It remains presently 
unclear whether early thrombolytic therapy will result in (minor) benefit in 
other patients with acute myocardial infarction. 
The optimal approach begins with intravenous administration of strep-
tokinase (500,000 U) followed by acute angiography and intracoronary ad-
ministration of streptokinase (250,000 U), unless signs of reperfusion have 
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appeared prior to angiography. When after successful thrombolysis a residual 
stenosis of70% or more in the infarct related coronary artery with poor run-off 
into the distal coronary artery bed is seen, immediate PTCA is recommended. 
If acute angiography was not performed after thrombolysis or acute PTCA was 
not feasible, angiography should be carried out within the first days following 
successful thrombolysis to assess suitability for elective PTCA. 
We expect this stepwise approach in the treatment of patients with acute 
myocardial infarction to be applicable to all thrombolytic agents, although the 
newer more effective thrombolytic agents may reduce the need for acute 
angiography and early PTCA. Large randomised clinical trials are presently 
underway, both in Europe and in the United States, to assess the efficacy of 
rt-P A, rscu-P A and APSAC in the treatment of patients with acute myocardial 
infarction and to determine the additional value of coronary angioplasty, 
either performed immediately or within the next days following successful 
thrombolysis. 
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Samenvatting 
Deze studie had ten doel de effecten van een behandeling met intracoronair 
toegediende streptokinase bij patienten met een acuut hartinfarct te analyse-
ren. Vijf ziekenhuizen namen aan deze studie deel, namelijk het Thoraxcen-
trum in Rotterdam (237 patienten), het Academisch ziekenhuis van de Vrije 
Universiteit van Amsterdam (93 patienten), het Zuiderziekenhuis in Rotter-
dam (61 patienten), het Academisch Ziekenhuis in Maastricht (123 patienten) 
en het Academisch Ziekenhuis Leiden (19 patienten). De studie werd verricht 
onder auspicien van het Interuniversitair Cardiologisch Instituut Nederland. 
Een behandeling gericht op vroegtijdige reperfusie met behulp van coronair-
angiografie en intracoronaire toediening van streptokinase werd vergeleken 
met een normale behandeling van patienten met een hartinfarct, dat wil 
zeggen een behandeling zonder acute angiografie en zonder toediening van 
fibrinolytica. Patienten kwamen aileen in aanmerking voor de studie indien zij 
werden opgenomen in het ziekenhuis binnen vier uur na het begin van de 
klachten. Het electrocardiogram moest duidelijk aangeven dater sprake was 
van een acuut hartinfarct. Patienten ouder dan 70 jaar en patienten met een 
verhoogd risico op bloedingen werden van deelname aan de studie uit-
gesloten. 
In totaal werden 533 patienten in de studie opgenomen. Tweehonderden-
vierenzestig patienten werden door randomisatie toegewezen aan de controle-
groep, 269 aan de trombolytische behandeling. Toestemming voor deelname 
aan de studie werd aileen gevraagd aan patienten die waren toegewezen aan de 
behandeling met trombolytica. De aangedane coronairarterie was na intraco-
ronaire toediening van streptokinase (meestal 250,000 E) doorgankelijk bij 
198 van de 234 patienten (85%). Van deze 234 patienten hadden er 98 tevoren 
ook streptokinase intraveneus toegediend gekregen (500,000 E). Het klini-
sche be loop van de patienten in de trombolysegroep was gunstiger dan van die 
in de controlegroep; met name kregen minder patienten in de trombolyse-
groep tekenen van decompensatio cordis of cardiogene shock. Ook trad 
ventrikelfibrilleren minder vaak op in de trombolysegroep. Bloedingen traden 
vrijwel aileen op random de insteekplaats van de catheter. De behandeling 
met streptokinase leidde tot een beperking van de enzymatische infarct-
grootte, gemeten door mid del van de cumulatieve release van alpha-hydroxy-
butyraat dehydrogenase. De mediane release was 770 E/1 in de trombolyse-
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groep en 1100 E/1 in de controlegroep (p = 0,0001). 
De linkerventrikel ejectiefractie (gemeten met behulp van contrastangio-
grafie 10 tot 40 dagen na opname) was hoger in de trombolysegroep (mediaan 
53% tegenover 47% in de controlegroep; p = 0,0001). De eenjaarsoverleving 
was ook beter in de trombolysegroep (90% tegenover 84% in de controle-
groep; p = 0,03). De behandeling met streptokinase leidde wel tot een 
toename van het aantal recidief infarcten gedurende het eerste jaar (13% 
tegenover 5% in de controlegroep; p = 0,001). 
De resultaten van multivariate regressieanalyse gaven aan dat de effecten 
van de behandeling met streptokinase afhingen van het tijdsverloop tussen het 
begin van de klachten en opname in het ziekenhuis, van de uitgebreidheid van 
de ischaemie en van het ontstaan van nieuwe Q golven op het electrocardio-
gram. Patienten met uitgebreide ischaemie, opgenomen binnen twee uur na 
het begin van de klachten, hadden de meeste baat bij de behandeling met 
streptokinase. 
In een kostenbatenanalyse werden de effecten op de mortaliteit en de 
morbiditeit gerelateerd aan de kosten van de interventie, van de ziekenhuisop-
names en van latere interventies. Bij patienten met een onderwandinfarct 
waren de gunstige effecten van de behandeling met streptokinase op de 
mortaliteit en de kwaliteit van het I even gering. De totale kosten bedroegen in 
het eerste jaar Fl20.000 voor de patienten in de controlegroep en Fl27.000 
voor de patienten in de trombolysegroep. De extra kosten per gewonnen 
levensjaar waren gerniddeld Fl10.000. Bij patienten met een voorwandinfarct 
was de mortaliteit wel duidelijk lager in de trombolysegroep (11% tegenover 
22% in de controlegroep; p = 0,01) en was ookde kwaliteitvanhetleven beter 
in de trombolysegroep in die zin, dat gemiddeld meer dagen werden doorge-
bracht zonder klachten van angina pectoris of decompensatio cordis. De totale 
kosten bedroegen Fl28. 000 in de trombolysegroep en Fl21. 000 in de controle-
groep. De extra kosten per gewonnen levensj aar war en gemiddeld Fl3. 800. In 
de subgroep van patienten met uitgebreide ischaernie, opgenomen binnen 
twee uur na het begin van de klachten, werd het grootste voordeel van de 
behandeling met streptokinase gezien. In deze groep bedroegen de kosten per 
gewonnen levensjaar slechts Fll.900. 
De effecten van PTCA na trombolyse werden geanalyseerd in een "mat-
ched pair" analyse. Patienten die een PTCA hadden ondergaan direct in 
aansluiting aan de behandeling met streptokinase werden vergeleken met 
patienten die met succes waren behandeld met streptokinase en die waren 
opgenomen in die ziekenhuizen waar geen acute PTCA werd verricht. PTCA, 
in aansluiting aan de behandeling met streptokinase, verbeterde de kwaliteit 
van het leven in die zin dat gerniddeld 128 weken (van de 156 weken) werden 
doorgebracht zonder klachten van angina pectoris of decompensatio cordis, 
tegen gerniddeld 102 we ken in de groep patienten die alleen met streptokinase 
was behandeld (p = 0,03). 
Een behandeling met trombolytica kan thans worden geadviseerd bij pa-
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tienten met een voorwandinfarct die zijn opgenomen in het ziekenhuis binnen 
twee uur na het begin van de klachten en bij patienten met uitgebreide 
ischaemie ( te zien op het electrocardiogram als een som van de ST eleva tie van 
minimaal 1,2 m V), opgenomen twee tot vier uur na het be ginn en van de 
klachten. Bij patienten met een onderwandinfarct zijn waarschijnlijk aileen 
gunstige effecten van een behandeling met trombolytica te verwachten bij 
patienten met uitgebreide ischaemie, opgenomen binnen twee uur na het 
begin van de klachten. Thans is het nog onduidelijk of andere patienten met 
een acuut hartinfarct mogelijk ook baat hebben bij deze behandeling. 
Het volgende behandelingsschema wordt voorgesteld ten aanzien van het 
gebruik van trombolytica bij patienten met een acuut hartinfarct. De behande-
ling begint met intraveneuze toediening van 500.000 eenheden streptokinase, 
direct gevolgd door hartcatheterisatie en intracoronaire toediening van 
250.000 eenheden streptokinase, tenzij tekenen van reperfusie zijn opgetre-
den voor het begin van de hartcatheterisatie. Wanneer na trombolyse een 
stenose van 70% of meer wordt gezien in de aangedane coronairarterie, 
bestaat er een indicatie voor acute PTCA. Indien acute catheterisatie na een 
trombolytische behandeling niet heeft plaatsgevonden of indien het niet mo-
gelijk was een acute PTCA te verrichten, dient, indien mogelijk, angiografie 
plaats te vinden binnen enkele dagen na de trombolytische behandeling ten 
einde vast te stellen of er een indicatie bestaat voor electieve PTCA. 
Deze stapsgewijze benadering van de trombolytische behandeling van pa-
tienten met een hartinfarct lijkt ons ook toepasbaar bij een behandeling met 
andere trombolytica, al zullen acute angiografie en PTCA wellicht minder 
vaak geindiceerd blijken te zijn na intraveneuze toediening van de nieuwe, 
effectievere trombolytica (rt-PA, rscu-PA en APSAC). De effectiviteit van 
deze middelen wordt thans onderzocht in grote gerandomiseerde studies, 
zowel in Europa als in de Verenigde Staten, waarbij tevens de waarde wordt 
bepaald van coronairangioplastiek, verricht direct in aansluiting aan een 
succesvolle behandeling met trombolytica dan wei binnen enkele dagen na 
deze behandeling. 
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